EESTI BIOEETIKA JA INIMUURINGUTE NÕUKOGU
OTSUS
14. aprill 2020 nr 1.1-12/678
Nõukogu koosseisus:
Esimees:
Liina Vahter Tallinna Ülikool
Aseesimees:
Aime Keis Tartu Ülikooli inimuuringute eetika komitee
Teadussekretär:
Aive Pevkur Tallinna Tehnikaülikool
Liikmed:
Kristi Rüütel Tervise Arengu Instituudi inimuuringute eetikakomitee
Irja Lutsar Tartu Ülikool
Kärt Salumaa-Lepik Tallinna Tehnikaülikool
Meego Remmel Eesti Kirikute Nõukogu
Agne Velthut-Meikas Tallinna Tehnikaülikool
Merike Sisask Tallinna Ülikool
Ingeri Luik-Tamme TGS Baltic Advokaadibüroo
Pärt Peterson Tartu Ülikool
Kristjan Kask Tallinna Ülikool
Arutas 7. aprillil 2020.a Tartu Ülikooli genoomika instituut projekti “ Varasemalt kirjeldamata
CYP450 geenivariatsioonide mõju ravimite metabolismile” („Study of the effects of previously
uncharacterized rare variants in genees encoding CYP450 enzymes ").
Uuringu viivad läbi Tartu Ülikool ja Karolinska Instituut.
Uuringu taotluse menetlusest taandas ennast Maarja Kirss, Andmekaitse Inspektsioonist.
Uuringu taotluse menetluses ei osalenud Priit Ennet, MTÜ Eesti Teadusajakirjanike Selts.
Läbiviidava uuringu üldine eesmärk on hinnata hiljuti Eesti populatsioonis avastatud
tsütokroomi ensüümide 2D6 ja 2C19 geenivariantide mõju ravimite metabolismile. Selleks
kutsutakse uuringukriteeriumitele vastavad geenidoonorid farmakokineetilisse uuringusse.
Uuringus osalema nõustunud geenidoonoritele manustatakse kahte ravimit ning hinnatakse
iga indiviidi ravimite metaboliseerimise kiirust sõltuvalt tema genotüübist, laborianalüüsi
tulemusest ja teistest teadaolevatest faktoritest.
Uuringus töödeldakse järgmise andmekategooriaid ja –koosseis on toodud Eesti
bioeetika ja inimuuringute nõukogule esitatud taotluse punktis 8.
Valimi moodustab kuni 215 000 geenidoonorit. Depseudonüümitakse kuni 900
geenidoonori andmed.
Andmeandjateks on geenivaramu.
Otsus: anda luba uuringu läbiviimiseks.
Otsuse lahutamatu lisad on Tartu Ülikooli Genoomika Instituudi“ Varasemalt kirjeldamata
CYP450 geenivariatsioonide mõju ravimite metabolismile” („Study of the effects of previously
uncharacterized rare variants in genees encoding CYP450 enzymes ").uuringutaotlus koos
lisadega.
/allkirjastatud digitaalselt/
Liina Vahter
Eesti bioeetika ja inimuuringute nõukogu esimees
Application to Estonian Committee on Bioethics and Human
Research for project approval
1. RESEARCH DATA
Name of the study:
Study of the effects of previously uncharacterized rare variants in genes
encoding CYP450 enzymes
Varasemalt kirjeldamata CYP450 geenivariatsioonide mõju ravimite
metabolismile
Sponsor of the study: Institute of Genomics, University of Tartu
Number of the study plan: 1-2019
Version: 2
Date: 25.02.2020
List of Collaborating Countries:
Estonia, Tartu, Tallinn
Sweden, Stockholm
The main aim of the study is to assess the effect of recently identified genetic variants in the
cytochrome 2D6 and 2C19 genes on the metabolizing activity of these enzymes in the Estonian
population. The effects of the genetic variants will be evaluated by re-contacting relevant
participants from the Estonian Biobank, and after review of their health status, invite them to
participate in a pharmacokinetic study. The eligible individuals comprise the study group and
will take an oral low dose of omeprazole and metoprolol. Venous blood will be drawn at fixed
time points to determine the metabolizing capacity of the enzymes based on the genetic profile,
laboratory analyses’ results and other known factors.
Uuringu põhiline eesmärk on hinnata hiljuti Eesti populatsioonis avastatud tsütokroomi
ensüümide 2D6 ja 2C19 geenivariantide mõju ravimite metabolismile. Selleks kutsutakse
uuringukriteeriumitele vastavad geenidoonorid farmakokineetilisse uuringusse. Uuringus
osalema nõustunud geenidoonoritele manustatakse kahte ravimit ning hinnatakse iga indiviidi
ravimite metaboliseerimise kiirust sõltuvalt tema genotüübist, laborianalüüsi tulemusest ja
teistest teadaolevatest faktoritest.
2. INVESTIGATORS AND PARTICIPATING INSTITUTIONS
2.1. Principal investigator
Dr. Alar Irs
Tartu University Hospital, Heart Clinic
511 8592
[email protected]
/signed electronically/
1
2.2. Sub-investigators
Dr. Lili Milani
Estonian Genome Centre
Institute of Genomics
University of Tartu
Riia 23b, 51010 Tartu
737 4039
[email protected]
/signed electronically/
Dr. Alar Irs
Tartu University Hospital
Heart Clinic
511 8592
[email protected]
/signed electronically/
Dr. Kersti Oselin
North Estonia Regional Hospital
Oncology and Haematology Clinic
617 1792
[email protected]
/signed electronically/
Dr. Jana Lass
Tartu University Hospital
Estonian Genome Centre
Institute of Genomics
University of Tartu
Riia 23b, 51010 Tartu731 8333
[email protected]
/signed electronically/
Kristi Krebs, MSc
Estonian Genome Centre
Institute of Genomics
University of Tartu
Riia 23b, 51010 Tartu737 4039
[email protected]
/signed electronically/
Tuuli Jürgenson, BSc (statistics)
Estonian Genome Centre
Institute of Genomics
University of Tartu
Riia 23b, 51010 Tartu
[email protected]
/signed electronically/
2
Dr. Anton Pohanka
Karolinska University Hospital
Department of Clinical Pharmacology
[email protected]
/signature in Annex/
Dr. Volker M Lauschke
Dept of Physiology and Pharmacology
Karolinska Institutet
[email protected]
/signature in Annex/
Prof. Erik Eliasson, MD
Department of Laboratory Medicine
Clinical Pharmacology
Karolinska Institutet
[email protected]
/signature in Annex/
2.3. Director of the institution or head of the structural unit of the principal investigator
Katrin Kaarna
Head of the Clinical Research Centre, University of Tartu
Ravila 19, 50411 Tartu
[email protected]
737 4119
/signed electronically/
2.4. Consent from director or authorised person of the institution(s)/partner organisation(s)
Institute of Genomics
University of Tartu
Riia 23b, 51010 Tartu
Mait Metspalu
Director
737 5052
[email protected]
/signed electronically/
COMMENT: the additional application will be submitted to the Estonian Committee on
Bioethics and Human Research for adding medical personnel from study centers (nurses) to the
list of investigators.
This application for ethical approval has been reviewed and approved by persons authorized by
the Chief Data Protection Officer of the University of Tartu, Helene Alavere, Head of Data
Collection Department and Project Manager of the Estonian Biobank, Institute of Genomics
and Evelin Tali, Analyst of the Estonian Biobank, Institute of Genomics.
3
3. STUDY FINANCING
Source:
1. PRG184 (PRG184) "Role of Rare and Common Genetic Variants in Adverse Drug
Reactions (1.01.2018−31.12.2022)", Lili Azin Milani, University of Tartu, Institute of
Genomics.
2. PP1GI Science base funding, University of Tartu, Institute of Genomics (yearly
allocation for 2020 ca 1M €).
Study costs:
Payment for the study nurse 150 EUR/per day.
Probe drugs: 150 EUR/total cost
Compensation for the study participants: compensation for participation will not be paid.
The study drug administration is scheduled for the weekend. During the study, it is planned to
cover the participant's transportation costs on the basis of expense receipt(s). As the research
centers are located in both Tallinn and Tartu, transport costs in Estonia are unlikely to exceed
50€/visit. As the participant has to come to the study center twice during the study, altogether
the travel compensation is up to 100€. If the subject is unable to come to the study center in the
morning on the day when the drug will be administered or travel home in the evening after the
day of the study, accommodation costs will also be reimbursed. As participants are healthy
subjects we do not foresee necessity for involving an accompanying person.
Insurance for the study participants: all of the study participants will be covered by insurance
during the study period. An insurance policy offer is attached to the application.
4. SHORT OVERVIEW OF SIMILAR STUDIES
Cytochrome P450 (CYP) enzymes play an important role in drug metabolism by being
responsible for oxidative metabolism of approximately 50 % of drugs and xenobiotics.
Variation in the CYP genes can produce enzyme products with abolished, reduced, altered or
increased enzyme activity. In addition to metabolizing enzymes of which the CYP genes are
the by far most well studied, drug transporter proteins are important sources of pharmacokinetic
variability in drug response (Kozyra et al, 2016).
Considerable inter- and intra-individual variability in the expression and function of CYP
enzymes exists, which is determined by multiple factors. A large degree of variability exists
within any particular genotype group, which confirms that in addition to known genetic
variants, novel rare genetic factors as well as non-genetic host factors (age, gender, disease
states), and environmental influences (such as smoking, diet, concomitant drugs) are also
important (Wilkinson et al, 2005). Consequently, each individual has its own CYP450
metabolic profile and the phenotype (i.e. the real activity) of an individual enzyme is important
for predicting possible therapeutic failures or toxic reactions to medicines.
4
Several common genetic variants have been described which lead to altered enzyme activity
and thus variation in treatment outcome (Reisberg et al, 2019). However, the effect of some
novel rare genetic variants is not known on drug metabolism. The aim of our study is to examine
in a clinical trial the effect of novel predicted loss-of-function (LoF), missense genetic variants
and large deletions that were detected in the Estonian population by analysing the whole
genome sequence data of 2500 participants of the Estonian Biobank (Tasa and Krebs et al,
2018). The effect of the variants was first assessed with bioinformatic tools, incl. Variant Effect
Predictor (VEP, https://www.ensembl.org/info/docs/tools/vep/index.html) and filtered for loss-
of-function and missense variants. For this study, we have also included missense variants that
were selected using a recently published framework for pharmacogenetic variants (Zhou et al,
2018).
In order to determine the effect of the previously uncharacterized genetic variants, we will use
in vivo phenotyping by using previously tested and validated phenotyping probe drugs. This
will allow us to determine the enzyme activities and describe the net effect of all influencing
factors on CYP activity. It has been shown that using phenotyping probe drugs is an accurate
and minimally invasive method for the in vivo assessment of CYP enzyme activities in a single
experiment. Probe drugs can be used in various combinations (Donzelli et al, 2014; Christensen
et al, 2003; Keller et al. 2017), allowing for the in vivo assessment of multiple pathways of drug
metabolism in a single experiment, taking into account genetic, non-genetic and environmental
influencing factors. Probe drugs should predominantly be metabolized by an individual CYP
enzyme, can be safely administered to humans and have no other significant cause of variability,
in addition to the one for which they will be used as a probe.
There are several phenotyping cocktails used in clinical studies, each of these having their
benefits and flaws. The basel phenotyping cocktail (containing caffeine, efavirenz, losartan,
omeprazole, metoprolol, and midazolam as probe drugs for CYP1A2, CYP2B6, CYP2C9,
CYP2C19, CYP2D6 and CYP3A4, respectively) has been well tolerated and has had good
correlations of metabolic ratios with AUC (Area Under The Curve - one of the most important
evaluation metrics for checking any classification model’s performance) ratios of the
corresponding probe drugs and their metabolites (Derungs et al. 2016).
References
1. Kozyra, M., Ingelman-Sundberg, M. & Lauschke, V. M. Rare genetic variants in
cellular transporters, metabolic enzymes, and nuclear receptors can be important
determinants of interindividual differences in drug response. Genet. Med. (2016).
doi:10.1038/gim.2016.33.
2. Wilkinson GR. Drug metabolism and variability among patients in drug response. N
Engl J Med. 2005;352(21):2211–21.
3. Reisberg et al. "Translating genotype data of 44,000 biobank participants into clinical
pharmacogenetic recommendations: challenges and solutions." Genetics in
Medicine 21.6 (2019): 1345.
4. Tasa, et al. "Genetic variation in the Estonian population: pharmacogenomics study of
adverse drug effects using electronic health records." European Journal of Human
Genetics 27.3 (2019): 442.
5
5. Donzelli, et al. The basel cocktail for simultaneous phenotyping of human cytochrome
P450 isoforms in plasma, saliva and dried blood spots. Clin. Pharmacokinet., 2014,
53(3), 271-282.
6. Christensen, et al. "The Karolinska cocktail for phenotyping of five human
cytochrome P450 enzymes." Clinical Pharmacology & Therapeutics 73.6 (2003):
517-528.
7. Keller, et al. "In vivo phenotyping methods: cytochrome P450 probes with emphasis
on the cocktail approach." Current pharmaceutical design 23.14 (2017): 2035-2049.
8. Derungs, et al. "Effects of cytochrome P450 inhibition and induction on the
phenotyping metrics of the basel cocktail: a randomized crossover study." Clinical
pharmacokinetics 55.1 (2016).
9. Zhou, et al. “Computational Methods for the Pharmacogenetic Interpretation of Next
Generation Sequencing Data.” Front Pharmacol 4;9:1437. (2018).
5. DETAILED OVERVIEW OF THE STUDY
The aim of the study is to assess if the newly described mutations and deletions in cytochrome
2D6 and 2C19 change the metabolizing activity of these enzymes.
A prospective study will be performed at Tartu University Clinic’s Hematology and Oncology
Clinic and North Estonia Medical Centre Foundation’s Oncology and Haematology Clinic.
The subjects will be selected and re-contacted based on the availability of whole genome
sequencing or genotype data, the health status of the subjects and their suitability for such a
study, according to standard ethical procedures regarding clinical studies involving drugs.
Based on initial review of the existing whole genome sequencing data (n=2500) and genotype
data (n=50,000) of the Estonian Biobank (EstBB) participants, we have detected the following
number of individuals with previously uncharacterized genetic variants in the CYP450 genes:
Table 1. Current1 number of individuals with rare genetic variants in the CYP450 genes
Allele 1 Allele 2 N Nmax Coordinate
CYP2C19_del+CYP2D6_del CYP2C19_Normal+CYP2D6_LoF 3 3
CYP2C19_del+CYP2D6_del CYP2C19_Normal+CYP2D6_Normal 3 3
CYP2C19_del+CYP2D6_del CYP2C19_Increased+CYP2D6_LoF 2 2
CYP2C19_del+CYP2D6_del CYP2C19_LoF+CYP2D6_Normal 2 2
CYP2C19_del+CYP2D6_del CYP2C19_Increased+CYP2D6_Normal 1 1
CYP2C19_del+CYP2D6_del CYP2C19_LoF+CYP2D6_LoF 1 1
CYP2C19_del CYP2C19_del 1 1
CYP2C19_del CYP2C19_Increased 162 10
CYP2C19_del CYP2C19_LoF 54 10
CYP2C19_del CYP2C19_Normal 324 10
CYP2C19_Novel_missense 1 1 chr10:96535248
CYP2C19_Novel_missense 1 1 chr10:96580257
CYP2C19_Novel_missense 4 4 chr10:96540331
1
The final number of individuals carrying different identified deletions or mutations may increase before the
study, as we analyze additional genotype data of 100,000 new biobank participants. We will still limit the
number of individuals with identical mutations/deletions that will be invited to participate in the study to max 10.
6
CYP2C19_Novel_missense 1 1 chr10:96541688
CYP2C19_Novel_missense 1 1 chr10:96580323
CYP2C19_Novel_missense 1 1 chr10:96602648
CYP2C19_Novel_missense 1 1 chr10:96535156
CYP2C19_Novel_missense 1 1 chr10:96602634
CYP2D6_Novel_LoF CYP2D6_normal 14 10 chr22:42524820
CYP2D6_Novel_LoF CYP2D6_LoF 12 10 chr22:42524820
CYP2D6_Novel_LoF 6 10 22:42522982
CYP2D6_Novel_LoF CYP2D6_LoF 1 1 chr22:42523847
CYP2D6_Novel_LoF 1 1 chr22:42522916
CYP2D6_Novel_missense 1 1 chr22:42523889
CYP2D6_Novel_missense 1 1 chr22:42523916
CYP2D6_Novel_missense 2 2 chr22:42523928
CYP2D6_missense? * 109 10 chr22:42522613
CYP2D6_missense? * 86 10 chr22:42523943
CYP2D6_missense? * 45 10 chr22:42526694
CYP2D6_missense? * 33 10 chr22:42524814
CYP2D6_missense? * 30 10 chr22:42526763
CYP2D6_missense? * 23 10 chr22:42525811
CYP2D6_missense? * 23 10 chr22:42525821
CYP2D6_missense? 10 10 chr22:42524947
CYP2D6_missense? 6 10 chr22:42523558
CYP2D6_missense? 4 4 chr22:42523613
CYP2D6_missense? 3 3 chr22:42523567
CYP2D6_missense? 3 3 chr22:42524310
CYP2D6_missense? 2 2 chr22:42523897
CYP2D6_missense? 2 2 chr22:42525115
CYP2D6_missense? 1 1 chr22:42522601
CYP2D6_missense? 1 1 chr22:42523844
CYP2D6_missense? 1 1 chr22:42526712
Total 984 197
*) depending on the function of the 2nd allele (normal, LoF, increased) we will invite 10 individuals from
each group to participate, i.e. Possibly multiply nr of individuals to recruit with 3.
Abbreviations: N = number of carriers, Nmax = number that will be recruited, del = deletion, LoF = Loss of
Function, Increased = Increased function, Normal = Normal function (wild type), missense = amino acid
change, missense? = amino acid change with unknown function
Coordinate = chromosome and position according to human genome build hg37. The deletion of CYP2C19
spans exons 1-5 and the deletion of CYP2D6 the entire gene.
Table 1 is shared to illustrate the complexity of the different mutations and deletions selected
for the study and the final number of individuals in each category may still change after analysis
of new genotype data from EstBB, but the principle will remain the same. We will not invite
hundreds of individuals with the same genetic profile, each novel allele will be characterized
by a subset of the healthiest individuals that best match the inclusion criteria of the study.
7
6. STUDY TIMELINES
Study start date: 03.2020
Study completion date: 02.2025
7. DESCRIPTION OF THE STUDY PARTICIPANTS AND THE METHOD OF
RECRUITMENT
Study participants will be selected from the EstBB participants whose whole genome has been
sequenced (n=2500) or genotyped (n=150,000) and found to carry deletions or mutations in
CYP2C19 and/or CYP2D6. The participants have joined EstBB voluntarily and signed an
informed consent. They have been informed that the research done at the EstBB is continuous
and not confined to presently available technology and that their pseudonymised data may be
used for further research
(https://www.riigiteataja.ee/aktilisa/1170/4201/9016/SOM_11042019_m39lisa.pdf).
Currently, 984 EstBB participants have been selected selected for the study based on their
genotype (please see Table 1- list of rare CYP enzyme variants). After the review of recently
generated genotype data for additional biobank participants, we estimate that this number may
increase to 1000 that can be invited to participate in the study. Finally, we aim to enrol up to
200 ± 50 participants for the clinical study. The genotypes of the participants represent different
genetic variants described in Table 1.
Based on the genetic profiles of the EstBB patients listed in the Table 1 above, the composition
of the basel cocktail has been reduced to 2 components (omeprazole and metoprolol) to cover
the most important and common drug metabolizing CYP enzymes (CYP2D6 and CYP2C19).
We will consider separate pharmacokinetic studies of novel missense mutations (n=2) and
deletion (n=1) in CYP2C9 and missense mutations (n=2) in CYP3A4 with separate substrates
and matched controls, if we are able to identify more mutation carriers based on genotype data
of the EstBB participants.
It is planned to describe the statistical pharmacokinetic (PK) parameters on a case-by-case
basis (individuals with different mutations vs wildtype) and the sample size estimate is
therefore not applicable.
Inclusion criteria:
1. All biobank participants (> 18 years, no upper limit of age) who have (according to
performed genotyping analysis) previously not described/studied mutations or
deletions in the metabolizing enzymes (CYP2D6 and CYP2C19)
2. Able to understand the nature of the study and content and meaning of consent.
Exclusion criteria:
1. Clinically relevant abnormality of renal or liver function or anemia identified at the
laboratory screening
2. Pregnancy or lactation
3. History or clinical evidence of alcoholism or drug abuse within the last year period
prior to screening
8
4. Excessive alcohol consumption within 2 days before the first drug administration
5. Previous treatment with any medicines interfering with the measurement of
phenotyping probe drugs
6. Any of the probe drugs contraindicated or had a history of allergy to any study
medication
7. Patient's weight 50% more or less than their ideal body weight (for assessment the on-
line calculator will be used e.g.https://www.calculator.net/ideal-weight-
calculator.html)
Informed consent will be taken from the study participants before the study-related procedures.
Informed consent form allows to:
- Take blood samples for the PK analysis
- Administer probe drugs
- Assess relevant electronic medical records to obtain drug-related information and for
checking presence of contraindications from the hospital information system
The study procedures will be described thoroughly during the first contact by the phone.
The informed consent will be sought by the responsible study team member who is
documented at the delegation log.
There will be 2 copies of informed consent sheet:
- For the study participant
- For the study record
8. REQUEST FOR DEPSEUDONYMISATION
We request the Estonian Committee on Bioethics and Human Research for an approval to
depseudonymise the personal data (name, ID code, e-mail, regular post address, phone number)
of up to 1000 EstBB participants who have the whole genome sequence or genotype data in the
EstBB database. A higher number of depseudonymised participants in comparison with
participants who will be recruited to the study (200±50) is required as not all subjects meet the
inclusion criteria and not all subjects agree to participate in the study. Depseudonymised data
is necessary for contacting participants.
Legal bases for depseudonymisation and contacting gene donors
It is permitted to depseudonymise data in order to identify a gene donor on the proposal of the
controller of the EstBB and with the consent of the Estonian Committee on Bioethics and
Human Research, to contact the gene donor and to renew, supplement or verify a description
of his or her state of health with his or her written consent (HGRA §24, section (2), 4).
Procedure of depseudonymisation and contacting gene donors
When performing depseudonymisation, the EstBB shall comply with all requirements of the
Human Gene Research Act.
9
● The data will be released only after the approval by the Estonian Committee on
Bioethics and Human Research.
● The specific persons who perform depseudonymisation shall be appointed by the
director of Institute of Genomics (HGRA § 22, section (3)). There are fixed procedures
in the EstBB to follow when contacting the gene donors.
9. DESCRIPTION OF THE STUDY-RELATED PROCEDURES
9.1 Study visits
1. Contacting participants (please see Table 2)
Selected biobank subjects (up to 1000 people) will be contacted and invited to participate in the
study first by e-mail or regular post if email address is not available (please see Invitation letter
Appendix 2). In case of nonresponse one reminder will be sent after 1 week, and a phone call
will be made 1 week after the reminder. The initial contact will only be made by personnel at
the EstBB who are specifically authorized by the director of the Institute of Genomics to handle
personal data.
2. All participants, who give positive response to the first invitation are scheduled for a phone
call with the authorized personnel at the EstBB in the course of which
introduction of the study and
pre-screening interview takes place
Pre-screening interview includes mapping of inclusion criteria.
Suitable subjects are offered to participate at the study and invited to the study centre (Tartu
University Hospital or North Estonia Medical Centre) for a pre-scheduled pre-dosing visit.
3. Pre-dosing visit at the hospitals:
Duration of the visit is approximately 1 hour (time spent at the hospital). During this visit
following procedures will be performed:
verify the inclusion criteria
sign informed consent
collect medical history (previous and current medical conditions, surgical
history, prior and concomitant medications, allergies) and baseline characteristics
perform local laboratory tests
o haematological parameters: WBC, haemoglobin, haematocrit, platelets
o renal function measurements: urea, creatinine
o other tests: Na, K, Ca, glucose, transaminases
perform clinical examination (weight, height, blood pressure, heart rate)
At the pre-dosing visit patient's eligibility for the study will be ascertained, including possible
contraindications to the probe drugs. Relevant medical history will be documented to the
electronic medical record. If necessary, the participant's previous medical history is reviewed.
Only the past electronic medical records will be examined that are relevant in the context of the
10
study (information on diagnoses, medications used and allergies) and with the consent of the
participant.
Eligible study subjects will be invited to receive a dose of the probe drugs at a separate visit
(Dosing and PK sampling visit) at the study centre (Tartu University Hospital (TUH) or North
Estonia Medical Centre (NEMC)).
4. Probe drugs administration and PK sampling visit
Duration of the visit is up to 10 hours (time spent in hospital). During this visit following
procedures will be performed:
● recheck eligibility according to the study inclusion and exclusion criteria
● verify the inclusion criteria
● perform clinical examination (evaluation of core body temperature, weight, height,
blood pressure, heart rate)
● pregnancy test from urine (for female participants until menopause)
● recording the concomitant medications (all OTC and prescription medications taken 24
hours before study dose)
The following contraindications exist for using phenotyping probe drugs and participants with
these conditions shall be excluded:
o known hypersensitivity for the study medicines
o severe hepatic impairment (ChildPugh Class C)
o uncontrolled heart failure (metoprolol)
o bradycardia (metoprolol)
o sick-sinus syndrome (metoprolol)
o Prinzmetal's angina (metoprolol)
o untreated phaeochromocytoma (metoprolol)
o metabolic acidosis (metoprolol)
o severe peripheral arterial disease (metoprolol)
o history of bronchospasm and asthma (metoprolol)
o hypotension (metoprolol)
o diabetes if associated with frequent episodes of hypoglycaemia (metoprolol)
o chronic obstructive pulmonary disease (metoprolol)
o renal or hepatic failure (metoprolol)
o therapy resistant hypokalaemia and hyponatraemia, hypercalcaemia,
symptomatic hyperuricaemia, anuria (metoprolol)
● single dose administration of probe drugs:
o 20 mg omeprazole (full 20mg capsule)
o 12,5 mg metoprolol (12,5 mg of metoprolol as an active substance which dose
is measured and packed according to the standard procedures (SOP) of the
11
hospital pharmacy of Tartu University Hospital). The reason to use
extemporaneous product is caused by the fact that no marketed product of
metoprolol is available at such a low dose.
● proceed to PK procedures
o 5 ml blood, 10 timepoints (altogether 50ml) will be taken from the inserted
venous cannula
● observation and monitoring of the patient during PK sampling period (8 hours)
● recording of the vital parameters (blood pressure, heart rate) and adverse events (ADR)
Participants will be asked not to eat in the morning before the study visit when probe drugs are
administered in order to assess the PK profile at fasting state.
After probe drug administration and first PK analyses, a breakfast will be served at the study
centres. The participants will be served a hot lunch. If requested, the subjects will receive one
additional light meal.
Administration of participant’s regular medicines in the morning before administration of probe
drugs will be discussed and agreed during the pre-dose visit at the study centres. Specific
instructions will be given to every participant.
5. Follow-up phone call 1 week after the phenotyping probe drugs administration to document
possible ADRs that have occurred since Day1. The call will be made a week after the study
medication is given as side effects are unlikely to occur later. The subject has the opportunity
to contact investigators by telephone throughout the study and to inform the investigator of any
adverse drug reaction.
Table 2. Schedule of study assessment
Contacting Phone Pre-dose Dosing and PK Follow-up phone call
contact, visit sampling visit
pre-
screening
interview
Invitation letter, e-mail (phone call) x
Inclusion criteria x x x
Medical history and patient x
characteristics
Informed consent x
Recheck eligibility x
Clinical examination x
x Immediately before
the Study Dose
Haematological parameters x
Na, K, Ca, glucose, transaminases x
Renal function
(urea, creatinine) x
Urine pregnancy test for female
x
participants
12
Study medicines administration x
PK Sampling x
Concomitant medications x
documentation
Adverse event reporting x x
9.2 Pharmacokinetic analysis
Blood samples for pharmacokinetic analysis of probe drugs and metabolites will be collected
before dosing and 0.25, 0.50, 0.75, 1, 2, 3, 4, 6 and 8 h after drug administration from an
antecubital vein into ethylenediaminetetraacetic acid tubes. A cannula is used for blood
sampling. The tubes will be centrifuged (1500g for 10 min at 4 °C) and plasma will be stored
at −80 °C until analysis.
Sampling schedule is based on the results of a previous phenotyping cocktail study (Donzelli
et al, 2014) that included slow metabolizers and showed that a shorter (8h) blood sampling
period was sufficient to describe the pharmacokinetic profile of the studied drugs. In addition,
the use of a shorter study period is also in the interest of subjects who do not have to spend the
night in the hospital.
For the plasma concentration measurements of probe drugs and metabolites (omeprazole,
metoprolol, hydroxymetoprolol, metoprolol, metoprolol-d7, omeprazole, 5-
hydroxyomeprazole, omeprazole-d3) high performance liquid chromatography (HPLC) will be
used at the Karolinska institute. The frozen plasma samples of all study participants will be
shipped on dry ice to the Pharmacological laboratory, at the Department of Clinical
Pharmacology, Karolinska University Hospital, Sweden (Collaborators listed in Section 2.2).
For issuing of plasma samples to Sweden a new application will be submitted to the Estonian
Committee on Bioethics and Human Research and thereafter to the Senate of the University of
Tartu.
Pharmacokinetic endpoints: A noncompartmental model of disposition of probe drugs and its
main metabolites (CL, Vd, AUC, Cmax, Tmax).
9.3 Patient health data
Volunteers will be screened and assessed to be eligible for the study by physical examination,
medical history, and laboratory evaluations.
The following information will be collected and recorded to the electronic case report form
(CRF) (Redcap): Age, gender, weight, height, blood pressure, heart rate, medical anamnesis,
known allergies to medicines, results of the physical examination, medical history, and
laboratory evaluations.
Side effects will be documented and reported to the State Agency of Medicines.
10. ANALYSIS OF THE ETHICAL ASPECTS RELATED TO THE STUDY
10.1 Informed consent
13
Informed consent will be obtained from the participant. This will allow the research team to
commence:
● Detailed monitoring of the patient
● Collection of samples at specific times
● Access to the patient’s medical notes or clinical data
The researchers will explain the risks of the study (probe drug administration and blood
sampling). The information will also be available on the information sheet.
The information sheet/informed consent will be provided and used to structure a discussion.
Patients will be allowed ample time to make their decision. They will be asked how long they
would like to consider the information and what time is convenient for them when the
researcher may return to answer any questions they may have.
The informed consent process will be delivered by the team member and listed on the delegation
log.
Subjects can withdraw consent at any time without prejudice. The investigator can withdraw a
subject from the study if, in his or her clinical judgment, it was in the best interest of the subject
or if the subject could not comply with elements of the protocol or what is necessary for the
scientific integrity of the study. If the investigator withdraws a subject from the study, the
investigators will explain the reason for withdrawing the participant. Subjects enrolled in the
study who withdraw after the recruitment or who the researchers decided for any reason should
not continue in the study (“dropouts”) will be replaced.
10.2 Ethical aspects related to the study procedures
The study will be conducted in accordance with the International Conference on
Harmonization (ICH) Guideline for Good Clinical Practice (GCP) and the Helsinki
Declaration.
a) Individual autonomy respect principle
All of the participants have joined EstBB voluntarily. Regulated by Human Genes Research
Act (HGRA) § 9 – Voluntary nature of gene donation
(https://www.riigiteataja.ee/akt/72581?leiaKehtiv). Nobody will be discriminated against upon
joining or for the fact of being a participant. (HGRA chapter 5 – prohibition of discrimination).
People’s rights with limited disability are regulated by HGRA § 13 – Persons with restricted
active legal capacity and persons without capacity to exercise will. The participant can
withdraw consent at any time (HGRA § 12 – Consent to becoming a gene donor).
Participation in this study is voluntary. The gene donor shall be provided with sufficient
information on the nature of the trial to assist him or her in making an informed decision. The
subject may at any time opt-out or discontinue the trial without justification.
The study data of the subject who discontinued the study shall be kept for 5 years, separately
from the data of the other subjects and shall not be included in the analysis. If a participant asks
14
the PI to delete their data, we will give them 2 options, a) delete data + destroy sample, or b)
delete the code key. The requested data will be deleted and this action will be documented.
b) Non-harming principle
The potential risks associated with this study are related to the phenotyping drug cocktail
administration and with taking blood samples. To minimize the risk of adverse effects of the
phenotyping cocktail medicines, healthy adult volunteers will be screened. The probe drugs
are administered at low doses and study participants will be monitored after the administration
at the hospital setting.
Although the magnitude of the benefits of the study cannot be known until the results of the
study are available, the risks of the study have been carefully considered. As a result of the
study, it is possible to describe the effect of previously unknown gene variants on the rate of
drug metabolism. The study uses drugs that are commonly used in clinical practice, for which
the risks and contraindications are well known, and the doses are as low as possible. The drugs
are administered in a hospital setting and are monitored by study physicians throughout the
study. Experienced nurses perform all examination procedures.
Taking blood samples can (rarely) cause pain, bleeding, bruises, or local infection at the site.
Moreover, some patients may experience vertigo or malaise during the procedure. To minimize
the risks and discomfort of the patient, trained and experienced study nurses are taking the
venous blood samples.
According to the protocol, all participating doctors and nurses will be obliged to report any
study related serious adverse effects to the State Agency of Medicines and Ethics Committee.
c) The principles of justice and well-meaning
The probe drug experiment has a potential value for the participants in the study group and the
Estonian population in general, as it would clarify the effect of the mutations detected in their
genes encoding CYP enzyme, and thereby help to adjust future treatment with medicines which
are metabolised via the respective CYP enzymes and further estimate the participants’ personal
metabolic activity for the studied drug metabolizing enzymes while taking into account the
patient’s lifestyle and environmental influences in addition to their personal genetic
background.
By the request the participants (please see consent form) results of the pharmacokinetic analysis
will be given in the form of a personal drug metabolism profile and genetic report. This
feedback will be prepared and delivered separately as “Feedback to the gene donors”
(“Tagasiside geenidoonoritele”), Approval of the Research Ethics Committee of the University
of Tartu 271/T-2, 19.06.2017).
The results are expected to benefit all participants of the EstBB, other Estonian residents and
other populations as well.
15
The current proposal is important because it helps to promote the advancement of science and
raises the importance of the EstBB. The compiled statistics of this work will be shared with a
wider audience through the publication of scientific papers in international peer-reviewed
journals to further the advances in scientific fields.
Data confidentiality
During the interaction with the study participants their personal data will be handled by
authorized personnel at the biobank or participating clinicians only. All collected and handled
data will remain confidential. Investigators who are mandated to access participant past
electronic medical records are documented at the study delegation log, are also employees of
the study centres (NEMC or TUH) and have access to electronic health systems of the hospitals.
Once all data has been collected, it will be submitted to the EstBB where it will only be used in
pseudonymized form.
All documents related to the trial will be archived for 15 years after the end of the trial by the
investigator sites and the sponsor. Investigators will ensure that records sources, including
medical charts, are available during this trial storage period. No trial document shall be
destroyed by the investigator sites after the deadline without prior written consent of the sponsor
or her representative. All generated individual level data will be submitted to the EstBB for
coding and incorporation into the biobank database at the end of the study.
Auditing / monitoring of the study
Regulatory authorities may conduct a regulatory inspection of this study. Such inspections can
occur at any time during or after completion of the study. If an audit or inspection occurs, the
investigator and institution agree to allow the inspector direct access to all relevant documents
and to allocate his/her time and the time of his/her staff to the inspector to discuss findings and
any relevant issues.
10.3 Monitoring of the patients
Subjects will be on study for up to 1 week after administration of study medicines. All of the
possible adverse effects will be documented.
11. ANALYSIS OF DATA PROTECTION ASPECTS OF THE STUDY
11.1 Issuing pseudonymised data
Legal basis for issuing data
Descriptions of DNA are issued from the Gene Bank only in pseudonymised form, as a set of
data and on the condition that data concerning at least five gene donors are issued at a time
(HGRA § 22, section (4)).
16
Procedure for issuing data
When issuing data, the biobank shall comply with all requirements of the Human Gene
Research Act.
● The prerequisite for issuing data is the approval by the Estonian Committee on Bioethics
and Human Research.
● The Director of the Institute of Genomics of the University of Tartu will appoint the
responsible people for the procedures of releasing the data and give the order to release
the data.
● The contract for the data release will be signed.
● The data transfer protocol will be signed by the parties.
Genetic data is transmitted to the data analysts using the sapu.cs.ut.ee (https://sapu.cs.ut.ee)
virtual environment.
Obligations of the principal investigator
The director of the institute responsible for the research will guarantee the confidentiality of the
data and follow all of the data protection regulations according to the signed contract and
general data protection regulations. The use of the data is limited to the project’s goals and
scope. The distribution of data to third parties is prohibited without the written consent of the
EstBB.
It is the obligation of the principal investigator to send the data resulting from the analysis
conducted during the research to the EstBB. The research results enrich the database of the
EstBB.
11.2 Storage of the paper forms containing personal data of participants
The consent forms will be stored at the North Estonia Medical Centre in the investigators room
in a locked drawer. At Tartu University Hospital the consent forms will be stored in the special
locked clinical research room, which is located on the premises of the hospital pharmacy. After
completion of the study the consent forms will be transferred to the EstBB and stored in similar
conditions and during the same time period as it is stated by the law for the consents of the gene
donors (HGRA, §12, section (6)).
11.3 Storage of data collected during study
The EstBB senior data encoder will depseudonymise the personal data of participants that is
necessary for contacting the study subjects. The initial contact and invitation to participate in
the study will only be done by the EstBB staff authorized to handle personal data. Once the
individuals have agreed to participate in the study, their first visit will be scheduled by the
EstBB staff. At this point, the personal data of the participants will be visible for the
investigators at the study centre. During the first visit at the study centres (hospital) participants
personal information (name, id code) will be used for documenting the study visit to the
17
electronic medical systems and for ordering study related medical analyses (blood tests) from
the local laboratories. For the study participants unique study codes will be designated and these
codes will be used for the further study related procedures. Same codes will be documented on
the consent form, used in the screening logs, and on each blood sample taken for PK analysis.
Plasma samples for the PK analyses will be sent to the laboratory at Karolinska Institute marked
with the same unique codes and no personal information (ID codes, names) will be sent out
from the study centres (TUC, NEMC). The samples will be analysed and the results will be sent
to the EstBB using the same codes. All study records, measurements, sample results will be
submitted to the EstBB and entered into the biobank database. The final results will then be
coded for research use and made accessible through the EstBB database for the researchers of
the study.
11.4 Storage of the blood samples
PK samples are stored after centrifugation at the study centres at −80 °C until shipment. The
samples are marked with the subject code and nr of the sample.
12. INFORMATION ABOUT THE SIMULTANEOUS ASSESSMENTS OR
APPROVALS OF THIS PROJECT
No other approvals will be sought.
13. Appendices
13.1 Informed consent forms
Informed consent form (Estonian)
Informed consent form (Russian)
13.2 Invitation letter in Estonian and in Russian
13.3 CVs of the investigators (included in separate files)
13.3 Liability insurance policy offer
18
Alar Irs
ORCID 0000-0002-2244-9699
E-post
[email protected]
Töökohad ja ametid
01.01.2018–... SA Tartu Ülikooli Kliinikum, Tartu Ülikooli Kliinikumi
radioloogiakliinik, arst-õppejõud kardioloogia erialal (0,50)
2017–... SA Tartu Ülikooli Kliinikum, Tartu Ülikooli Kliinikumi
Südamekliinik, arst-õppejõud kardioloogia erialal (0,50)
01.01.2012–... Ravimiamet, meditsiininõunik
01.02.2009– Tartu Ülikool, Kliinilise farmakoloogia lektor (0,25)
31.12.2017
03.08.2004– Newcastle-i Ülikool, Austraalia, kliinilise farmakoloogia
03.11.2004 külalisteadur (1,00)
2004–31.01.2009 Tartu Ülikool, kliinilise farmakoloogia assistent (0,25)
01.01.2003– Ravimiamet, peadirektori asetäitja (1,00)
31.12.2011
01.01.2001– Ravimiamet, registreerimisosakonna juhataja
31.12.2003
01.01.1998– Ravimiamet, kliiniliste ravimiuuringute spetsialist
31.12.2001
01.09.1997– Tartu Ülikool, lepinguline õppetöö kliinilise farmakoloogia alal
31.12.2003 (0,50)
Teadusorganisatsiooniline ja -administratiivne tegevus
2018−... Eesti Kardioloogide Seltsi juhatuse liige
2017−... Eesti Haigekassa ravimikomisjoni esimees
2017−... Riikliku Siirdemeditsiini ja Kliiniliste Teadusuuringute Keskuse
kliiniliste uuringute keskuse juhtkomitee liige
2012−... Eesti ravijuhendite nõukoja liige
2010−... Euroopa Ravimiameti kardiovaskulaartöörühma liige (2017
asejuhataja)
2009−... Ravimiameti ravimite müügilubade komisjoni ase-esimees
2004−... Euroopa Ravimiameti inimravimite komitee liige
2013−2016 TÜ arstiteaduse programminõukogu liige
2013−2017 Programmi „Tervishoiuteaduste võimekuse edendamine“ (TerVE)
tervisetehnoloogiate hindamise (TTH) nõukogu, liige
2011−2016 Ravimiinfo Assotsiatsiooni Euroopa nõukoja liige
2010−2013 Eesti Farmakoloogia Selts, juhatuse liige (president)
2009−2017 Euroopa kliilise farmakoloogia ja teraapia assotsiatsiooni hariduse
alakomitee, liige
2008−2013 Maailma Terviseorganisatsiooni esmavajalike ravimite komitee
liige
2008−2013 Euroopa kliilise farmakoloogia ja teraapia assotsiatsiooni nõukogu
liige
2004−2017 Sotsiaalministeeriumi ravimikomisjoni liige
Teadustöö põhisuunad
ETIS KLASSIFIKAATOR: 3. Terviseuuringud; 3.7. Kliiniline meditsiin; CERCS
KLASSIFIKAATOR: B530 Südame-veresoonkonna haigused ; TÄPSUSTUS:
Aterosklerootilise kardiovaskulaarhaiguse ennetus ja ravi
Jooksvad projektid
• (RITA1/01-42-01) "Personaalmeditsiini kliinilised juhtprojektid rinnavähi ja südame-
veresoonkonna haiguste täppisennetuses (1.01.2018−31.12.2020)", Peeter Padrik, SA
Tartu Ülikooli Kliinikum.
Publikatsioonid
2019
Alver, Maris; Palover, Marili; Saar, Aet; Läll, Kristi; Zekavat, Seyedeh Maryam; Tõnisson, Neeme;
Leitsalu, Liis; Reigo, Anu; Nikopensius, Tiit; Ainla, Tiia; Kals, Mart; Mägi, Reedik; Gabriel, Stacey B;
Eha, Jaan; Lander, Eric S; Irs, Alar; Philippakis, Anthony; Marandi, Toomas; Natarajan, Pradeep;
Metspalu, Andres ... Esko, Tõnu (2019). Recall by genotype and cascade screening for familial
hypercholesterolemia in a population-based biobank from Estonia. Genetics in medicine,
1−8.10.1038/s41436-018-0311-2.
Freemantle, Nick; Irs, Alar; De Paulis, Ruggero; Pagano, Domenico; Falk, Volkmar; Beyersdorf,
Friedhelm (2019). Transcatheter versus surgical aortic valve replacement: what does the latest evidence
tell us? European Journal of Cardio-thoracic Surgery, 56 (1), 7−9.10.1093/ejcts/ezz163.
2016
Hatswell AJ, Baio G, Berlin JA, Irs A, Freemantle N. (2016). Regulatory approval of pharmaceuticals
without a randomised controlled study: analysis of EMA and FDA approvals 1999-2014. BMJ Open, 2016
(6, 6), e011666.10.1136/bmjopen-2016-011666.
Bueno H, de Graeff P, Richard-Lordereau I, Emmerich J, Fox KA, Friedman CP, Gaudin C, El-Gazayerly
A, Goldman S, Hemmrich M, Henderson RA, Himmelmann A, Irs A, Jackson N, James SK, Katus HA,
Laslop A, Laws I, Mehran R, Ong S, Prasad K, Roffi M, Rosano GM, Rose M, Sinnaeve PR, Stough WG,
Thygesen K, Van de Werf F, Varin C, Verheugt FW, de Los Angeles Alonso García M. (2016). Report of
the European Society of Cardiology Cardiovascular Round Table regulatory workshop update of the
evaluation of new agents for the treatment of acute coronary syndrome: Executive summary. European
Heart Journal, 2016 (Jun 29, Eur Heart J Acute Cardiovasc Care), pii:
2048872616649859.10.1177/2048872616649859 [ilmumas].
Sonn, K.; Irs, A.; Laius, O. (2016). Clinical pharmacology and trends in use of sedative-hypnotic and
anxiolytic medications in Estonia. 25. HOBOKEN: Wiley-blackwell, 188−188. (25).
2013
Hoebert, J; Irs, A; Mantel-Teeuwisse, A; Leufkens, H. (2013). Future of the European Union regulatory
network in the context of the uptake of new medicines. British Journal of Clinical Pharmacology, 76 (1),
1−6.10.1111/j.1365-2125.2012.04476.x.
Lass, J.; Odlind, V.; Irs, A.; Lutsar, I. (2013). Antibiotic prescription preferences in paediatric outpatient
setting in Estonia and Sweden. SpringerPlus, 2, 124−x.10.1186/2193-1801-2-124.
Pintson, Madli; Irs, Alar (2013). Involvement of Residents in the National Guideline Development Process
in Estonia. 10th EACPT Summer School, Edinburgh, UK, 4-6.07.2013.
2012
Kalda, Ruth; Viigimaa, Margus; Irs, Alar; Meren, Mari; Uuetoa, Tiina; Luman, Merike; Muda, Piibe;
Oona, Marje; Jaanson, Eret; Martinson, Katrin; Põldema, Ingrid; Ridaste, Kadri; Palm, Kairit; Habicht,
Triin; Teeäär, Tuuli; Saluse, Janek; Kropotuhhina, Irina; Heidmets, Lenne-Triin; Laidmäe, Erki; Esnar,
Kersti (2012). Täiskasvanute kõrgvererõhktõve käsitlus esmatasandil: Eesti ravijuhend. Eesti Haigekassa,
Tartu Ülikool 2012.
2011
Lass, J.; Irs, A.; Pisarev, H.; Leinemann, T.; Lutsar, I. (2011). Off label use of prescription medicines in
children in outpatient setting in Estonia is common. Pharmacoepidemiology and Drug Safety, 20 (5),
474−481.10.1002/pds.2125.
Raudsepp, D.; Lass, J.; Saar, M.; Kuld, L.; Irs, A. (2011). Ravimite koos- või kõrvaltoimed erakorralise
meditsiini osakonda pöördumise põhjusena - prospektiivne vaatlusuuring. Eesti Arst, 3, 122−128.
2010
Irs, A.; Salupere, R.; Sinisalu, V. (2010). Mittesteroidsete põletikuvastaste ravimite ohutu kasutamine.
Eesti Arst, 89 (6), 417−422.
Kirss, Anne; Maipuu, Lea; Eelmäe, Imbi; Metsvaht, Tuuli; Sirotkina, Meeli; Irs, Alar (2010).
Angiotensiini konverteeriva ensüümi inhibiitori ja angiotensiini II retseptori blokaatori kasutamise ohud
raseduse ajal: haigusjuhu kirjeldus ja kirjanduse ülevaade. Eesti Arst, 89, 502−509.
Lass, J.; Iljuhhina, J.; Laius, O.; Pisarev, H.; Irs, A. (2010). Retseptiravimite raseduseaegne kasutamine
Eestis. Eesti Arst: TÜ Arstiteaduskonna teaduskonverents, 7-8.okt. 2010.
2009
Laius, O.; Irs, A.; Kiivet, R. -A. (2009). FROM USSR TO EU - LONG-TERM TRENDS IN ESTONIAN
DRUG UTILIZATION. 105. MALDEN: Wiley-blackwell Publishing, Inc, 96−96. (105).
Lass, J.; Laius, O.; Leinemann, T.; Pisarev, H.; Irs, A.; Lutsar, I. (2009). Availability of paediatric
information in Summaries of Product Characteristics of drugs prescribed to children in Estonia. 12th
Congress of European Society for Developmental Perinatal & Paediatric Pharmacology, Chamonix,
Prantsusmaa, 17-20.06.2009.
Lass, J.; Laius, O.; Pisarev, H.; Irs, A.; Lutsar, I. (2009). Substantial proportion of ambulatory prescribing
for children is off-label in Estonia. 9th Congress of the European Association for Clinical Pharmacology
and Therapeutics, Edinburgh, Šotimaa, 12-15.07.2009.
2008
Freemantle, N.; Irs, A. (2008). Observational evidence for determining drug safety. British Medical
Journal, 336 (7645), 627−628.10.1136/bmj.39491.493252.80.
Zarkovski, Aleksander; Kalda, Anti; Gavronski, Maia; Hartikainen, Sirpa; Irs, Alar (2008). Kliinik 2008 :
ravimitest tulenevad ohud [Videosalvestis]. Kliinik 2008, Tartu Ülikooli Kliinikumi õenduskonverents;
Tartu; 4.-6. veebruar 2008. Tartu: TÜ IT Multimeedia talitus,. (TÜ filmiarhiiv).
2006
Johnson, K.R.; Ringland, C.; Stokes, B.J.; Anthony, D.M.; Freemantle, N.; Irs, A.; Hill, S.R.; Ward, R.L.
(2006). Response rate or time to progression as predictors of survival in trials of metastatic colorectal
cancer or non-small-cell lung cancer: a meta-analysis. The Lancet Oncology, 7 (9), 741−746.
Raal, A.; Fischer, K.; Irs, A. (2006). Determination of drug information needs of health care professionals
in Estonia. Medicina (Kaunas), 42 (12), 1030−1034.
2005
Ristimäe, T.; Irs, A.; Teesalu, R. (2005). Arteriaalne hüpertensioon kui südame-veresoonkonnahaiguste
oluline riskitegur. Eesti Arst, 4, 277−282.
Jesse, M.; Habicht, J.; Aaviksoo, A.; Koppel, A.; Irs, A.; Thomson, S. (2005). Tervisesüsteem muutustes:
Eesti. Tallinn: World Health Organization.
2004
Jesse, M.; Habicht, J.; Aaviksoo, A.; Koppel, A.; Irs, A.; Thomson, S. (2004). Health care systems in
transition: Estonia. Copenhagen: World Health Organization.
2001
Rootslane, L.; Irs, A.; Kiivet, R. (2001). ATC/DDD methodology: a country perspective. WHO Drug
Information, 15 (1), 26−30.
Irs, A.; Rootslane, Ly (2001). The use of antihypertensive drugs in in Estonia compared to the Nordic
countries. Pharmacology & Toxicology, 89, suppl.. 50.
1999
Pahkla, R.; Irs, A.; Oselin, K.; Rootslane, L. (1999). Digoxin: use pattern in Estonia and bioavailability of
the local market leader. Journal of Clinical Pharmacy and Therapeutics, 24 (5), 375−380.
Kask, A.; Pahkla, R.; Irs, A.; Rago, L.; Wikberg, JES.; Schioth, HB. (1999). Long-term administration of
MC4 receptor antagonist HS014 causes hyperphagia and obesity in rats. Neuroreport, 10 (4), 707−711.
2019‐11‐25
Curriculum vitae
Anton Pohanka
Karolinska University Hospital
Department of Clinical Pharmacology
S‐141 86 Stockholm
Sweden
Telephone: +46‐8‐58581195
E‐mail:
[email protected]
Profile
Analytical chemist with expertise of quantitative and qualitative bioanalysis. Leadership position for
eight years for the SWEDAC/CAP/WADA accredited Karolinska Pharmacology Laboratory, Stockholm.
Long experience in alternative biomatrices as DBS, saliva and breath.
Teaching merits
Mentor for Laboratory Managers through the Karolinska University Hospital Mentor Supervision
Program. 2019‐
PhD supervision:
Currently co‐supervisor for Fadiea Al‐Aieshy. Evaluation of biomarkers for the new oral
anticoagulants apixaban and rivaroxaban, to increase safety and efficacy in individual patients.
Department of Medicine, Karolinska Institute
Main supervisor for PhD/student Camilla Linder, dissertation 20190614. Possibilities of dried blood
spots as a matrix in therapeutic drug monitoring of antiepileptic drugs in children., Department of
Laboratory Medicine, Karolinska Institute.
Co‐supervisor for Dr Rana Said, dissertation 20100922. Application of new technology: MEPS and LC‐
MS/MS for determination of therapeutic drugs. Department of Laboratory Medicine, Karolinska
Institute.
Main supervisor for several Master thesis projects. Karolinska Institute, Uppsala University,
Stockholm University.
Research merits
Co‐applicant ALF Medicine 2013 ”Concept study for individualized treatment of children with
epilepsy: a micromethod for monitoring drug levels in a home environment by dried blood spots on
filter paper”. The application received a two‐year grant of a total of 1,8 million SEK.
Co‐applicant HMT (Health, Medicine, Technique) project funds 2014 ” Enabling Therapeutic Drug
Monitoring from Home through Dried Blood Spot (DBS) Sampling”, The application received a two‐
year grant of a total of 2 million SEK.
Co‐applicant ALF Medicine 2016 ”Individualized treatment of children with epilepsy of children with
epilepsy and at immunosuppression “with filter paper kit” for sampling and analysis of drug levels
and laboratory parameters at home”. The application received a three‐year grant of a total of 1,85
million SEK.
2019‐11‐25
Work experience
Sept 2019‐ Acting Interim Director, Swedish Doping Control Laboratory Clinical
Pharmacology, Karolinska University Hospital, Stockholm, Sweden.
Aug 2017‐ Head of Pharmacological Laboratory, Clinical Pharmacology, Karolinska
University Hospital, Stockholm, Sweden.
Aug 2017 – Dec 2017 Acting Head of Drugs of Abuse and Therapeutic Drug Monitoring
Laboratory, Clinical Pharmacology, Karolinska University Hospital,
Stockholm, Sweden
Apr 2011‐Jul 2017 Head of Therapeutic Drug Monitoring Laboratory, Clinical
Pharmacology, Karolinska University Hospital, Stockholm, Sweden
Nov 2007‐Mar 2011 1st Hospital Chemist, Therapeutic Drug Monitoring Laboratory, Clinical
Pharmacology, Karolinska University Hospital, Stockholm, Sweden
Feb 1999‐Mar 2000 Laboratory Engineer, Quality Assurance, Fresenius Kabi AB, Stockholm,
Sweden
Positions and memberships
2014‐ Member of the International Association of Therapeutic Drug
Monitoring and Clinical Toxicology
2017‐ Scientific Director of the Drugs of Abuse Laboratory under the current
CAP Accreditation
Education
2000 ‐2006 PhD in Chemistry. Departement of Chemistry, Swedish Agricultural University.
Dissertation: ”Antimicrobial Antibiotics from Potential Biocontrol Microorganisms”
1993‐1999 MSc. in Biology, Uppsala University, Sweden. Profile of analytical chemistry and
pharmacognosy. Master thesis: Minor Field Study, Sri Lanka: ”Identification of
Ayurvedic Medicinal Plants ‐ with Special Reference to Plants Used Against Atopic
Dermatitis”
International Scientific conferences last five years
WADA World Conference on Doping in Sports, Katowice, 2019
USADA Symposium on Anti‐Doping Science, Tokyo 2019
MSACL, Stuttgart, 2018
IATDMCT 15 Kyoto, 2017, 5 posters
IATDMCT 14 Rotterdam, 2015, 3 posters
Publications
Part of 31 peer reviewed articles.
Curriculum vitae
Name Jana Lass
Place and date of birth Tallinn, Estonia, 30.10.1979
Citizenship Estonian
Address, Phone, e-mail Tähtvere 18a-3, Tartu 51007
533 18 333
[email protected]
Education Tartu University Medical Faculty, Institute of Microbiology,
2013, Phd
The Queen`s University Belfast, 2006, MSc Clin Pharm
Tartu Univeristy Medical Faculty, Institute of Pharmacy, 2003,
Msc
Languages English, russian, finnish, passive german
Career
2020-…Lecturer (0.1p), University of Tartu, Institute of
Pharmacy
2018 - …. Research Fellow of Clinical pharmacology (0.4 p),
University of Tartu, Institute of Genomics, Estonian Genome
Center Science Center
2016 - 2019 Research Fellow of Medical Microbiology (0.1 p),
University of Tartu, Faculty of Medicine, Institute of
Biomedicine and Translational Medicine, Department of
Microbiology
01.01.2013–... European Medicines Agency, Paediatric
Committee, alternate member
2007–... Tartu University Hospital, clinical pharmacist (1,0 p)
01.01.2016–31.01.2016 University of Tartu, Faculty of
Medicine, Institute of Biomedicine and Translational Medicine,
University of Tartu, Faculty of Medicine, Department of
Microbiology, Specialist (0,75)
01.01.2012–31.03.2014 University of Tartu, Faculty of
Medicine, Department of Pediatrics, Specialist (0,15)
01.01.2004–31.12.2007 North Estonia Regional Hospital,
pharmacist
Academic degree Jana Lass, Doctor's Degree, 2013, (sup) Irja Lutsar,
Epidemiological and clinical aspects of medicines use in
children in Estonia, University of Tartu.
1
Honours & awards The Association of Pharmaceutical Manufacturers in Estonia
(APME) research price „Hospitalised neonates in Estonia
commonly receive potentially harmful excipients“ 2012
Academic projects in progress
PRG184 (PRG184) "Role of Rare and Common Genetic Variants in Adverse Drug Reactions
(1.01.2018−31.12.2022)", Lili Azin Milani, University of Tartu, Institute of Genomics.
IUT34-24 "Management of infections in the immunocompromised host – from bench to
bedside (1.01.2015−31.12.2020)", Irja Lutsar, University of Tartu, Faculty of Medicine,
Institute of Biomedicine and Translational
PUT718 (PUT718) "The effects of augmented renal clearance on the
pharmacokinetic/pharmacodynamic profile of selected ß-lactam antibiotics in children and
young adults with cancer (1.01.2015−31.08.2019)", Lenne-Triin Kõrgvee, University of
Tartu, Faculty of Medicine, Institute of Biomedicine and Translational Medicine.
Completed projects
SF0180004s12 "Infection and immunocompromised host - from mechanisms to translation
into clinical practice (1.01.2012−31.12.2014)", Irja Lutsar, University of Tartu, Faculty of
Medicine.
SARLA11077E "Paediatric Accelerator Mass Spectrometry Evaluation Research Study
(1.04.2011−31.12.2014)", Heili Varendi, University of Tartu, University of Tartu, Faculty of
Medicine, Department of Pediatrics.
ETF8799 "Pharmacokinetics of meropenem in very low birth weight infants - short vs long
infusion (1.01.2011−31.12.2012)", Irja Lutsar, University of Tartu, Faculty of Medicine.
SF0182726s06 "HIV infection in Estonia: molecular and clinical implications of host and
virus interactions. (1.01.2006−31.12.2011)", Irja Lutsar, University of Tartu, Faculty of
Medicine.
Dissertations under supervision
Inge Mesek, Phd student, (sup) Irja Lutsar; Jana Lass, Euroopas kasutusel olevate
ravimvormide sobilikkus vastsündinutele ja väikelastele (Availability of age-appropriate drug
formulations and extent of extemporaneous medicines use in hospitalised), University of
Tartu.
Recent publications
Kogermann, Karin; Lass, Jana et al. (2018). Age-appropriate formulations including
pharmaceutical excipients in neonatal medicines. Current Pharmaceutical Design, 23,
5779−5789.10.2174/1381612823666170926122613.
Takkis, Kalev; Aro, Rudolf; Kõrgvee, Lenne-Triin; Varendi, Heili; Lass, Jana;
Herodes, Koit; Kipper, Karin (2017). Signal Enhancement in the HPLC-ESI-MS/MS
2
Analysis of Spironolactone and its Metabolites Using HFIP and NH4F as Eluent
Additives. Analytical and Bioanalytical Chemistry, 409 (12), 3145−3151.s00216-017-
0255-4.
Lass, Jana; Tamme, Kadri; Kipper, Karin; Starkopf, Joel (2017). Dosing of Ertapenem
in an Extreme Obesity: A Case Report of 250 kg Patient. Case Reports in Critical
Care, 1−3.10.1155/2017/5310768.
Nellis, Georgi; Metsvaht, Tuuli; Varendi, Heili; Lass, Jana; Duncan, Jennifer; Nunn,
Anthony J; Turner, Mark A; Lutsar, Irja (2016). Product Substitution as a Way
Forward in Avoiding Potentially Harmful Excipients in Neonates. Paediatric drugs, 18
(3), 221−230.10.1007/s40272-016-0173-5.
Mesek, Inge; Nellis, Georgi; Metsvaht, Tuuli; Visk, Helle; Lass, Jana; Lutsar, Irja
(2016). The impact of gestational age and geographical region on anti-infectives’ use
in European neonatal intensive care units (NICU). In: .34th Annual Meeting of the
European Society for Paediatric Infectious Diseases (ESPID), 10.-14.05.2016,
Brighton, UK.
Garner, RC.; Park, BK.; French, NS.; Earnshaw, C.; Schipani, A.; Selby, AM.; Byrne,
L.; Siner, S.; Crawley, FP.; Vaes, WH.; van Duijn, E.; deLigt, RA.; Varendi, H.; Lass,
J.; Grynkiewicz, G.; Maruszak, W.; Turner, MA. (2015). Observational infant
exploratory [14 C]paracetamol pharmacokinetic microdose/therapeutic dose study
with accelerator mass spectrometry bioanalysis. British Journal of Clinical
Pharmacology, 80 (1), 157−167.10.1111/bcp.12597.
Nellis, Georgi; Metsvaht, Tuuli; Varendi, Heili; Toompere, Karolin; Lass, Jana;
Mesek, Inge; Nunn, Anthony; Turner, Mark; Lutsar, Irja (2015). Potentially harmful
excipients in neonatal medicines: a pan-European observational study. Archives of
Disease in Childhood, 100 (7), 694−699.10.1136/archdischild-2014-307793.
Mesek, Inge; Nellis, Georgi; Lass, Jana; Lutsar, Irja (2014). Age-appropriateness of
cardiovascular medicine’s formulations for neonates. 43rd ESCP Symposium on
Clinical Pharmacy, Copenhagen, Denmark 22-24 October.
Turner, MA.; Park, BK.; French, NS.; Earnshaw, A.; Schipani, A.; Selby, AM.; Byrne,
L.; Siner, S.; Vaes, WHJ.; Van Dujin, E.; De Ligt, RAF.; Varendi, H.; Lass, J.;
Grynkiewicz, G.; Maruszak, W.; Crawley, FP.; Garner, RC. (2014). Comparative
pediatric acetaminophen pharmacokinetics between a microdose and a therapeutic
dose using accelerator mass spectrometry bioanalysis. 5th congress of the European
Academy of Paediatric Societies. October 17-21, Barcelona, Spain.
Other academic activities
Estonian Society of Hospital Pharmacists (ESHP), member of the board since 2006
Estonian Society of Pharmacology, member since2013
Teaching activities
ARFA.01.104 Clinical pharmacy (pharmacy students) since 2016
ARAI.00.009 Clinical Pharmacology Club (pharmacy and medical students) 2016/2017
ARFR.02.052 Pharmacotherapy (medical students) since 2016
Jana Lass
03.01.2020
3
Curriculum Vitae, Erik Eliasson
Born 1963 in Stockholm, Swedish citizen, married, family
1. University degree
1994, Medical doctor, Karolinska Institutet (KI), Stockholm, Sweden
2. PhD
1992, KI, Physiological Chemistry, supervisor prof Magnus Ingelman-Sundberg
3. Post-doctoral visits
1994-95 Imperial College School of Medicine, Pharmacology & Toxicology, London, UK
1996, KI, Institute of Environmental Medicine, Molecular Toxicology, Stockholm
4. Associate professor/Docent at Karolinska Institutet
2000, Drug toxicology, switch to Clinical Pharmacology in 2006
5. Clinical specialist competence
2004, Clinical Pharmacology, certified by the National Board of Health & Welfare
6. Current position and employer(s)
Professor and senior physician, a joint affiliation since 2012, at Karolinska Institutet,
Department of Laboratory Medicine, Division of Clinical Pharmacology, and Karolinska
University Hospital, Stockholm.
Medical head of the Karolinska University Hospital Pharmacology Laboratory (including
therapeutic drug monitoring and clinical pharmacogenetics) since 2004, and in the
steering board of the Clinical Pharmacology Department since 2009. Line manager with
staff responsibility as section head.
7. Previous position and employments
National Expert on Secondment, European Medicines Agency, Scientific Advice Office,
London, UK 2016-2017
Senior lecturer (KI) since 2010, and clinical specialist since 2004, Karolinska University
Hospital, Clinical Pharmacology
Research physician, AstraZeneca R&D, Södertälje, 2007-2008
Resident in Clinical Pharmacology, Huddinge University Hospital 2000-2004, including
internal medicine service in Gastroenterology and Nephrology
Clinical Houseman, Huddinge/KI 1997-2000
9. PhD-student supervision at Karolinska Institutet
Main supervisor for: Mia Sandberg-Lundblad (MPharmSci) completed PhD 2005, Staffan
Rosenborg (MD) completed PhD 2010, Johan Holm (MD) expected completion of PhD in
2020, Gustaf Beijer (MD), registration as PhD-student spring 2020.
Co-supervision of: Etienne Neve (MSc) completed PhD in 2000, Ümit Yasar (MD)
completed PhD 2002, Buster Mannheimer (MD) completed PhD 2009, Jessica Mwinyi
(MD) completed PhD in 2010, Cristine Skogastierna (MSc) completed PhD in 2012,
Linda Thorén (MD), ongoing since 2015
10. Teaching
Annual teaching since the mid-1980s of Medical students at KI (medical biochemistry,
pharmacology, clinical pharmacology). Additional teaching of graduate students or MD-
residents in toxicology and clinical pharmacology.
11. Commissions of trust
a. Vice-chairman in the Genomic Medicine Sweden Pharmacogenetics subsection
since 2018
b. KI-representantive in the Laboratory Medicine-section of the Stockholm
County Council, since 2010
c. Steering group member of the Karolinska Laboratory Medicine metabolomics
platform
d. Member of the Swedish Reference Group on Antibiotics, since 2010
e. Member of the Swedish Reference Group on Antimycotics, since 2004
f. Member of the Regional Ethics Committee, Stockholm, 2010-16
g. Member of the Stockholm County Council Expert group on infectious
diseases, 2010-2016
h. Board member of the Swedish Foundation for Clinical Pharmacology, 2001-10
i. Board member of the Swedish Association for Clinical Pharmacology 2003-
2006
j. Member of the KI internal grants groups, 2003-2006
k. Local representative for the Swedish Medical Association, 2004
12. Publications
In total, 90 published articles in PubMed and among these around 75 original papers or
reviews, and accepted manuscripts or reviews in peer-reviewed journals 77 peer-
reviewed-publikationer with 2910 citations and h-index of 29, in average 38 citations per
article (source Web of Science Feb 2019). Swedish textbooks co-authorships: Sepsis på
akuten och IVA, 2013, (Hanberger H, Editor), and Att lyckas med läkemedel, by Böttiger,
Eliasson, and Lindh (Studentlitteratur, 2014).
Five recent references on the topic:
Hallberg P, Yue Q-Y, Eliasson E, Ås J, Melhus H, Wadelius M. SWEDEGENE – a
national DNA biobank for pharmacogenomic studies of adverse drug reactions.
Pharmacogenomics J 2019, in press.
He W, Grassmann F, Eriksson M, Eliasson E, Thorén L, Margolin S, Hall P, Czene K,
CYP2D6 genotype predicts tamoxifen discontinuation and prognosis in breast cancer
patients. J Clin Oncol, 2019, Dec 4
Haslemo T, Eliasson E, Jukić MM, Ingelman-Sundberg M, Molden E. Significantly lower
CYP2D6 metabolism measured as the O/N-desmethylvenlafaxine metabolic ratio in carriers
of CYP2D6*41 versus CYP2D6*9 or CYP2D6*10 - A study on therapeutic drug monitoring
data from 1,003 genotyped Scandinavian patients. Br J Clin Pharmacol. 2019;85:194-201
Holm J, Eiermann B, Eliasson E, Mannheimer B. A limited number of prescribed drugs
account for the great majority of drug-drug interactions. Eur J Clin Pharmacol,
2014;70:1375-83
Margolin S, Lindh JD, Thorén L, Xie H, Koukel L, Dahl M-L, Eliasson E. CYP2D6 and
adjuvant tamoxifen: Possible differences of outcome in pre- and postmenopausal patients.
Pharmacogenomics, 2013;14:613-22
13. Other merits
• Editorial Board member of Therapeutic Drug Monitoring since 2005, Clinical
Pharmacokinetics since 2006, Frontiers in Pharmacogenetics since 2010. Additional
referee-work for Nature Med, Mol Pharmacol, Brit J Clin Pharmacol, Basic Clin
Pharmacol Toxicol, Hepatology, J Hepatol, Chem Biol Interact, Pharmacogenetics &
Genom, Eur J Clin Pharmacol, Clin Pharmacol Ther, etc
• Recent research funding Stockholm County Council, Vinnova Swe Innovation Agency
(Platinea), Public Health Agency Sweden
14. EC-related collaborations, previous experiences
EUROHEPATOX – drug induced liver injury
(associate partner, to PI JG Kenna, 1996-1999)
EUDRAGENE - a biobank to study the genetic basis for serious drug toxicity (associate
contractor, PI M Molokhia, 2003-07)
SWEDEGENE - ongoing DNA collection of Swe ADR cases reported to the MPA
(www.swedegene.se)
Üldandmed Isiku kontaktandmed
Eesnimi Lili Azin Telefon 737 4039
Perenimi Milani E-post
[email protected]
Sünniaeg 27.11.1981 Teine telefon 5304 5400 (5400)
Researcher ID C-8759-2011 Lisainfo Keeled: rootsi keel -
emakeel, inglise keel -
ORCID 0000-0002-5323-3102
väga hea, eesti keel - väga
hea, pärsia keel - väga hea,
prantsuse keel - hea, vene
keel - vähe.
Töökohad ja ametid
Periood Kirjeldus
01.11.2018–... Tartu Ülikool, Tartu Ülikooli genoomika instituut, epi- ja
farmakogenoomika juhtivteadur (1,00)
2017 -2018 Uppsala ülikool, meditsiiniteaduste teaduskond, Associate Senior Lecturer
& SciLifeLab teadur
2013–01.06.2018 Tartu Ülikool, Tartu Ülikooli Eesti Geenivaramu, Vanemteadur (1,00)
01.06.2018– Tartu Ülikool, Tartu Ülikooli genoomika instituut, epi- ja
31.10.2018 farmakogenoomika juhtivteadur (0,50)
01.01.2018– Tartu Ülikool, Tartu Ülikooli genoomika instituut, farmakogenoomika
31.05.2018 vanemteadur (0,50)
01.02.2016– Tartu Ülikool, Tartu Ülikooli Eesti Geenivaramu, farmakogenoomika
31.12.2017 vanemteadur (1,00)
01.01.2016– Tartu Ülikool, Tartu Ülikooli Eesti Geenivaramu, farmakogenoomika
31.01.2016 peaspetsialist (1,00)
01.04.2013– Tartu Ülikool, Tartu Ülikooli Eesti Geenivaramu, vanemteadur (1,00)
31.12.2015
01.01.2013– Tartu Ülikool, Tartu Ülikooli Eesti Geenivaramu, vanemteadur (0,60)
31.03.2013
01.12.2012– Tartu Ülikool, Tartu Ülikooli Eesti Geenivaramu, teadur (0,50)
31.12.2012
10.09.2012– Tartu Ülikool, Tartu Ülikooli Eesti Geenivaramu, direktori kohusetäitja
30.11.2012
01.09.2011– Eesti Biokeskus, Erakorraline vanemteadur (0,50)
31.12.2012
2011– Tartu Ülikool, Tartu Ülikooli Eesti Geenivaramu, Sekveneerimise ja
31.03.2017 genotüpiseerimise tuumiklabori juhataja (0,20)
01.12.2010– Tartu Ülikool, Tartu Ülikooli Eesti Geenivaramu, teadur (1,00)
30.11.2012
01.02.2010– Tartu Ülikool, Tartu Ülikooli Eesti Geenivaramu, teadur (0,20)
30.11.2010
2010–2012 Tartu Ülikool, Tartu Ülikooli Eesti Geenivaramu, Järeldoktor (1,00)
01.01.2010– Tartu Ülikool, Tartu Ülikooli Eesti Geenivaramu, teadur (0,50)
31.01.2010
01.01.2009– Uppsala Ülikool, Lapsepuhkus (0.80)
31.12.2010
01.01.2009– Uppsala Ülikool, Teadur (0.20)
31.12.2010
01.01.2004– Uppsala Ülikool, doktorant
31.12.2009
01.01.2004– Uppsala Ülikooli WCN SNP genotüpiseerimise osakond, laborant
31.12.2004
2001–2003 Tartu Ülikool, Arstiteaduskond, Patoloogilise anatoomia ja
kohtuarstiteaduse instituut, Patoloogilise anatoomia õppetool, laborant
(0,50)
Haridustee
Periood Kirjeldus
2004–2009 Uppsala ülikool, Meditsiiniliste Teaduste Osakond, Molekulaarne
Meditsiin; PhD
2000–2004 Tartu Ülikool, Molekulaar- ja Rakubioloogia Instituut; BSc
1994–2000 Tallinna Inglise Kolledz; keskkool
Teadusorganisatsiooniline ja -administratiivne tegevus
Periood Kirjeldus
2005−2007 WCN praktilise kursuse “Applied bioinformatics and methodologies in
SNP genotyping” juhendaja, Uppsala Ülikool
2004−2006 EU/EMBO praktilise kursuse “Advanced techniques in molecular
medicine” korraldaja ja juhendaja, Uppsala Ülikool
Teaduskraadid
Lili Azin Milani, doktorikraad, 2009, (juh) Ann-Christine Syvänen, Gene Expression in Cancer
Cells: Detection of Splice Variants, Allele-specific Expression and DNA Methylation, Uppsala
Ülikool.
Teaduspreemiad ja tunnustused
Aasta Kirjeldus
2015 Vabariigi Presidendi kultuurirahastu noore teadlase preemia
2012 Eesti Teadusfondi uurimistoetus (4 aastaks)
2011 MOBILITAS Järeldoktori uurimistoetus (3 aaastaks)
2008 Anna Lundins stipendium väljapaistvatele doktorantidele
2008 Keystone Symposia stipendium: Vähi genoomika ja epigenoomika konverentsiks
2008 Hedströms stipendium väljapaistavatele vanem doktorantidele
2007 Anna Lundins stipendium väljapaistvatele doktorantidele
Teadustöö põhisuunad
VALDKOND: 1. Bio- ja keskkonnateadused; 1.3. Geneetika
VALDKOND: 1. Bio- ja keskkonnateadused; 1.3. Geneetika; PÕHISUUND: epigeneetika,
geeniekspressioon, molekulaarne meditsiin
VALDKOND: 3. Terviseuuringud; 3.11. Terviseuuringutega seotud uuringud, näiteks
biokeemia, geneetika, mikrobioloogia, biotehnoloogia, molekulaarbioloogia, rakubioloogia,
biofüüsika ja bioinformaatika; CERCS ERIALA: B220 Geneetika, tsütogeneetika
Lisainfo
Osalemine WCN kursustel “Applied bioinformatics and methodologies in SNP genotyping”,
Uppsala ja Stockholm, Rootsi 13-19 november, 2004
Osalemine J.D. Terwilliger kursustel “Study design issues for gene mapping in complex traits”,
Tartu, Estonia 24-26 mai, 2004
Osalemine CSHL kursustel “Eukaryotic gene expression”, Cold Spring Harbor Laboratory,
USA 25. juuni - 15. august, 2005
Jooksvad projektid
SLTMR16142T "Genoomika ja Siirdemeditsiini Tippkeskus (TK142) (1.01.2016−1.03.2023)",
Andres Metspalu, Tartu Ülikool, Tartu Ülikooli Eesti Geenivaramu.
PRG184 (PRG184) "Haruldaste ja sagedaste geenivariantide mõju ravimite kõrvaltoimetele
(1.01.2018−31.12.2022)", Lili Azin Milani, Tartu Ülikool, Tartu Ülikooli genoomika instituut.
MP1GI18442R "Personaalne meditsiin parema elukvaliteedi tagamiseks insuldi ennetava
modelleerimise kaudu (1.05.2018−30.04.2022)", Lili Azin Milani, Tartu Ülikool, Tartu
Ülikooli genoomika instituut.
IUT20-60 "Oomiksi põhised meetodid terviseuuringutes: integreeritud lähenemine haiguste
tekkeprotsesside mõistmiseks ja prognoosimiseks (1.01.2014−31.12.2019)", Andres Metspalu,
Tartu Ülikool, Tartu Ülikooli Eesti Geenivaramu, Tartu Ülikool, Tartu Ülikooli genoomika
instituut.
Lõppenud projektid
MLTAT18497R "Ühistaristu loomine Euroopa, Kanada ja Aafrika rahvuslike kohortide jaoks
(1.01.2019−31.12.2022)", Kaur Alasoo, Tartu Ülikool, Loodus- ja täppisteaduste valdkond,
arvutiteaduse instituut.
ETF9293 "Ravimite metabolismiga seotud geenide põhjalik geneetiline ja epigeneetiline
analüüs uue põlvkonna sekveneerimistehnoloogiaga (1.01.2012−31.12.2015)", Lili Azin
Milani, Tartu Ülikool, Tartu Ülikooli Eesti Geenivaramu.
MJD71 "IN-DEPTH GENETIC AND EPIGENETIC ANALYSIS OF THE CYTOCHROME
P450 SYSTEM BY NEXT-GENERATION SEQUENCING (1.03.2011−28.02.2014)", Lili
Azin Milani, Tartu Ülikool, Tartu Ülikool, Tartu Ülikooli Eesti Geenivaramu.
SF0180142Cs08 "Geneetiline varieeruvus, elustiil ja keskkonnategurid kui peamised tervise
mõjurid - EGV (1.01.2008−31.12.2013)", Andres Metspalu, Tartu Ülikool, Tartu Ülikool,
Tartu Ülikooli Eesti Geenivaramu.
Juhendamisel väitekirjad
Anu Tammiste, doktorant, (juh) Andres Metspalu; Eduard Maron; Lili Azin Milani, Genetic
factors influencing antidepressant response (Antidepressantide toimet ennustavad geneetilised
tegurid), Tartu Ülikool.
Kristi Krebs, doktorant, (juh) Lili Azin Milani; Andres Metspalu, Genome wide analysis of
genetic and epigenetic variants associated with drug metabolism using modern sequencing
technology (Ravimite lagundamisega seotud geenide põhjalik geneetiline ja epigeneetiline
analüüs uue põlvkonna sekveneerimisetehnoloogiaga), Tartu Ülikool, Tartu Ülikooli Eesti
Geenivaramu.
Epp Kaleviste, doktorant, (juh) Kai Kisand; Pärt Peterson; Lili Azin Milani, The impact of
transcription factors STAT1 and AIRE on immune cells and cytokine signaling pathways
(Transkriptsioonifaktorite STAT1 ja AIRE mõju immuunrakkudele ja tsütokiinide
signaaliradadele), Tartu Ülikool, Meditsiiniteaduste valdkond, bio- ja siirdemeditsiini instituut.
Kelli Grand, doktorant, (juh) Lili Azin Milani; Pärt Peterson; Andres Metspalu, Investigating
immune related diseases using high-throughput methods (Immuunsüsteemiga seotud haiguste
uurimine uue põlvkonna meetoditega), Tartu Ülikool.
Tõnis Tasa, doktorant, (juh) Jaak Vilo; Lili Azin Milani, Management and analysis of massive
full-scale genome data. (Suuremahuline täisgenoomsete andmete haldus ja analüüs), Tartu
Ülikool, Loodus- ja täppisteaduste valdkond, arvutiteaduse instituut.
Juhendatud väitekirjad
Kaie Lokk, doktorikraad, 2017, (juh) Neeme Tõnisson; Lili Azin Milani, Comparative genome-
wide DNA methylation studies of healthy human tissues and non-small cell lung cancer tissue
(Inimese tervete kudede ja mitteväikerakulise kopsuvähi võrdlevad ülegenoomsed DNA
metülatsiooni uuringud), Tartu Ülikool, Loodus- ja täppisteaduste valdkond, molekulaar- ja
rakubioloogia instituut.
Riin Tamm, doktorikraad, 2017, (juh) Andres Metspalu; Lili Azin Milani, In-depth analysis of
factors affecting variability in thiopurine methyltransferase activity (Uute
tiopuriinmetüültransferaasi aktiivsust mõjutavate biomarkerite otsingul), Tartu Ülikool,
Loodus- ja täppisteaduste valdkond, molekulaar- ja rakubioloogia instituut.
Silva Kasela, doktorikraad, 2017, (juh) Lili Azin Milani; Krista Fischer; Andres Metspalu,
Genetic regulation of gene expression: detection of tissue- and cell type-specific effects, Tartu
Ülikool, Loodus- ja tehnoloogiateaduskond, Tartu Ülikooli Molekulaar- ja Rakubioloogia
Instituut, Biotehnoloogia õppetool.
Liis Haljasmägi, magistrikraad, 2018, (juh) Kai Kisand; Lili Azin Milani; Pärt Peterson, I tüüpi
interferoonide vastased neutraliseerivad autoantikehad süsteemse erütematoosse luupuse
patsientidel, Tartu Ülikool, Loodus- ja täppisteaduste valdkond, molekulaar- ja rakubioloogia
instituut.
Marili Palover, magistrikraad, 2016, (juh) Lili Azin Milani; Silva Kasela, Telomeeride pikkuste
seosed DNA metülatsiooniga, Tartu Ülikool, Loodus- ja tehnoloogiateaduskond, Tartu Ülikooli
Molekulaar- ja Rakubioloogia Instituut.
Hanna Rein, magistrikraad, 2016, (juh) Kai Kisand; Lili Azin Milani, TaqMan tehnoloogia
põhine metülatsioonimustri tuvastamine enneaegselt vananeva immuunsüsteemi
monitoorimiseks, Tartu Ülikool, Meditsiiniteaduste valdkond, bio- ja siirdemeditsiini instituut.
Kelli Grand, magistrikraad, 2016, (juh) Lili Azin Milani; Pärt Peterson, Funktsioonikaoga
mutatsioonide analüüs 2300 inimese genoomi ja terviseandmete põhjal, Tartu Ülikool, Loodus-
ja tehnoloogiateaduskond, Tartu Ülikooli Molekulaar- ja Rakubioloogia Instituut.
Epp Kaleviste, magistrikraad, 2015, (juh) Lili Azin Milani; Kai Kisand, STAT1 geeni
uudikfunktsiooniga mutatsiooni mõju JAK-STAT signaalirajale, Tartu Ülikool.
Liina Pappa, magistrikraad, 2014, (juh) Lili Azin Milani; Tiit Nikopensius, Eksoomide
sekveneerimine kahel unilateraalse neeru hüpoplaasiaga patsiendil, Tartu Ülikool, Loodus- ja
tehnoloogiateaduskond, Tartu Ülikooli Molekulaar- ja Rakubioloogia Instituut.
Mari-Liis Reim, magistrikraad, 2013, (juh) Riin Tamm; Lili Azin Milani; Andres Metspalu,
Inimese tiopuriinmetüültransferaasi aktiivsust mõjutavad faktorid maksas, Tartu Ülikool,
Loodus- ja tehnoloogiateaduskond, Tartu Ülikooli Molekulaar- ja Rakubioloogia Instituut,
Biotehnoloogia õppetool.
Silva Kasela, magistrikraad, 2013, (juh) Krista Fischer; Lili Azin Milani, DNA metülatsioon:
normaliseerimine ja analüüs, Tartu Ülikool, Matemaatika-informaatikateaduskond,
Matemaatilise statistika instituut.
Publikatsioonid
2019
Tasa, T,; Krebs, K.; Kals, M.; Mägi, R.; Lauschke, V.M.; Haller, T.; Puurand, T.; Remm, M.;
Esko, T.; Metspalu, A.; Vilo, J.; Milani, L. (2019). Genetic variation in the Estonian population:
pharmacogenomics study of adverse drug effects using electronic health records. European
Journal of Human Genetics, 0−0.10.1038/s41431-018-0300-6 [ilmumas].
Virtanen, V.B.; Salo, P.P.; Cao, J.; Löf-Granström, A.; Milani, L.; Metspalu, A.; Rintala, R.J.;
Saarenpää-Heikkilä, O.; Paunio, T.; Wester, T.; Nordenskjöld, A.; Perola, M.; Pakarinen, M.P.
(2019). Noncoding RET variants explain the strong association with Hirschsprung disease in
patients without rare coding sequence variant. European Journal of Medical
Genetics.10.1016/j.ejmg.2018.07.019 [_isbeingpublished].
2018
Sung, Yun J.; Winkler, Thomas W.; de las Fuentes, Lisa; Bentley, Amy R.; Brown, Michael R.;
Kraja, Aldi T.; Schwander, Karen; Ntalla, Ioanna; Guo, Xiuqing; Franceschini, Nora; Lu,
Yingchang; Cheng, Ching-Yu; Sim, Xueling; Vojinovic, Dina; Marten, Jonathan; Musani,
Solomon K.; Li, Changwei; Feitosa, Mary F.; Kilpelainen, Tuomas O.; Richard, Melissa A. ...
Chasman, Daniel I. (2018). A Large-Scale Multi-ancestry Genome-wide Study Accounting for
Smoking Behavior Identifies Multiple Significant Loci for Blood Pressure. American Journal of
Human Genetics, 102 (3), 375−400.10.1016/j.ajhg.2018.01.015.
Lee, James J; Wedow, Robbee; Okbay, Aysu; Kong, Edward; Maghzian, Omeed; Zacher,
Meghan; Nguyen-Viet, Tuan Anh; Bowers, Peter; Sidorenko, Julia; Karlsson Linnér, Richard;
Fontana, Mark Alan; Kundu, Tushar; Lee, Chanwook; Li, Hui; Li, Ruoxi; Royer, Rebecca;
Timshel, Pascal N; Walters, Raymond K; Willoughby, Emily A; Yengo, Loïc ... Cesarini, David
(2018). Gene discovery and polygenic prediction from a genome-wide association study of
educational attainment in 1.1 million individuals. Nature genetics, 50 (8),
1112−1121.10.1038/s41588-018-0147-3.
Evangelou, Evangelos; Warren, Helen R; Mosen-Ansorena, David; Mifsud, Borbala; Pazoki,
Raha; Gao, He; Ntritsos, Georgios; Dimou, Niki; Cabrera, Claudia P; Karaman, Ibrahim; Ng, Fu
Liang; Evangelou, Marina; Witkowska, Katarzyna; Tzanis, Evan; Hellwege, Jacklyn N; Giri,
Ayush; Velez Edwards, Digna R; Sun, Yan V; Cho, Kelly; Gaziano, J Michael ... Caulfield,
Mark J (2018). Genetic analysis of over 1 million people identifies 535 new loci associated with
blood pressure traits. Nature genetics, 50 (10), 1412−1425.10.1038/s41588-018-0205-x.
Zhou, Yitian; Mägi, Reedik; Milani, Lili; Lauschke, Volker M (2018). Global genetic diversity
of human apolipoproteins and effects on cardiovascular disease risk. Journal of lipid research, 59
(10), 1987−2000.10.1194/jlr.P086710.
Feitosa, Mary F; Kraja, Aldi T; Chasman, Daniel I; Sung, Yun J; Winkler, Thomas W; Ntalla,
Ioanna; Guo, Xiuqing; Franceschini, Nora; Cheng, Ching-Yu; Sim, Xueling; Vojinovic, Dina;
Marten, Jonathan; Musani, Solomon K; Li, Changwei; Bentley, Amy R; Brown, Michael R;
Schwander, Karen; Richard, Melissa A; Noordam, Raymond; Aschard, Hugues ... Levy, Daniel
(2018). Novel genetic associations for blood pressure identified via gene-alcohol interaction in
up to 570K individuals across multiple ancestries. PLoS ONE, 13 (6),
e0198166−e0198166.10.1371/journal.pone.0198166.
Reisberg, Sulev; Krebs, Kristi; Lepamets, Maarja; Kals, Mart; Mägi, Reedik; Metsalu, Kristjan;
Lauschke, Volker M.; Vilo, Jaak; Milani, Lili; (2018). Translating genotype data of 44,000
biobank participants into clinical pharmacogenetic recommendations: challenges and solutions.
Genetics in medicine.10.1038/s41436-018-0337-5.
Lauschke, Volker M.; Milani, Lili; Ingelman-Sundberg, Magnus (2018). Pharmacogenomic
Biomarkers for Improved Drug Therapy- Recent Progress and Future Developments. Aaps
Journal, 20 (1), UNSP 4.10.1208/s12248-017-0161-x.
Wray, Naomi R.; Ripke, Stephan; Mattheisen, Manuel; Trzaskowski, Maciej; Byrne, Enda M.;
Abdellaoui, Abdel; Adams, Mark J.; Agerbo, Esben; Air, Tracy M.; Andlauer, Till M. F.;
Bacanu, Silviu-Alin; Baekvad-Hansen, Marie; Beekman, Aartjan F. T.; Bigdeli, Tim B.; Binder,
Elisabeth B.; Blackwood, Douglas R. H.; Bryois, Julien; Buttenschon, Henriette N.; Bybjerg-
Grauholm, Jonas; Cai, Na ... Sullivan, Patrick F. (2018). Genome-wide association analyses
identify 44 risk variants and refine the genetic architecture of major depression. Nature Genetics,
50 (5), 668−684.10.1038/s41588-018-0090-3.
Wahl, Annika; Kasela, Silva; Carnero-Montoro, Elena; van Iterson, Maarten; Stambuk, Jerko;
Sharma, Sapna; van den Akker, Erik; Klaric, Lucija; Benedetti, Elisa; Razdorov, Genadij;
Trbojevic-Akmacic, Irena; Vuckovic, Frano; Ugrina, Ivo; Beekman, Marian; Deelen, Joris; van
Heemst, Diana; Heijmans, Bastiaan T.; Wuhrer, Manfred; Plomp, Rosina; Keser, Toma ...
Gieger, Christian (2018). IgG glycosylation and DNA methylation are interconnected with
smoking. Biochimica et Biophysica Acta - General Subjects, 1862 (3),
637−648.10.1016/j.bbagen.2017.10.012.
Lu, Y.; Pouget, J. G.; Andreassen, O. A.; Djurovic, S.; Esko, T.; Hultman, C. M.; Metspalu, A.;
Milani, L.; Werge, T.; Sullivan, P. F. (2018). Genetic risk scores and family history as predictors
of schizophrenia in Nordic registers. Psychological Medicine, 48 (7),
1201−1208.10.1017/S0033291717002665.
Ruderfer, Douglas M.; Ripke, Stephan; McQuillin, Andrew; Boocock, James; Stahl, Eli A.;
Pavlides, Jennifer M. Whitehead; Mullins, Niamh; Charney, Alexander W.; Ori, Anil P. S.;
Loohuis, Loes M. Olde; Domenici, Enrico; Di Florio, Arianna; Papiol, Sergi; Kalman, Janos L.;
Trubetskoy, Vassily; Adolfsson, Rolf; Agartz, Ingrid; Agerbo, Esben; Akil, Huda; Albani, Diego
... Kendler, Kenneth S. (2018). Genomic Dissection of Bipolar Disorder and Schizophrenia,
Including 28 Subphenotypes. Cell, 173 (7), ARTN 1715.e16−1732.10.1016/j.cell.2018.05.046.
Aru, Juhan; Espak, Peeter; Grossberg, Maarja; Heinsalu, Els; Karjust, Kristo; Kogermann, Karin;
Kurig, Heisi; Köster, Kajar; Küngas, Rainer; Leijen, Äli; Liiv, Innar; Milani, Lili; Mõtus, Kerli;
Näripea, Eva; Ojavee, Kärt; Oras, Ester; Preegel, Gert; Purge, Priit; Raju, Marju; Raudla, Ringa
... Voll, Hendrik (2018). Mis tunne on olla (noor) naisteadlane? Sirp : Eesti kultuurileht, 8−9.
Turcot, Valerie; Lu, Yingchang; Highland, Heather M.; Schurmann, Claudia; Justice, Anne E.;
Fine, Rebecca S.; Bradfield, Jonathan P.; Esko, Tonu; Giri, Ayush; Graff, Mariaelisa; Guo,
Xiuqing; Hendricks, Audrey E.; Karaderi, Tugce; Lempradl, Adelheid; Locke, Adam E.;
Mahajan, Anubha; Marouli, Eirini; Sivapalaratnam, Suthesh; Young, Kristin L.; Alfred, Tamuno
... Loos, Ruth J. F. (2018). Protein-altering variants associated with body mass index implicate
pathways that control energy intake and expenditure in obesity (vol 50, pg 26, 2018). Nature
Genetics, 50 (5), 766−767.10.1038/s41588-018-0082-3.
Flannick, Jason; Fuchsberger, Christian; Mahajan, Anubha; Teslovich, Tanya M; Agarwala,
Vineeta; Gaulton, Kyle J; Caulkins, Lizz; Koesterer, Ryan; Ma, Clement; Moutsianas, Loukas;
McCarthy, Davis J; Rivas, Manuel A; Perry, John R B; Sim, Xueling; Blackwell, Thomas W;
Robertson, Neil R; Rayner, N William; Cingolani, Pablo; Locke, Adam E; Tajes, Juan Fernandez
... McCarthy, Mark I (2018). Erratum: Sequence data and association statistics from 12,940 type
2 diabetes cases and controls. Scientific Data, 5, 180002−180002.10.1038/sdata.2018.2.
2017
Wahl, Simone; Drong, Alexander; Lehne, Benjamin; Loh, Marie; Scott, William R; Kunze,
Sonja; Tsai, Pei-Chien; Ried, Janina S; Zhang, Weihua; Yang, Youwen; Tan, Sili; Fiorito,
Giovanni; Franke, Lude; Guarrera, Simonetta; Kasela, Silva; Kriebel, Jennifer; Richmond,
Rebecca C; Adamo, Marco; Afzal, Uzma; Ala-Korpela, Mika ... Chambers, John C (2017).
Epigenome-wide association study of body mass index, and the adverse outcomes of adiposity.
Nature, 541 (7635), 81−86.10.1038/nature20784.
Hinney A, Kesselmeier M, Jall S, Volckmar AL, Föcker M, Antel J; GCAN; WTCCC3, Heid
IM, Winkler TW; GIANT, Grant SF; EGG, Guo Y, Bergen AW, Kaye W, Berrettini W,
Hakonarson H; Price Foundation Collaborative Group; Children’s Hospital of Philadelphia/Price
Foundation, Herpertz-Dahlmann B, de Zwaan M, Herzog W, Ehrlich S, Zipfel S, Egberts KM,
Adan R, Brandys M, van Elburg A, Boraska Perica V, Franklin CS, Tschöp MH, Zeggini E,
Bulik CM, Collier D, Scherag A, Müller TD, Hebebrand J. (2017). Evidence for three genetic
loci involved in both anorexia nervosa risk and variation of body mass index. Molecular
Psychiatry, 22 (2), 192−201.10.1038/mp.2016.71.
Guha M, Saare M, Maslovskaja J, Kisand K, Liiv I, Haljasorg U, Tasa T, Metspalu A, Milani L,
Peterson P. (2017). DNA breaks and chromatin structural changes enhance the transcription of
Autoimmune Regulator target genes. Journal of Biological Chemistry, 292 (16),
6542−6554.jbc.M116.764704.
Guo, Michael H.; Nandakumar, Satish K.; Ulirsch, Jacob C.; Zekavat, Seyedeh M.; Buenrostro,
Jason D.; Natarajan, Pradeep; Salem, Rany M.; Chiarle, Roberto; Mitt, Mario; Kals, Mart; Parn,
Kalle; Fischer, Krista; Milani, Lili; Magi, Reedik; Palta, Priit; Gabriel, Stacey B.; Metspalu,
Andres; Lander, Eric S.; Kathiresan, Sekar; Hirschhorn, Joel N. ... Sankaran, Vijay G. (2017).
Comprehensive population-based genome sequencing provides insight into hematopoietic
regulatory mechanisms. Proceedings Of The National Academy Of Sciences Of The United
States Of America, 114 (3), E327−E336.10.1073/pnas.1619052114.
R Tamm, R Mägi, R Tremmel, S Winter, E Mihailov, A Smid, A Möricke, K Klein, M Schrappe,
M Stanulla, R Houlston, R Weinshilboum, Irena Mlinarič Raščan, A Metspalu, L Milani, M
Schwab, E Schaeffeler. (2017). Polymorphic Variation in TPMT Is the Principal Determinant of
TPMT Phenotype: A Meta-Analysis of Three Genome-Wide Association Studies. Clinical
Pharmacology & Therapeutics, 101 (5), 684−695.10.1002/cpt.540.
Nath, Artika P.; Ritchie, Scott C.; Byars, Sean G.; Fearnley, Liam G.; Havulinna, Aki S.;
Joensuu, Anni; Kangas, Antti J.; Soininen, Pasi; Wennerstrom, Annika; Milani, Lili; Metspalu,
Andres; Mannisto, Satu; Wurtz, Peter; Kettunen, Johannes; Raitoharju, Emma; Kahonen, Mika;
Juonala, Markus; Palotie, Aarno; Ala-Korpela, Mika; Ripatti, Samuli ... Inouye, Michael (2017).
An interaction map of circulating metabolites, immune gene networks, and their genetic
regulation. Genome Biology, 18, ARTN 146.10.1186/s13059-017-1279-y.
Robinson, Matthew R.; English, Geoffrey; Moser, Gerhard; Lloyd-Jones, Luke R.; Triplett,
Marcus A.; Zhu, Zhihong; Nolte, Ilja M.; van Vliet-Ostaptchouk, Jana V.; Snieder, Harold; Esko,
Tonu; Milani, Lili; Magi, Reedik; Metspalu, Andres; Magnusson, Patrik K. E.; Pedersen, Nancy
L.; Ingelsson, Erik; Johannesson, Magnus; Yang, Jian; Cesarini, David; Visscher, Peter M.
(2017). Genotype-covariate interaction effects and the heritability of adult body mass index.
Nature Genetics, 49 (8), 1174−1186.10.1038/ng.3912.
Mihailov, E.; Nikopensius, T.; Reigo, A.; Nikkolo, C.; Kals, M.; Aruaas, K.; Milani, L.; Seepter,
H.; Metspalu, A. (2017). Whole-exome sequencing identifies a potential TTN mutation in a
multiplex family with inguinal hernia. Hernia, 21 (1), 95−100.10.1007/s10029-016-1491-9.
Manning, Alisa; Highland, Heather M.; Gasser, Jessica; Sim, Xueling; Tukiainen, Taru;
Fontanillas, Pierre; Grarup, Niels; Rivas, Manuel A.; Mahajan, Anubha; Locke, Adam E.;
Cingolani, Pablo; Pers, Tune H.; Vinuela, Ana; Brown, Andrew A.; Wu, Ying; Flannick, Jason;
Fuchsberger, Christian; Gamazon, Eric R.; Gaulton, Kyle J.; Im, Hae Kyung ... Lindgren, Cecilia
M. (2017). A Low-Frequency Inactivating AKT2 Variant Enriched in the Finnish Population Is
Associated With Fasting Insulin Levels and Type 2 Diabetes Risk. Diabetes, 66 (7),
2019−2032.10.2337/db16-1329.
Marshall, Christian R.; Marshall, Christian R.; Howrigan, Daniel P.; Merico, Daniele;
Thiruvahindrapuram, Bhooma; Wu, Wenting; Greer, Douglas S.; Antaki, Danny; Shetty, Aniket;
Holmans, Peter A.; Pinto, Dalila; Gujral, Madhusudan; Brandler, William M.; Malhotra,
Dheeraj; Wang, Zhouzhi; Fajarado, Karin V. Fuentes; Maile, Michelle S.; Ripke, Stephan;
Agartz, Ingrid; Albus, Margot ... Sebat, Jonathan (2017). Contribution of copy number variants
to schizophrenia from a genome-wide study of 41,321 subjects. Nature Genetics, 1,
27−35.10.1038/ng.3725.
Mandaviya PR, Aïssi D, Dekkers KF, Joehanes R, Kasela S, Truong V, Stolk L, Heemst DV,
Ikram MA, Lindemans J, Slagboom PE, Trégouët DA, Uitterlinden AG, Wei C, Wells P,
Gagnon F, van Greevenbroek MM, Heijmans BT, Milani L, Morange PE, van Meurs JB, Heil
SG; BIOS Consortium. (2017). Homocysteine levels associate with subtle changes in leukocyte
DNA methylation: an epigenome-wide analysis. Epigenomics, 9 (11), 1403−1422.10.2217/epi-
2017-0038.
Kasela, Silva; Kisand, Kai; Tserel, Liina; Kaleviste, Epp; Remm, Anu; Fischer, Krista; Esko,
Tõnu; Westra, Harm-Jan; Fairfax, Benjamin P; Makino, Seiko; Knight, Julian C; Franke, Lude;
Metspalu, Andres; Peterson, Pärt; Milani, Lili (2017). Pathogenic implications for autoimmune
mechanisms derived by comparative eQTL analysis of CD4(+) versus CD8(+) T cells. PLoS
genetics, 13 (3, 3), ARTN e1006643.10.1371/journal.pgen.1006643.
Flannick, Jason; Fuchsberger, Christian; Mahajan, Anubha; Teslovich, Tanya M.; Agarwala,
Vineeta; Gaulton, Kyle J.; Caulkins, Lizz; Koesterer, Ryan; Ma, Clement; Moutsianas, Loukas;
McCarthy, Davis J.; Rivas, Manuel A.; Perry, John R. B.; Sim, Xueling; Blackwell, Thomas W.;
Robertson, Neil R.; Rayner, N. William; Cingolani, Pablo; Locke, Adam E.; Tajes, Juan
Fernandez ... McCarthy, Mark I. (2017). Data Descriptor: Sequence data and association
statistics from 12,940 type 2 diabetes cases and controls. Scientific Data, 4, ARTN
170179.10.1038/sdata.2017.179.
Day, Felix R.; Thompson, Deborah J.; Helgason, Hannes; Chasman, Daniel I.; Finucane, Hilary;
Sulem, Patrick; Ruth, Katherine S.; Whalen, Sean; Sarkar, Abhishek K.; Albrecht, Eva;
Altmaier, Elisabeth; Amini, Marzyeh; Barbieri, Caterina M.; Boutin, Thibaud; Campbell, Archie;
Demerath, Ellen; Giri, Ayush; He, Chunyan; Hottenga, Jouke J.; Karlsson, Robert ... Perry, John
R. B. (2017). Genomic analyses identify hundreds of variants associated with age at menarche
and support a role for puberty timing in cancer risk. Nature Genetics, 49 (6),
834−845.10.1038/ng.3841.
Linner, R. Karlsson; Marioni, R. E.; Rietveld, C. A.; Simpkin, A. J.; Davies, N. M.; Watanabe,
K.; Armstrong, N. J.; Auro, K.; Baumbach, C.; Bonder, M. J.; Buchwald, J.; Fiorito, G.; Ismail,
K.; Iurato, S.; Joensuu, A.; Karell, P.; Kasela, S.; Lahti, J.; Mcrae, A. F.; Mandaviya, P. R. ...
Benjamin, D. J. (2017). An epigenome-wide association study meta-analysis of educational
attainment. Molecular Psychiatry, 22 (12), 1680−1690.10.1038/mp.2017.210.
Gupta, R; Qaiser, B; He, L; Hiekkalinna, T S; Zheutlin, A B; Therman, S; Ollikainen, M; Ripatti,
S; Perola, M; Salomaa, V; Milani, L; Cannon, T D; Madden, P A F; Korhonen, T; Kaprio, J;
Loukola, A (2017). Neuregulin signaling pathway in smoking behavior. Translational psychiatry,
7 (8), e1212−e1212.10.1038/tp.2017.183.
Kantojärvi, Katri; Liuhanen, Johanna; Saarenpää-Heikkilä, Outi; Satomaa, Anna-Liisa;
Kylliäinen, Anneli; Pölkki, Pirjo; Jaatela, Julia; Toivola, Auli; Milani, Lili; Himanen, Sari-
Leena; Porkka-Heiskanen, Tarja; Paavonen, Juulia; Paunio, Tiina (2017). Variants in calcium
voltage-gated channel subunit Alpha1 C-gene (CACNA1C) are associated with sleep latency in
infants. PLoS ONE, 12 (8), e0180652−e0180652.10.1371/journal.pone.0180652.
Joshi, P. K., Pirastu, N., Kentistou, K. A., Fischer, K., Hofer, E., Schraut, K. E., Clark D.W.,
Nutile T., Barnes C.L.K., Timmers P.R.H.J., Shen X., Gandin I., McDaid A.F., Hansen T.F.,
Gordon S.D., Giulianini F., Boutin T.S., Abdellaoui A., Zhao W., Medina-Gomez C., Bartz
T.M., Trompet S., Lange L.A., Raffield L., van der Spek A.,/.../,Bertram L., Pendleton N.,
Kardia S.L.R., Ciullo M., Becker D.M., Wong A., Psaty B.M., van Duijn C.M., Wilson J.G.,
Jukema J.W., Kiemeney L., Uitterlinden A.G, Franceschini N., North K.E., Weir D.R., Metspalu
A., Boomsma D.I., Hayward C., Chasman D., Martin N.G., Sattar N., Campbell H., Esko T.,
Kutalik Z., Wilson J.F. (2017). Genome-wide meta-analysis associates HLA-DQA1/DRB1 and
LPA and lifestyle factors with human longevity. Nature Communications, 8,
910.10.1038/s41467-017-00934-5.
Aru, Juhan; Espak, Peeter; Grossberg, Maarja; Heinsalu, Els; Karjust, Kristo; Kogermann, Karin;
Kurig, Heisi; Köster, Kajar; Küngas, Rainer; Leijen, Äli; Liiv, Innar; Milani, Lili; Mõtus, Kerli;
Näripea, Eva; Ojavee, Kärt; Oras, Ester; Preegel, Gert; Purge, Priit; Raju, Marju; Raudla, Ringa
... Voll, Hendrik (2017). Teadlaste koostöö ettevõtetega – kellele seda vaja on? Sirp : Eesti
kultuurileht, 37−37.
Aru, Juhan; Espak, Peeter; Grossberg, Maarja; Heinsalu, Els; Karjust, Kristo; Kogermann, Karin;
Kurig, Heisi; Köster, Kajar; Küngas, Rainer; Leijen, Äli; Liiv, Innar; Milani, Lili; Mõtus, Kerli;
Näripea, Eva; Ojavee, Kärt; Oras, Ester; Preegel, Gert; Purge, Priit; Raju, Marju; Raudla, Ringa
... Voll, Hendrik (2017). Põlevkivist elektri tootmisest on kujunemas piinlik igand. Sirp : Eesti
kultuurileht, 28−29.
Aru, Juhan; Espak, Peeter; Grossberg, Maarja; Heinsalu, Els; Karjust, Kristo; Kogermann, Karin;
Kurig, Heisi; Köster, Kajar; Küngas, Rainer; Leijen, Äli; Liiv, Innar; Milani, Lili; Mõtus, Kerli;
Näripea, Eva; Ojavee, Kärt; Oras, Ester; Preegel, Gert; Purge, Priit; Raju, Marju; Raudla, Ringa
... Voll, Hendrik (2017). Teadus kui haridusuuenduse toetuspunkt, vundament, vaade ja garantii.
Sirp : Eesti kultuurileht, 34−35.
Aru, Juhan; Espak, Peeter; Grossberg, Maarja; Heinsalu, Els; Karjust, Kristo; Kogermann, Karin;
Kurig, Heisi; Köster, Kajar; Küngas, Rainer; Leijen, Äli; Liiv, Innar; Milani, Lili; Mõtus, Kerli;
Näripea, Eva; Ojavee, Kärt; Oras, Ester; Preegel, Gert; Purge, Priit; Raju, Marju; Raudla, Ringa
... Voll, Hendrik (2017). Teadlaste otselepingud ja vaesus. Sirp : Eesti kultuurileht, 33−35.
Aru, Juhan; Espak, Peeter; Grossberg, Maarja; Heinsalu, Els; Karjust, Kristo; Kogermann, Karin;
Kurig, Heisi; Köster, Kajar; Küngas, Rainer; Leijen, Äli; Liiv, Innar; Milani, Lili; Mõtus, Kerli;
Näripea, Eva; Ojavee, Kärt; Oras, Ester; Preegel, Gert; Purge, Priit; Raju, Marju; Raudla, Ringa
... Voll, Hendrik (2017). Kuhu viib teadlaste karjääriredel? Sirp : Eesti kultuurileht, 7−8.
Lokk, Kaie; Vooder, Tõnu; Kolde, Raivo; Välk, Kristjan; Võsa, Urmo; Roosipuu, Retlav;
Milani, Lili; Fischer, Krista; Koltsina, Marina; Urgard, Egon; Annilo, Tarmo; Metspalu, Andres;
Tõnisson, Neeme (2017). Correction: Methylation Markers of Early-Stage Non-Small Cell Lung
Cancer. PLoS ONE, 12 (1), e0170833−e0170833.10.1371/journal.pone.0170833.
Lokk, Kaie; Vooder, Tonu; Kolde, Raivo; Valk, Kristjan; Vosa, Urmo; Roosipuu, Retlav;
Milani, Lili; Fischer, Krista; Koltsina, Marina; Urgard, Egon; Annilo, Tarmo; Metspalu, Andres;
Tonisson, Neeme (2017). Methylation Markers of Early-Stage Non-Small Cell Lung Cancer (vol
7, e39813, 2012). PLoS ONE, 1, ARTN e0170833.10.1371/journal.pone.0170833.
2016
Lessard, Samuel; Manning, Alisa K; Low-Kam, Cécile; Auer, Paul L; Giri, Ayush; Graff,
Mariaelisa; Schurmann, Claudia; Yaghootkar, Hanieh; Luan, Jian'an; Esko, Tonu; Karaderi,
Tugce; Bottinger, Erwin P; Lu, Yingchang; Carlson, Chris; Caulfield, Mark; Dubé, Marie-Pierre;
Jackson, Rebecca D; Kooperberg, Charles; McKnight, Barbara; Mongrain, Ian ... Lettre,
Guillaume (2016). Testing the role of predicted gene knockouts in human anthropometric trait
variation. Human Molecular Genetics, 25 (10), 1−11.10.1093/hmg/ddw055.
Ivanov, Maxim; Kals, Mart; Lauschke, Volker; Barragan, Isabel; Ewels, Philip; Käller, Max;
Axelsson, Tomas; Lehtiö, Janne; Milani, Lili; Ingelman-Sundberg, Magnus (2016). Single base
resolution analysis of 5-hydroxymethylcytosine in 188 human genes: implications for hepatic
gene expression. Nucleic acids research, 44 (14), 6756−6769.doi:10.1093/nar/gkw316.
Franke, B; Stein, JL; Ripke, S; Anttila, V; Hibar, DP; van, Hulzen, KJ; Arias-Vasquez, A;
Smoller, JW; Nichols, TE; Neale, MC; McIntosh, AM; Lee, P; McMahon, FJ; Meyer-
Lindenberg, A; Mattheisen, M; Andreassen, OA; Gruber, O; Sachdev, PS; Roiz-Santiañez, R;
Saykin, AJ ... Sullivan, PF . (2016). Genetic influences on schizophrenia and subcortical brain
volumes: large-scale proof of concept. Nature Neuroscience, 19 (3), 420−433.10.1038/nn.4228.
Pettai, Kristi; Milani, Lili; Tammiste, Anu; Võsa, Urmo; Kolde, Raivo; Eller, Triin; Nutt, David;
Metspalu, Andres; Maron, Eduard (2016). Whole-genome expression analysis reveals genes
associated with treatment response to escitalopram in major depression. European
neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology,
26 (9), 1475−1483.10.1016/j.euroneuro.2016.06.007.
Limbach, Maia; Saare, Mario; Tserel, Liina; Kisand, Kai; Eglit, Triin; Sauer, Sascha; Axelsson,
Tomas; Syvänen, Ann-Christine; Metspalu, Andres; Milani, Lili; Peterson, Pärt (2016).
Epigenetic profiling in CD4+ and CD8+ T cells from Graves' disease patients reveals changes in
genes associated with T cell receptor signaling. Journal of Autoimmunity, 67,
46−56.10.1016/j.jaut.2015.09.006.
Thiéry, Odile; Vasar, Martti; Jairus, Teele; Davison, John; Roux, Christophe; Kivistik, Paula-
Ann; Metspalu, Andres; Milani, Lili; Saks, Ülle; Moora, Mari; Zobel, Martin; Öpik, Maarja
(2016). Sequence variation in nuclear ribosomal small subunit, internal transcribed spacer and
large subunit regions of Rhizophagus irregularis and Gigaspora margarita is high and isolate-
dependent. Molecular ecology, 25 (12), 2816−2832.10.1111/mec.13655.
Fuchsberger, Christian; Flannick, Jason; Teslovich, Tanya M; Mahajan, Anubha; Agarwala,
Vineeta; Gaulton, Kyle J; Ma, Clement; Fontanillas, Pierre; Moutsianas, Loukas; McCarthy,
Davis J; Rivas, Manuel A; Perry, John R B; Sim, Xueling; Blackwell, Thomas W; Robertson,
Neil R; Rayner, N William; Cingolani, Pablo; Locke, Adam E; Tajes, Juan Fernandez; Highland,
Heather M ... McCarthy, Mark I (2016). The genetic architecture of type 2 diabetes. Nature, 536
(7614), 41−47.10.1038/nature18642.
Okbay, Aysu; Beauchamp, Jonathan P; Fontana, Mark Alan; Lee, James J; Pers, Tune H;
Rietveld, Cornelius A; Turley, Patrick; Chen, Guo-Bo; Emilsson, Valur; Meddens, S Fleur W;
Oskarsson, Sven; Pickrell, Joseph K; Thom, Kevin; Timshel, Pascal; de Vlaming, Ronald;
Abdellaoui, Abdel; Ahluwalia, Tarunveer S; Bacelis, Jonas; Baumbach, Clemens; Bjornsdottir,
Gyda ... Benjamin, Daniel J (2016). Genome-wide association study identifies 74 loci associated
with educational attainment. Nature, 533 (7604), 539−542.10.1038/nature17671.
Gormley, Padhraig; Anttila, Verneri; Winsvold, Bendik S; Palta, Priit; Esko, Tonu; Pers, Tune
H; Farh, Kai-How; Cuenca-Leon, Ester; Muona, Mikko; Furlotte, Nicholas A; Kurth, Tobias;
Ingason, Andres; McMahon, George; Ligthart, Lannie; Terwindt, Gisela M; Kallela, Mikko;
Freilinger, Tobias M; Ran, Caroline; Gordon, Scott G; Stam, Anine H ... Palotie, Aarno (2016).
Meta-analysis of 375,000 individuals identifies 38 susceptibility loci for migraine. Nature
genetics, 48 (8), 856−866.10.1038/ng.3598.
Barban N, Jansen R, de Vlaming R, Vaez A, Mandemakers JJ, Tropf FC, Shen X, Wilson JF,
Chasman DI, Nolte IM, Tragante V, van der Laan SW, Perry JR, Kong A; BIOS Consortium,
Ahluwalia TS, Albrecht E, Yerges-Armstrong L, Atzmon G, Auro K, Ayers K, Bakshi A, Ben-
Avraham D, Berger K, Bergman A, Bertram L, Bielak LF, Bjornsdottir G, Bonder MJ, Broer L,
Bui M, Barbieri C, Cavadino A, Chavarro JE, Turman C, Concas MP, Cordell HJ, Davies G,
Eibich P, Eriksson N, Esko T, Eriksson J, Falahi F, Felix JF, Fontana MA, Franke L, Gandin I,
Gaskins AJ, Gieger C, Gunderson EP, Guo X, Hayward C, He C, Hofer E, Huang H, Joshi PK,
Kanoni S, Karlsson R, Kiechl S, Kifley A, Kluttig A, Kraft P, Lagou V, Lecoeur C, Lahti J, Li-
Gao R, Lind PA, Liu T, Makalic E, Mamasoula C, Matteson L, Mbarek H, McArdle PF,
McMahon G, Meddens SF, Mihailov E, Miller M, Missmer SA, Monnereau C, van der Most PJ,
Myhre R, Nalls MA, Nutile T, Kalafati IP, Porcu E, Prokopenko I, Rajan KB, Rich-Edwards J,
Rietveld CA, Robino A, Rose LM, Rueedi R, Ryan KA, Saba Y, Schmidt D, Smith JA, Stolk L,
Streeten E, Tönjes A, Thorleifsson G, Ulivi S, Wedenoja J, Wellmann J, Willeit P, Yao J, Yengo
L, Zhao JH, Zhao W, Zhernakova DV, Amin N, Andrews H, Balkau B, Barzilai N, Bergmann S,
Biino G, Bisgaard H, Bønnelykke K, Boomsma DI, Buring JE, Campbell H, Cappellani S, Ciullo
M, Cox SR, Cucca F, Toniolo D, Davey-Smith G, Deary IJ, Dedoussis G, Deloukas P, van Duijn
CM, de Geus EJ, Eriksson JG, Evans DA, Faul JD, Sala CF, Froguel P, Gasparini P, Girotto G,
Grabe HJ, Greiser KH, Groenen PJ, de Haan HG, Haerting J, Harris TB, Heath AC, Heikkilä K,
Hofman A, Homuth G, Holliday EG, Hopper J, Hyppönen E, Jacobsson B, Jaddoe VW,
Johannesson M, Jugessur A, Kähönen M, Kajantie E, Kardia SL, Keavney B, Kolcic I, Koponen
P, Kovacs P, Kronenberg F, Kutalik Z, La Bianca M, Lachance G, Iacono WG, Lai S, Lehtimäki
T, Liewald DC; LifeLines Cohort Study, Lindgren CM, Liu Y, Luben R, Lucht M, Luoto R,
Magnus P, Magnusson PK, Martin NG, McGue M, McQuillan R, Medland SE, Meisinger C,
Mellström D, Metspalu A, Traglia M, Milani L, Mitchell P, Montgomery GW, Mook-Kanamori
D, de Mutsert R, Nohr EA, Ohlsson C, Olsen J, Ong KK, Paternoster L, Pattie A, Penninx BW,
Perola M, Peyser PA, Pirastu M, Polasek O, Power C, Kaprio J, Raffel LJ, Räikkönen K,
Raitakari O, Ridker PM, Ring SM, Roll K, Rudan I, Ruggiero D, Rujescu D, Salomaa V,
Schlessinger D, Schmidt H, Schmidt R, Schupf N, Smit J, Sorice R, Spector TD, Starr JM,
Stöckl D, Strauch K, Stumvoll M, Swertz MA, Thorsteinsdottir U, Thurik AR, Timpson NJ,
Tung JY, Uitterlinden AG, Vaccargiu S, Viikari J, Vitart V, Völzke H, Vollenweider P,
Vuckovic D, Waage J, Wagner GG, Wang JJ, Wareham NJ, Weir DR, Willemsen G, Willeit J,
Wright AF, Zondervan KT, Stefansson K, Krueger RF, Lee JJ, Benjamin DJ, Cesarini D,
Koellinger PD, den Hoed M, Snieder H, Mills MC. (2016). Genome-wide analysis identifies 12
loci influencing human reproductive behavior. Nature Genetics, 48 (12),
1462−1472.10.1038/ng.3698.
Ried JS, Jeff M J, Chu AY, Bragg-Gresham JL, van Dongen J, Huffman JE, Ahluwalia TS,
Cadby G, Eklund N, Eriksson J, Esko T, Feitosa MF, Goel A, Gorski M, Hayward C, Heard-
Costa NL, Jackson AU, Jokinen E, Kanoni S, Kristiansson K, Kutalik Z, Lahti J, Luan J, Mägi R,
Mahajan A, Mangino M, Medina-Gomez C, Monda KL, Nolte IM, Pérusse L, Prokopenko I, Qi
L, Rose LM, Salvi E, Smith MT, Snieder H, Stančáková A, Ju Sung Y, Tachmazidou I, Teumer
A, Thorleifsson G, van der Harst P, Walker RW, Wang SR, Wild SH, Willems SM, Wong A,
Zhang W, Albrecht E, Couto Alves A, Bakker SJ, Barlassina C, Bartz TM, Beilby J, Bellis C,
Bergman RN, Bergmann S, Blangero J, Blüher M, Boerwinkle E, Bonnycastle LL, Bornstein SR,
Bruinenberg M, Campbell H, Chen YI, Chiang CW, Chines PS, Collins FS, Cucca F, Cupples
LA, D'Avila F, de Geus EJ, Dedoussis G, Dimitriou M, Döring A, Eriksson JG, Farmaki AE,
Farrall M, Ferreira T, Fischer K, Forouhi NG, Friedrich N, Gjesing AP, Glorioso N, Graff M,
Grallert H, Grarup N, Gräßler J, Grewal J, Hamsten A, Harder MN, Hartman CA, Hassinen M,
Hastie N, Hattersley AT, Havulinna AS, Heliövaara M, Hillege H, Hofman A, Holmen O,
Homuth G, Hottenga JJ, Hui J, Husemoen LL, Hysi PG, Isaacs A, Ittermann T, Jalilzadeh S,
James AL, Jørgensen T, Jousilahti P, Jula A, Marie Justesen J, Justice AE, Kähönen M,
Karaleftheri M, Tee Khaw K, Keinanen-Kiukaanniemi SM, Kinnunen L, Knekt PB, Koistinen
HA, Kolcic I, Kooner IK, Koskinen S, Kovacs P, Kyriakou T, Laitinen T, Langenberg C, Lewin
AM, Lichtner P, Lindgren CM, Lindström J, Linneberg A, Lorbeer R, Lorentzon M, Luben R,
Lyssenko V, Männistö S, Manunta P, Leach IM, McArdle WL, Mcknight B, Mohlke KL,
Mihailov E, Milani L, Mills R, Montasser ME, Morris AP, Müller G, Musk AW, Narisu N, Ong
KK, Oostra BA, Osmond C, Palotie A, Pankow JS, Paternoster L, Penninx BW, Pichler I, Pilia
MG, Polašek O, Pramstaller PP, Raitakari OT, Rankinen T, Rao DC, Rayner NW, Ribel-Madsen
R, Rice TK, Richards M, Ridker PM, Rivadeneira F, Ryan KA, Sanna S, Sarzynski MA,
Scholtens S, Scott RA, Sebert S, Southam L, Sparsø TH, Steinthorsdottir V, Stirrups K, Stolk
RP, Strauch K, Stringham HM, Swertz MA, Swift AJ, Tönjes A, Tsafantakis E, van der Most PJ,
Van Vliet-Ostaptchouk JV, Vandenput L, Vartiainen E, Venturini C, Verweij N, Viikari JS,
Vitart V, Vohl MC, Vonk JM, Waeber G, Widén E, Willemsen G, Wilsgaard T, Winkler TW,
Wright AF, Yerges-Armstrong LM, Hua Zhao J, Carola Zillikens M, Boomsma DI, Bouchard C,
Chambers JC, Chasman DI, Cusi D, Gansevoort RT, Gieger C, Hansen T, Hicks AA, Hu F,
Hveem K, Jarvelin MR, Kajantie E, Kooner JS, Kuh D, Kuusisto J, Laakso M, Lakka TA,
Lehtimäki T, Metspalu A, Njølstad I, Ohlsson C, Oldehinkel AJ, Palmer LJ, Pedersen O, Perola
M, Peters A, Psaty BM, Puolijoki H, Rauramaa R, Rudan I, Salomaa V, Schwarz PE, Shudiner
AR, Smit JH, Sørensen TI, Spector TD, Stefansson K, Stumvoll M, Tremblay A, Tuomilehto J,
Uitterlinden AG, Uusitupa M, Völker U, Vollenweider P, Wareham NJ, Watkins H, Wilson JF,
Zeggini E, Abecasis GR, Boehnke M, Borecki IB, Deloukas P, van Duijn CM, Fox C, Groop LC,
Heid IM, Hunter DJ, Kaplan RC, McCarthy MI, North KE, O'Connell JR, Schlessinger D,
Thorsteinsdottir U, Strachan DP, Frayling T, Hirschhorn JN, Müller-Nurasyid M, Loos RJ.
(2016). A principal component meta-analysis on multiple anthropometric traits identifies novel
loci for body shape. Nature Communications, e13357, 1−11.10.1038/ncomms13357.
Guerra, D.; Ghiselli, F.; Milani, L.; Breton, S.; Passamonti, M. (2016). Early replication
dynamics of sex-linked mitochondrial DNAs in the doubly uniparental inheritance species
Ruditapes philippinarum (Bivalvia Veneridae). Heredity, 116 (3),
314−322.10.1038/hdy.2015.105.
Marioni RE, Ritchie SJ, Joshi PK, Hagenaars SP, Okbay A, Fischer K, Adams MJ, Hill WD,
Davies G; Social Science Genetic Association Consortium, Nagy R, Amador C, Läll K,
Metspalu A, Liewald DC, Campbell A, Wilson JF, Hayward C, Esko T, Porteous DJ, Gale CR,
Deary IJ. (2016). Genetic variants linked to education predict longevity. PNAS, 113 (47),
13366−13371.10.1073/pnas.1605334113.
Sekar, Aswin; Bialas, Allison R.; de Rivera, Heather; Davis, Avery; Hammond, Timothy R.;
Kamitaki, Nolan; Tooley, Katherine; Presumey, Jessy; Baum, Matthew; Van Doren, Vanessa;
Genovese, Giulio; Rose, Samuel A.; Handsaker, Robert E.; Daly, Mark J.; Carroll, Michael C.;
Stevens, Beth; McCarroll, Steven A. (2016). Schizophrenia risk from complex variation of
complement component 4. Nature, 530 (7589), 177−194.10.1038/nature16549.
Tasa, Tonis; Metsvaht, Tuuli; Kalamees, Riste; Milani, Lili; Vilo, Jaak; Lutsar, Irja (2016).
Personalised Bayesian Dose Adjustment of Vancomycin in Neonates. Human Heredity, 81 (4),
236−236.
Peterson, P.; Tserel, L.; Kolde, R.; Limbach, M.; Tretyakov, K.; Kasela, S.; Kisand, K.; Saare,
M.; Vilo, J.; Metspalu, A.; Milani, L. (2016). Age-related profiling of DNA methylation in
CD8+T cells reveals changes in immune response and transcriptional regulator genes. European
Journal of Immunology, 879−879.
Kantojarvi, K.; Liuhanen, J.; Saarenpaa-Heikkila, O.; Satomaa, A. -L; Kylliainen, A.; Polkki, P.;
Jaatela, J.; Milani, L.; Himanen, S. -L.; Porkka-Heiskanen, T.; Paavonen, J.; Paunio, T. (2016).
Variants in CACNA1C are associated with sleep regulation in infants. European
Neuropsychopharmacology, 192−192.WOS:000413843800345.
Gormley, Padhraig; Anttila, Verneri; Winsvold, Bendik S; Palta, Priit; Esko, Tonu; Pers, Tune
H; Farh, Kai-How; Cuenca-Leon, Ester; Muona, Mikko; Furlotte, Nicholas A; Kurth, Tobias;
Ingason, Andres; McMahon, George; Ligthart, Lannie; Terwindt, Gisela M; Kallela, Mikko;
Freilinger, Tobias M; Ran, Caroline; Gordon, Scott G; Stam, Anine H ... Palotie, Aarno. (2016).
Corrigendum: Meta-analysis of 375,000 individuals identifies 38 susceptibility loci for migraine.
Nature genetics, 48 (10), 1296−1296.10.1038/ng1016-1296c.
Nikopensius, T.; Saag, M.; Jagomagi, T.; Annilo, T.; Kals, M.; Kivistik, P. A.; Milani, L.;
Metspalu, A. (2016). A missense mutation in DUSP6 is associated with Class III malocclusion
(vol 92, pg 893, 2013). Journal Of Dental Research, 8, 955−955.10.1177/0022034516651438.
2015
Westra, HJ; Arends, D; Esko, T; Peters, MJ; Schurmann, C; Schramm, K; Kettunen, J;
Yaghootkar, H; Fairfax, BP; Andiappan, AK; Li, Y; Fu, J; Karjalainen, J; Platteel, M;
Visschedijk, M; Weersma, RK; Kasela, S; Milani, L; Tserel, L; Peterson, P ... Franke, L. (2015).
Cell Specific eQTL Analysis without Sorting Cells. Plos Genetics, 11 (5),
e1005223.10.1371/journal.pgen.1005223.
Bulik-Sullivan, BK.; Loh, PR.; Finucane, HK.; Ripke, S.; Yang, J.; Schizophrenia Working
Group of the Psychiatric, Genomics Consortium; Patterson, N.; Daly, MJ.; Price, AL.; Neale,
BM. (2015). LD Score regression distinguishes confounding from polygenicity in genome-wide
association studies. Nature Genetics, 47 (3), 291−295.10.1038/ng.3211.
Peyrot, WJ; Lee, SH; Milaneschi, Y; Abdellaoui, A; Byrne, EM; Esko, T; de, Geus, EJ; Hemani,
G; Hottenga, JJ; Kloiber, S; Levinson, DF; Lucae, S; Martin, NG; Medland, SE; Metspalu, A;
Milani, L; Noethen, MM; Potash, JB; Rietschel, M; Rietveld, CA ... SSGAC, Corporate,
Collaborator. (2015). The association between lower educational attainment and depression
owing to shared genetic effects? Results in ~25 000 subjects. Molecular Psychiatry, 20 (6),
735−743.10.1038/mp.2015.50.
Huan, Tianxiao; Esko, Tõnu; Peters, Marjolein J; Pilling, Luke C; Schramm, Katharina;
Schurmann, Claudia; Chen, Brian H; Liu, Chunyu; Joehanes, Roby; Johnson, Andrew D; Yao,
Chen; Ying, Sai-Xia; Courchesne, Paul; Milani, Lili; Raghavachari, Nalini; Wang, Richard; Liu,
Poching; Reinmaa, Eva; Dehghan, Abbas; Hofman, Albert ... Levy, Daniel. (2015). A Meta-
analysis of Gene Expression Signatures of Blood Pressure and Hypertension. Plos Genetics, 11
(3), e1005035.10.1371/journal.pgen.1005035.
Zhu, Z; Bakshi, A; Vinkhuyzen, AA; Hemani, G; Lee, SH; Nolte, IM; van, Vliet-Ostaptchouk,
JV; Snieder, H; The, LifeLines, Cohort, Study; Esko, T; Milani, L; Mägi, R; Metspalu, A; Hill,
WG; Weir, BS; Goddard, ME; Visscher, PM; Yang, J. (2015). Dominance Genetic Variation
Contributes Little to the Missing Heritability for Human Complex Traits. American Journal of
Human Genetics, 96 (3), 377−85.10.1016/j.ajhg.2015.01.001.
Shungin, D; Winkler, TW; Croteau-Chonka, DC; Ferreira, T; Locke, AE; Mägi, R; Strawbridge,
RJ; Pers, TH; Fischer, K; Justice, AE; Workalemahu, T; Wu, JM; Buchkovich, ML; Heard-
Costa, NL; Roman, TS; Drong, AW; Song, C; Gustafsson, S; Day, FR; Esko, T ... Mohlke, KL.
(2015). New genetic loci link adipose and insulin biology to body fat distribution. Nature, 518
(7538), 187−196.10.1038/nature14132.
Putku, Margus; Kals, Mart; Inno, Rain; Kasela, Silva; Org, Elin; Kožich, Viktor; Milani, Lili;
Laan, Maris (2015). CDH13 promoter SNPs with pleiotropic effect on cardiometabolic
parameters represent methylation QTLs. Human Genetics, 134 (3), 291−303.10.1007/s00439-
014-1521-6.
Milani, Lili; Leitsalu, Liis; Metspalu, Andres (2015). An epidemiological perspective of
personalized medicine: the Estonian experience. Journal of Internal Medicine, 277 (2),
188−200.10.1111/joim.12320.
The, Coffee, and, Caffeine, Genetics, Consortium; Cornelis, MC; Byrne, EM; Esko, T; Nalls,
MA; Ganna, A; Paynter, N; Monda, KL; Amin, N; Fischer, K; Renstrom, F; Ngwa, JS; Huikari,
V; Cavadino, A; Nolte, IM; Teumer, A; Yu, K; Marques-Vidal, P; Rawal, R; Manichaikul, A ...
Chasman, DI. (2015). Genome-wide meta-analysis identifies six novel loci associated with
habitual coffee consumption. Molecular Psychiatry, 20 (5), 647−656.10.1038/mp.2014.107.
Joshi, PK; Esko, T; Mattsson, H; Eklund, N; Gandin, I; Nutile, T; Jackson, AU; Schurmann, C;
Smith, AV; Zhang, W; Okada, Y; Stančáková, A; Faul, JD; Zhao, W; Bartz, TM; Concas, MP;
Franceschini, N; Enroth, S; Vitart, V; Trompet, S ... Wilson, JF. (2015). Evidence for directional
dominance on complex traits relating to size and cognition in a wide range of human
populations. Nature, 46 (11), 1173−1186.10.1038/nature14618.
Yang, J; Bakshi, A; Zhu, Z; Hemani, G; Vinkhuyzen, AAE; Lee, SH (; Robinson, MR; Perry,
JRB; Nolte, IM; van Vliet-Ostaptchouk, JV; Snieder, H; Esko, T; Milani, L; Magi, R; Metspalu,
A; Hamsten, A; Magnusson, PKE; Pedersen, NL; Ingelsson, E; Soranzo, N ... Visscher, PM.
(2015). Genetic variance estimation with imputed variants finds negligible missing heritability
for human height and body mass index. Nature Genetics, 47 (10), 1114−1120.10.1038/ng.3390.
Peters, MJ; Joehanes, R; Pilling, LC; Schurmann, C; Conneely, KN; Powell, J; Reinmaa, E;
Sutphin, GL; Zhernakova, A; Schramm, K; Wilson, YA; Kobes, S; Tukiainen, T;
NABEC/UKBEC, Consortium; Ramos, YF; Göring, HH; Fornage, M; Liu, Y; Gharib, SA;
Stranger, BE ... Johnson, AD. (2015). The transcriptional landscape of age in human peripheral
blood. Nature Communications, 6 (8570), 1−14.10.1038/ncomms9570.
Kato, N; Loh, M; Takeuchi, F; Verweij, N; Wang, X; Zhang, W; Kelly, TN; Saleheen, D; Lehne,
B; Mateo, Leach, I; Drong, AW; Abbott, J; Wahl, S; Tan, ST; Scott, WR; Campanella, G;
Chadeau-Hyam, M; Afzal, U; Ahluwalia, TS; Bonder, MJ ... Chambers, JC. (2015). Trans-
ancestry genome-wide association study identifies 12 genetic loci influencing blood pressure and
implicates a role for DNA methylation. Nature Genetics, 47 (11), 1282−1293.10.1038/ng.3405.
Winkler, T.W.; Justice, A.E.; Graff, M.; Barata, L.; Feitosa, M.F.; Chu, S; Czajkowski, J.; Esko,
T.; Fall, T.; Kilpeläinen, T.O.; Lu, Y.; Mägi, R.; Mihailov, E.; ... Milani, L.; Nelis, M.;
Pervjakova, N.; Perola, M.; ... Loos, RJF. (2015). The Influence of Age and Sex on Genetic
Associations with Adult Body Size and Shape: A Large-Scale Genome-Wide Interaction Study.
Plos Genetics, 11 (10), e1005378−42.10.1371/journal.pgen.1005378.
Locke, AE.; Kahali, B.; Berndt, SI.; Justice, AE.; Pers, TH.; Day, FR.; Powell, C.; Vedantam, S.;
Buchkovich, ML.; Yang, J.; Croteau-Chonka, DC.; Esko, T.; Fall, T.; Ferreira, T.; Gustafsson,
S.; Kutalik, Z.; Luan, J.; Mägi, R.; Randall, JC.; Winkler, TW. ... Speliotes, EK. (2015). Genetic
studies of body mass index yield new insights for obesity biology. Nature, 518 (7538),
197−206.10.1038/nature14177.
Day, Felix R; Ruth, Katherine S; Thompson, Deborah J; Lunetta, Kathryn L; Pervjakova,
Natalia; Chasman, Daniel I; Stolk, Lisette; Finucane, Hilary K; Sulem, Patrick; Bulik-Sullivan,
Brendan; Esko, Tõnu; Johnson, Andrew D; Elks, Cathy E; Franceschini, Nora; He, Chunyan;
Altmaier, Elisabeth; Brody, Jennifer A; Franke, Lude L; Huffman, Jennifer E; Keller, Margaux F
... Murray, Anna (2015). Large-scale genomic analyses link reproductive aging to hypothalamic
signaling, breast cancer susceptibility and BRCA1-mediated DNA repair. Nature Genetics, 47
(11), 1294−303.10.1038/ng.3412.
Peters, Marjolein J; Joehanes, Roby; Pilling, Luke C; Schurmann, Claudia; Conneely, Karen N;
Powell, Joseph; Reinmaa, Eva; Sutphin, George L; Zhernakova, Alexandra; Schramm,
Katharina; Wilson, Yana A; Kobes, Sayuko; Tukiainen, Taru; ,; Ramos, Yolande F; Göring,
Harald H H; Fornage, Myriam; Liu, Yongmei; Gharib, Sina A; Stranger, Barbara E ... Johnson,
Andrew D (2015). The transcriptional landscape of age in human peripheral blood. Nature
communications, 6, 8570−8570.10.1038/ncomms9570.
Tserel, Liina; Kolde, Raivo; Limbach, Maia; Tretyakov, Konstantin; Kasela, Silva; Kisand, Kai;
Saare, Mario; Vilo, Jaak; Metspalu, Andres; Milani, Lili; Peterson, Pärt (2015). Age-related
profiling of DNA methylation in CD8+ T cells reveals changes in immune response and
transcriptional regulator genes. Scientific Reports, 5 (13107), 1−11.10.1038/srep13107.
Leitsalu, Liis; Haller, Toomas; Esko, Tõnu; Tammesoo, Mari-Liis; Alavere, Helene; Snieder,
Harold; Perola, Markus; Ng, Pauline C; Mägi, Reedik; Milani, Lili; Fischer, Krista; Metspalu,
Andres (2015). Cohort Profile: Estonian Biobank of the Estonian Genome Center, University of
Tartu. International Journal of Epidemiology, 44 (4), 1137−1147.10.1093/ije/dyt268.
Day, Felix R.; Ruth, Katherine S.; Thompson, Deborah J.; Lunetta, Kathryn L.; Pervjakova,
Natalia; Chasman, Daniel I.; Stolk, Lisette; Finucane, Hilary K.; Sulem, Patrick; Bulik-Sullivan,
Brendan; Esko, Tonu; Johnson, Andrew D.; Elks, Cathy E.; Franceschini, Nora; He, Chunyan;
Altmaier, Elisabeth; Brody, Jennifer A.; Franke, Lude L.; Huffman, Jennifer E.; Keller, Margaux
F. ... Murray, Anna (2015). Large-Scale Genomic Analyses Link Reproductive Aging to
Hypothalamic Signaling, Breast Cancer Susceptibility, and BRCA1-Mediated DNA Repair
EDITORIAL COMMENT. Obstetrical & Gynecological Survey, 12,
758−762.10.1097/01.ogx.0000473766.71624.99.
Yang, Jian; Bakshi, Andrew; Zhu, Zhihong; Hemani, Gibran; Vinkhuyzen, Anna A E; Nolte, Ilja
M; van Vliet-Ostaptchouk, Jana V; Snieder, Harold; , ; Esko, Tonu; Milani, Lili; Mägi, Reedik;
Metspalu, Andres; Hamsten, Anders; Magnusson, Patrik K E; Pedersen, Nancy L; Ingelsson,
Erik; Visscher, Peter M (2015). Genome-wide genetic homogeneity between sexes and
populations for human height and body mass index. Human Molecular Genetics, 24 (25),
7445−7449.10.1093/hmg/ddv443.
Joshi, Peter K; Esko, Tonu; Mattsson, Hannele; Eklund, Niina; Gandin, Ilaria; Nutile, Teresa;
Jackson, Anne U; Schurmann, Claudia; Smith, Albert V; Zhang, Weihua; Okada, Yukinori;
Stančáková, Alena; Faul, Jessica D; Zhao, Wei; Bartz, Traci M; Concas, Maria Pina;
Franceschini, Nora; Enroth, Stefan; Vitart, Veronique; Trompet, Stella ... Wilson, James F
(2015). Directional dominance on stature and cognition in diverse human populations. Nature,
523 (7561), 459−462.10.1038/nature14618.
Milani, L. (2015). Toome geenid lauale. Sirp : Eesti kultuurileht.
Benyamin, B; Esko, T; Ried, JS; Radhakrishnan, A; Vermeulen, SH; Traglia, M; Gögele, M;
Anderson, D; Broer, L; Podmore, C; Luan, J; Kutalik, Z; Sanna, S; van, der, Meer, P; Tanaka, T;
Wang, F; Westra, HJ; Franke, L; Mihailov, E; Milani, L ... Whitfield, JB. (2015). Novel loci
affecting iron homeostasis and their effects in individuals at risk for hemochromatosis. Nature
Communications, 6, 6542.10.1038/ncomms7542.
Benyamin, Beben; Esko, Tonu; Ried, Janina S.; Radhakrishnan, Aparna; Vermeulen, Sita H.;
Traglia, Michela; Goegele, Martin; Anderson, Denise; Broer, Linda; Podmore, Clara; Luan,
Jianan; Kutalik, Zoltan; Sanna, Serena; van der Meer, Peter; Tanaka, Toshiko; Wang, Fudi;
Westra, Harm-Jan; Franke, Lude; Mihailov, Evelin; Milani, Lili ... Whitfield, John B. (2015).
Novel loci affecting iron homeostasis and their effects in individuals at risk for hemochromatosis
(vol 5, 4926, 2014). Nature Communications, ARTN 6542.10.1038/ncomms7542.
2014
Benyamin, B; Esko, T; Ried, JS; Radhakrishnan, A; Vermeulen, SH; Traglia, M; Gögele, M;
Anderson, D; Broer, L; Podmore, C; Luan, J; Kutalik, Z; Sanna, S; van, der, Meer, P; Tanaka, T;
Wang, F; Westra, HJ; Franke, L; Mihailov, E; Milani, L ... Whitfield, JB. (2014). Novel loci
affecting iron homeostasis and their effects in individuals at risk for hemochromatosis. Nature
Communications, 5 (4926), 1−7.10.1038/ncomms5926.
Knappskog, S.; Gansmo, L.B.; Dibirova, K.; Metspalu, A.; Cybulski, C.; Peterlongo, P.;
Aaltonen, L.; Vatten, L.; Romundstad, P.; Hveem, K.; Devilee, P.; Evans, G.D.; Lin, D.; Van,
Camp, G.; Manolopoulos, V.G.; Osorio, A.; Milani, L.; Ozcelik, T.; Zalloua, P.; Mouzaya, F. ...
Lønning, P.E. (2014). Population, distribution, and, ancestry, of, the, cancer, protective, MDM2,
SNP285, (rs117039649). Oncotarget, 5 (18), 8224−8234.
Bonder, MJ; Kasela, S; Kals, M; Tamm, R; Lokk, K; Barragan, I; Buurman, WA; Deelen, P;
Greve, J-W; Ivanov, M; Rensen, SS; van Vliet-Ostaptchouk, JV; Wolfs, MG; Fu, J; Hofker, MH;
Wijmenga, C; Zhernakova, A; Ingelman-Sundberg, M; Lude Franke, L; Milani, L. (2014).
Genetic and epigenetic regulation of gene expression in fetal and adult human livers. BMC
Genomics, 15 (860), 1−28.10.1186/1471-2164-15-860.
Dumas, O.; Laurent, E.; Bousquet, J.; Metspalu, A.; Milani, L.; Kauffmann, F.; Le Moual, N.
(2014). Occupational irritants and asthma: an Estonian cross-sectional study of 34 000 adults.
European Respiratory Journal, 44 (3), 647−656.10.1183/09031936.00172213.
González, JR; Cáceres, A; Esko, T; Cuscó, I; Puig, M; Esnaola, M; Reina, J; Siroux, V;
Bouzigon, E; Nadif, R; Reinmaa, E; Milani, L; Bustamante, M; Jarvis, D; Antó, JM; Sunyer, J;
Demenais, F; Kogevinas, M; Metspalu, A; Cáceres, M ... Pérez-Jurado, LA. (2014). A Common
16p11.2 Inversion Underlies the Joint Susceptibility to Asthma and Obesity. American Journal of
Human Genetics, 94 (3), 361−372.10.1016/j.ajhg.2014.01.015.
Perry, J.R.B.; Day, F.; Elks, C.E.; Sulem, P.; Thompson, D.J.; Ferreira, T.; He, C.; Chasman,
D.I.; Esko, T.; Thorleifsson, G.; Albrecht, E.; Ang, W.Q.; Corre, T.; Cousminer, D.L.; Feenstra,
B.; Franceschini, N.; Ganna, A.; Johnson, A.D.; Kjellqvist, S.; Lunetta, K.L. ... Ong, K.K.
(2014). Parent-of-origin-specific allelic associations among 106 genomic loci for age at
menarche. Nature, 514 (7520), 92.10.1038/nature13545.
Schizophrenia Working Group of the Psychiatric Genomics Consortium ... Metspalu, A; Milani,
L; Nelis, M; Esko, T. (2014). Biological insights from 108 schizophrenia-associated genetic loci.
Nature, 511 (7510), 421−427.10.1038/nature13595.
Metsalu, Tauno; Viltrop, Triin; Tiirats, Airi; Rajashekar, Balaji; Reimann, Ene; Kõks, Sulev;
Rull, Kristiina; Milani, Lili; Acharya, Ganesh; Basnet, Purusotam; Vilo, Jaak; Mägi, Reedik;
Metspalu, Andres; Peters, Maire; Haller-Kikkatalo, Kadri; Salumets, Andres (2014). Using RNA
sequencing for identifying gene imprinting and random monoallelic expression in human
placenta. Epigenetics, 9 (10), 1397−1409.10.4161/15592294.2014.970052.
Winkler, T.W.; Day, FR.; Croteau-Chonka, DC.; Wood, AR.; Locke, AE.; Magi, R.; Ferreira, T.;
Fall, T.; Graff, M.; Justice, AE.; Luan, JA.; Gustafsson, S.; Randall, JC.; Vedantam, S.;
Workalemahu, T.; Kilpelainen, TO.; Scherag, A.; Esko, T.; Kutalik, Z.; Heid, IM. ... Loos, RJF
(2014). Quality control and conduct of genome-wide association meta-analyses. Nature
Protocols, 9 (5), 1192−1212.10.1038/nprot.2014.071.
Tserel, Liina; Limbach, Maia; Saare, Mario; Kisand, Kai; Metspalu, Andres; Milani, Lili;
Peterson, Pärt (2014). CpG sites associated with NRP1, NRXN2 and miR-29b-2 are
hypomethylated in monocytes during ageing. Immunity and Ageing, 11 (1), Article Number: 1
(1-5).
Evangelou, E; Kerkhof, HJ; Styrkarsdottir, U; Ntzani, EE; Bos, SD; Esko, T; Evans, DS;
Metrustry, S; Panoutsopoulou, K; Ramos, YF; Thorleifsson, G; Tsilidis, KK; arcOGEN,
Consortium; Arden, N; Aslam, N; Bellamy, N; Birrell, F; Blanco, FJ; Carr, A; Chapman, K ...
Valdes, AM. (2014). A meta-analysis of genome-wide association studies identifies novel
variants associated with osteoarthritis of the hip. Annals of the Rheumatic Diseases, 73 (12),
2130−2136.10.1136/annrheumdis-2012-203114.
Wood, AR; Esko, T; Yang, J; Vedantam, S; Pers, TH; Gustafsson, S; Chu, AY; Estrada, K;
Luan, J; Kutalik, Z; Amin, N; Buchkovich, ML; Croteau-Chonka, DC; Day, FR; Duan, Y14;
Fall, T; Fehrmann, R; Ferreira, T; Jackson, AU; Karjalainen, J ... Frayling, TM. (2014). Defining
the role of common variation in the genomic and biological architecture of adult human height.
Nature Genetics, 46 (11), 1173−1186.10.1038/ng.3097.
Knappskog, Stian; Gansmo, Liv B.; Dibirova, Khadizha; Metspalu, Andres; Cybulski, Cezary;
Peterlongo, Paolo; Aaltonen, Lauri; Vatten, Lars; Romundstad, Pal; Hveem, Kristian; Devilee,
Peter; Evans, Gareth D.; Lin, Dongxin; Van Camp, Guy; Manolopoulos, Vangelis G.; Osorio,
Ana; Milani, Lili; Ozcelik, Tayfun; Zalloua, Pierre; Mouzaya, Francis ... Lonning, Per E. (2014).
Population distribution and ancestry of the cancer protective MDM2 SNP285 (rs117039649).
Oncotarget, 5 (18), 8223−8234.
Kretschmer, A.; Moeller, G.; Lee, H.; Laumen, H.; von Toerne, C.; Schramm, K.; Prokisch, H.;
Eyerich, S.; Wahl, S.; Baurecht, H.; Franke, A.; Claussnitzer, M.; Eyerich, K.; Teumer, A.;
Milani, L.; Klopp, N.; Hauck, S. M.; Illig, T.; Peters, A.; Waldenberger, M. ... Weidinger, S.
(2014). A common atopy-associated variant in the Th2 cytokine locus control region impacts
transcriptional regulation and alters SMAD3 and SP1 binding. Allergy, 69 (5),
632−642.10.1111/all.12394.
Viltrop, T.; Metsalu, T.; Tiirats, A.; Rajashekar, B.; Reimann, E.; Koks, S.; Rull, K.; Milani, L.;
Vilo, J.; Maegi, R.; Metspalu, A.; Peters, M.; Haller-Kikkatalo, K.; Salumets, A. (2014).
Imprinting landscape of human placenta as discovered by whole transcriptome RNA-sequencing
and exome variant data analysis. Human Reproduction, 29, 72−72.
2013
Ivanov, M; Kals, M; Kacevska, M; Barragan, I; Kasuga, K; Rane, A; Metspalu, A; Milani, L;
Ingelman-Sundberg, M. (2013). Ontogeny, distribution and potential roles of 5-
hydroxymethylcytosine in human liver function. Genome Biology, 14 (8), R83.
Westra, HJ; Peters, MJ; Esko, T; Yaghootkar, H; Schurmann, C; Kettunen, J; Christiansen, MW;
Fairfax, BP; Schramm, K; Powell, JE; Zhernakova, A; Zhernakova, DV; Veldink, JH; Van den
Berg, LH; Karjalainen, J; Withoff, S; Uitterlinden, AG; Hofman, A; Rivadeneira, F; 't Hoen, PA
... Franke, L. (2013). Systematic identification of trans eQTLs as putative drivers of known
disease associations. Nature Genetics, 45 (10), 1238−U195.10.1038/ng.2756.
Nikopensius, T; Saag, M; Jagomägi, T; Annilo, T; Kals, M; Kivistik, P.A; Milani, L; Metspalu,
A. (2013). A Missense Mutation in DUSP6 is Associated with Class III Malocclusion. Journal of
Dental Research, 92 (10), 893−898.10.1177/0022034513502790.
Rietveld, CA; Medland, SE; Derringer, J; Yang, J; Esko, T; Martin, NW; Westra, HJ;
Shakhbazov, K; Abdellaoui, A; Agrawal, A; Albrecht, E; Alizadeh, BZ; Amin, N; Barnard, J;
Baumeister, SE; Benke, KS; Bielak, LF; Boatman, JA; Boyle, PA; Davies, G ... Koellinger, PD.
(2013). GWAS of 126,559 Individuals Identifies Genetic Variants Associated with Educational
Attainment. Science, 340 (6139), 1467−1471.10.1126/science.1235488.
den Hoed, M; Eijgelsheim, M; Esko, T; Brundel, BJ; Peal, DS; Evans, DM; Nolte, IM; Segrè,
AV; Holm, H; Handsaker, RE; Westra, HJ; Johnson, T; Isaacs, A; Yang, J; Lundby, A; Zhao,
JH; Kim, YJ; Go, MJ; Almgren, P; Bochud, M ... Loos, RJ. (2013). Identification of heart rate-
associated loci and their effects on cardiac conduction and rhythm disorders. Nature Genetics, 45
(6), 621.
Berndt, SI; Gustafsson, S; Mägi, R; Ganna, A; Wheeler, E; Feitosa, MF; Justice, AE; Monda,
KL; Croteau-Chonka, DC; Day, FR; Esko, T; Fall, T; Ferreira, T; Gentilini, D; Jackson, AU;
Luan, J; Randall, JC; Vedantam, S; Willer, CJ; Winkler, TW ... Ingelsson, E. (2013). Genome-
wide meta-analysis identifies 11 new loci for anthropometric traits and provides insights into
genetic architecture. Nature Genetics, 45 (5), 501−U69.10.1038/ng.2606.
Ivanov, Mart; Kals, Mart; Kacevska, Marina; Metspalu, Andres; Ingelman-Sundberg, Magnus;
Milani, Lili. (2013). In-solution hybrid capture of bisulfite-converted DNA for targeted bisulfite
sequencing of 174 ADME genes. Nucleic Acids Research, 2013/01/15, 1−9.
Perry, JR; Corre, T; Esko, T; Chasman, DI; Fischer, K; Franceschini, N; He, C; Kutalik, Z;
Mangino, M; Rose, LM; Smith, AV; Stolk, L; Sulem, P; Weedon, MN; Zhuang, WV; Arnold, A;
Ashworth, A; Bergmann, S; Buring, JE; Burri, A ... Murray, A (2013). A genome-wide
association study of early menopause and the combined impact of identified variants. Human
Molecular Genetics, 22(7) (1), 1465−1472.10.1093/hmg/dds551.
2012
Kacevska, Marina; Ivanov, Maxim; Wyss, Annika; Kasela, Silva; Milani, Lili; Rane, Anders;
Ingelman-Sundberg, Magnus (2012). DNA methylation dynamics in the hepatic CYP3A4 gene
promoter. Biochimie, 94 (11), 2338−2344.10.1016/j.biochi.2012.07.013.
McQuillan, R.; Eklund, N.; Pirastu, N.; Kuningas, M.; McEvoy, BP.; Esko, T.; Corre, T.; Davies,
G.; Kaakinen, M.; Lyytikäinen, LP.; Kristiansson, K.; Havulinna, AS.; Gögele, M.; Vitart, V.;
Tenesa, A.; Aulchenko, Y.; Hayward, C.; Johansson, A.; Boban, M.; Ulivi, S. ... on behalf of the
ROHgen, Consortium. (2012). Evidence of Inbreeding Depression on Human Height. Plos
Genetics, 8 (7), e1002655.10.1371/journal.pgen.1002655.
Lokk, Kaie; Vooder, Tõnu; Kolde, Raivo; Välk, Kristjan; Võsa, Urmo; Roosipuu, Retlav;
Milani, Lili; Fischer, Krista; Koltšina, Marina; Urgard, Egon; Annilo, Tarmo; Metspalu, Andres;
Tõnisson, Neeme (2012). Methylation Markers of Early-Stage Non-Small Cell Lung Cancer.
PLoS ONE, 7 (6), e39813− .10.1371/journal.pone.0039813.
Nordlund, J.; Milani, L.; Lundmark, A.; Lönnerholm, G.; Syvänen, AC. (2012). DNA
methylation analysis of bone marrow cells at diagnosis of acute lymphoblastic leukemia and at
remission. PLoS ONE, 7 (4), e34513.
Tserel, L.; Saare, M.; Kisand, K.; Milani, L.; Metspalu, A.; Peterson, P. (2012). Patterns of DNA
methylation in the T-cells and monocytes from the elderly and the young. Immunology, 137,
432−433.
Tõnisson, N.; Lokk, K.; Vooder, T.; Kolde, R.; Välk, K.; Roosipuu, R.; Võsa, U.; Milani, L.;
Fischer, K.; Koltšina, M.; Urgard, E.; Annilo, T.; Metspalu, A. (2012). Altered DNA methylation
in early-stage non-small-cell lung cancer. European Journal of Human Genetics: European
Human Genetics Conference; Nürnberg, Saksamaa; 23.–26. juuni, 2012. Nature Publishing
Group, 174−174. (20; Suppl 1).
Kaasik, Aidula-Taie; Keis, Aime; Metspalu, Andres; Allik, Annely; Mölder, Ene; Leego, Erkki;
Alavere, Helene; Lilienthal, Kadri Fischer, Krista; Leitsalu-Moynihan, Liis; Milani, Lili;
Tammesoo, Mari-Liis; Väli-Täht, Maris; Leego, Merike; Hass, Merli; Tamm, Riin; Nikopensius,
Tiit; Esko, Tõnu; Haller, Toomas (2012). Estonian Genome Center : 2001-2011. Tartu:
University of Tartu.
2011
Metspalu, A.; Leitsalu, L.; Milani, L.; Esko, T.; Allik, A.; Lilienthal, M.-L.; Haller, T.; Kaasik,
A.-T.;Nelis, M.; Hass, M.; Fischer, K.; Krjutškov, K.; Leego, E.; Alavere, H.; Perola, M. (2011).
The Estonian biobank - the gateway for the stratified medicine. In: Engelbrecht, J.
(_EditorsAbbr). Research in Estonia. Present and future. (283−301).. Tallinn: Estonian Academy
of Sciences.
2010
Milani, L.; Lundmark, A.; Kiialainen, A.; Nordlund, J.; Flaegstad, T.; Forestier, E.; Heyman, M.;
Jonmundsson, G.; Kanerva, J.; Schmiegelow, K.; Söderhäll, S.; Gustafsson, M. G.; Lönnerholm,
G.; Syvänen, A. C. (2010). DNA methylation for subtype classification and prediction of
treatment outcome in patients with childhood acute lymphoblastic leukemia. Blood, 115 (6),
1214−1225.10.1182/blood-2009-04-214668.
2009
Mukonzo, J. K.; Roshammar, D.; Waako, P.; Andersson, M.; Fukasawa, T.; Milani, L.;
Svensson, J. O.;Ogwal-Okeng, J.;Gustafsson, L. L.;Aklillu, E. (2009). A novel polymorphism in
ABCB1 gene, CYP2B6*6 and sex predict single-dose efavirenz population pharmacokinetics in
Ugandans. British Journal of Clinical Pharmacology, 68, 690−699.
Ghotbi R, Gomez A, Milani L, Tybring G, Syvänen A-C, Bertilsson L, Ingelman-Sundberg M,
Aklillu E (2009). Allele-specific expression and gene methylation in the control of CYP1A2
mRNA level in human livers. The pharmacogenomics journal, 9 (3),
208−217.10.1038/tpj.2009.4.
Milani, L.; Lundmark, A.; Nordlund, J.; Kiialainen, A.; Flaegstad, T.; Jonmundsson, G.;
Kanerva, J.; Schmiegelow, K.; Gunderson, K.L.; Lönnerholm, G.; Syvänen, A-C. (2009). Allele-
specific gene expression patterns in primary leukemic cells reveal regulation of gene expression
by CpG site methylation. Genome Research, 19 (1), 1−11.10.1101/gr.083931.108.
Milani, Lili; Syvänen, Ann-Christine. (2009). Genotyping single nucleotide polymorphisms by
multiplex minisequencing using tag-arrays. In: DNA Microarrays for Biomedical Research
(215−229).. Humana Press. (Methods in Molecular Biology).
2008
Schnorrer, F.; Ahlford, A.; Chen, D.; Milani, L.; Syvänen, AC. (2008). Positional cloning by
fast-track SNP-mapping in Drosophila melanogaster. Nature Protocols, 3 (11),
1751−1765.10.1038/nprot.2008.175.
Kristjansdottir, G.; Sandling, JK.; Bonetti, A.; Roos, IM.; Milani, L.; Wang, C.; Gustafsdottir,
SM.; Sigurdsson, S.; Lundmark, A.; Tienari, PJ.; Koivisto, K.; Elovaara, I.; Pirttilä, T.;
Reunanen, M.; Peltonen, L.; Saarela, J.; Hillert, J.; Olsson, T.; Landegren, U.; Alcina, A. ...
Syvänen, A-C. (2008). Interferon regulatory factor 5 (IRF5) gene variants are associated with
multiple sclerosis in three distinct populations. Journal of Medical Genetics, 45 (6), 362−369.
Sigurdsson, S.; Goring, HH.; Kristjansdottir, G.; Milani, L.; Nordmark, G.; Sandling, JK.;
Eloranta, ML.; Feng, D.; Sangster-Guity, N.; Gunnarsson, I.; Svenungsson, E.; Sturfelt, G.;
Jonsen, A.; Truedsson, L.; Barnes, BJ.; Alm, G.; Rönnblom, L.; Syvänen, A-C.. (2008).
Comprehensive evaluation of the genetic variants of interferon regulatory factor 5 (IRF5) reveals
a novel 5 bp length polymorphism as strong risk factor for systemic lupus erythematosus. Human
Molecular Genetics, 17 (6), 872−881.10.1093/hmg/ddm359.
Gupta M, Milani L, Hermansson M, Simonsson B, Markevarn B, Syvänen A-C, Barbany G.
(2008). Expression of BCR-ABL1 oncogene relative to ABL1 gene changes overtime in chronic
myeloid leukemia. Biochemical and Biophysical Research Communications, 366 (3),
848−851.10.1016/j.bbrc.2007.12.029.
2007
Dideberg, V; Kristjansdottir, G; Milani, L; Libioulle, C; Sigurdsson, S; Louis, E; Wiman, AC;
Vermeire, S; Rutgeerts, P; Belaiche, J; Franchimont, D; Van Gossum, A; Bours, V; Syvänen, A-
C. (2007). An insertion-deletion polymorphism in the interferon regulatory Factor 5 (IRF5) gene
confers risk of inflammatory bowel diseases. Human Molecular Genetics, 16 (24),
3008−3016.10.1093/hmg/ddm259.
Milani L, Gupta M, Andersen M, Dhar S, Fryknäs M, Isaksson A, Larsson R, Syvänen A-C.
(2007). Allelic imbalance in gene expression as a guide to cis-acting regulatory single nucleotide
polymorphisms in cancer cells. Nucleic Acids Research, 35, e34−e34.10.1093/nar/gkl1152.
2006
Milani L, Fredriksson M, Syvänen A-C. (2006). Detection of alternatively spliced transcripts in
leukemia cell lines by minisequencing on microarrays. Clinical Chemistry, 52,
202−211.10.1373/clinchem.2005.062042.
Tööstusomand
Patentne leiutis: Marker BMP5 geenis SSRI klassi ravimite toimet ennustava tegurina;
Omanikud: Tartu Ülikooli Eesti Geenivaramu; Autorid: Anu Tammiste, Lili Azin Milani,
Krista Fischer, Tõnu Esko, Kristi Pettai, Kaarel Krjutškov, Reedik Mägi, Merike Leego,
Eduard Maron, Andres Metspalu; Prioriteedi number: US61/546.607; Prioriteedi kuupäev:
13.10.2011.
ELULOOKIRJELDUS
Nimi: Tuuli Jürgenson
Sünniaeg: 18. mai 1997
E-post:
[email protected]
Haridus:
2019–... Tartu Ülikool, matemaatika ja statistika magistriõpe
2016–2019 Tartu Ülikool, BSc matemaatilise statistika erialal (cum laude)
2013–2016 Hugo Treffneri Gümnaasium (kuldmedal)
Teenistuskäik:
06.2019–... Tartu Ülikooli Eesti Geenivaramu, statistik (0,5)
09.2018–02.2019 Tartu Ülikooli matemaatika ja statistika instituut, õppeassistent aines
Analüütiline geomeetria
09.2017–02.2018 Tartu Ülikooli matemaatika ja statistika instituut, õppeassistent aines
Matemaatiline maailmapilt
Curriculum Vitae
Isiklik informatsioon
Nimi: Kristi Krebs
Sünniaeg: 09.01.1990, Tallinn, Estonia
Aadress: Vaksali 21-20, 50409, Tartu
Telefon, email: +372 56 47 3303,
[email protected]
Teenistuskäik
Haridustee:
2015–... Doktoriõpe molekulaarse biomeditsiini eralal, Tartu Ülikool, Eesti
Geenivaramu
15.01.2018–17.12.2018 Uppsala Ülikool, Molekulaarse meditsiini õppetool,
külalisdoktorant
2012–2014 Magistriõpe geenitehnoloogia erialal, Tallinna Tehnikaülikool, cum laude
2009–2012 Bakalaureuseõpe geenitehnoloogia erialal,Tallinna Tehnikaülikool
Töökohad ja ametid:
01.01.2018–... Tartu Ülikool, Tartu Ülikooli genoomika instituut, spetsialist (0,30)
01.01.2017–... Tartu Ülikool, Tartu Ülikooli Eesti Geenivaramu, spetsialist (0,30)
2014–2015 Repforce, Tervisenõustaja/ravimiesitleja (1,00)
2012–2014 Tallinna Tehnikaülikool, Matemaatika-loodusteaduskond,
Geenitehnoloogia instituut, Molekulaarbioloogia õppetool, Spetsialist (0,75)
Teadusorganisatsiooniline ja -administratiivne tegevus
2016 (aprill) -2016(aprill) Biotehnoloogia praktikumi juhendamine
2012- ....Inimesegeneetika ühingu liige
Teenistuskäigu lisainfo:
2018, kursus “Genetic Analysis of Population-based Association Studies”, Wellcome
Genome Campus Advanced Course, Hinxton, Inglismaa
2017, Bioinformaatika suvekool, Wellcome Genome Campus, Hinxton, Inglismaa
2016, kursus “Statistical Practice in Epidemiology using R”, Eesti Geenivaramu ja Tartu
Ülikooli Matemaatika ja Statistika instituut
2013, English for Science and Research, Tallinna Tehnikaülikool, B2/C1 2012,
2012, Laboratory Animal Techniques, Tallinna Tehnikaülikool
2007, Keelepraktika: Berlin Humboldt (Saksamaa)
Kvalifikatsioon
Teaduskraadid
Kristi Krebs, doktorant 2015- …, (juh) Lili Milani; Andres Metspalu, Ravimite
lagundamisega seotud geenide põhjalik geneetiline ja epigeneetiline analüüs uue
põlvkonna sekveneerimisetehnoloogiaga, Tartu Ülikool, Tartu Ülikool Eesti
Geenivaramu.
Kristi Krebs, Magistrikraad, 2014, (juh) Teet Velling, Filamiin A roll PKB/Akt’i
lokalisatsiooni ja kineetika regulatsioonis integriinide ja retseptor türosiinkinaaside
poolt, Tallinna tehnikaülikool, geenitehnoloogia instituut
Teaduspreemiad ja tunnustused
2017 Dora Pluss doktorantide õpirände stipendium
2017 Kristi Krebs, Kristjan Jaagu välissõidu stipendium: ettekandega esinemine
konverentsil
2017 ESHG konverentsi stipendium Euroopa riikidele
2016 ECNP seminari auhind
2016 Eesti Teaduste Akadeemia "Teadus 3 minutiga" loengute konkursi finalist ja
laureaat (loengu teema "Ravimiretsept – allkirjastatud geneetikaga")
2016 Kõrghariduse erialastipendium nutika spetsialiseerumise kasvuvaldkondades
Teadustöö põhisuunad
VALDKOND: 1. Bio- ja keskkonnateadused; 1.3. Geneetika; CERCS ERIALA:
B220 Geneetika, tsütogeneetika; PÕHISUUNAD: Farmakogenoomika
Jooksvad projektid
PRG184 (PRG184) "Haruldaste ja sagedaste geenivariantide mõju ravimite
kõrvaltoimetele (1.01.2018−31.12.2022)", Lili Azin Milani, Tartu Ülikool, Tartu
Ülikooli genoomika instituut.
IUT20-60 "Oomiksi põhised meetodid terviseuuringutes: integreeritud lähenemine
haiguste tekkeprotsesside mõistmiseks ja prognoosimiseks (1.01.2014−31.12.2019)",
Andres Metspalu, Tartu Ülikool, Tartu Ülikooli Eesti Geenivaramu, Tartu Ülikool,
Tartu Ülikooli genoomika instituut.
Publikatsioonid
2019
Tasa, T & Krebs, K.; Kals, M.; Mägi, R.; Lauschke, V.M.; Haller, T.; Puurand, T.; Remm,
M.; Esko, T.; Metspalu, A.; Vilo, J.; Milani, L. (2019). Genetic variation in the Estonian
population: pharmacogenomics study of adverse drug effects using electronic health records.
European Journal of Human Genetics, 0−0.10.1038/s41431-018-0300-6 [ilmumas].
2018
Reisberg, Sulev; Krebs, Kristi; Lepamets, Maarja; Kals, Mart; Mägi, Reedik; Metsalu,
Kristjan; Lauschke, Volker M.; Vilo, Jaak; Milani, Lili; (2018). Translating genotype data of
44,000 biobank participants into clinical pharmacogenetic recommendations: challenges and
solutions. Genetics in medicine.10.1038/s41436-018-0337-5.
2015
Krebs, Kristi; Ruusmann, Anu; Simonlatser, Grethel; Velling, Teet (2015). Expression of
FLNa in human melanoma cells regulates the function of integrin α1β1 and phosphorylation
and localisation of PKB/AKT/ERK1/2 kinases. European Journal of Cell Biology, 564−575.
Kersti Oselin
https://www.etis.ee/CV/Kersti_Oselin/est
E-post
[email protected]
ORCID
0000-0002-3862-3882
Teenistuskäik
Töökohad ja ametid
28.09.2015–...
North Estonian Medical Centre, onkoloog (keemiaraviarst) (0,90)
2003 - 2004 AS EGeen farmakogeneetiliste uuringute projektijuht
2002 - 2003 TÜ farmakoloogia instituut assistent
2000 - 2002 Humboldti Ülikool Charité Kliinik kliinilis farmakoloogia instituut teadur
1999 - 2000 TÜ farmakoloogia instituut assistent
01.09.2012–31.08.2015
Tartu Ülikool, Arstiteaduskond, Anestesioloogia ja intensiivravi kliinik, anestesioloogia ja intensiivravi teadur
(0,25)
2012–01.09.2015
SA Tartu Ülikooli Kliinikum, Teadur (0,25)
01.09.2011–31.08.2015
SA Tartu Ülikooli Kliinikum, arst-resident onkoloogias (1,00)
01.09.2007–01.09.2007
Tartu Ülikool, Arstiteaduskond, Farmakoloogia instituut, farmakoloogia vanemteadur (1,00)
01.02.2007–31.08.2007
Tartu Ülikool, Arstiteaduskond, Farmakoloogia instituut, erakorraline vanemteadur (1,00)
2007–30.04.2007
Tartu Ülikool, Arstiteaduskond, Farmakoloogia instituut, Farmakoloogia ja toksikoloogia õppetool,
farmakoloogia vanemteadur (1,00)
01.01.2007–31.12.2011
Suurbritannia Ravimiamet, kliiniline hindaja
2006–2007
Tartu Ülikool, Arstiteaduskond, Farmakoloogia instituut, erakorraline vanemteadur (1,00)
01.09.2004–31.01.2007
Tartu Ülikool, Arstiteaduskond, Farmakoloogia instituut, farmakoloogia teadur (1,00)
Haridustee
1998 - 2003 TÜ arstiteaduskond kliiniline farmakoloogia doktorantuur
1997 - 1998 SA TÜ Kliinikum internatuur
1991 - 1997 TÜ arstiteaduskond ravi eriala
01.09.2011–31.08.2015
Arstiteaduse residentuur onkoloogia erialal
Teadusorganisatsiooniline ja -administratiivne tegevus
2016−...
American Society of Clinical Oncology, liige
2015−...
European Society of Medical Oncology, liige
2015−...
EORTC Lung Cancer Group
2009−...
Eesti Farmakoloogia Selts, liige
1999−...
Eesti Onkoteraapia Ühing, juhatuse liige
Loometöö
PK, PD, kliiniliste uuringute disain, onkoloogia.
Kvalifikatsioon
Teaduskraadid
Kersti Oselin, doktorikraad, 2003, (juh) Lembit Rägo; Rein Pähkla, Studies on the human MDR1, MRP1 and
MRP2 ABC transporters: Functional relevance of the genetic polymorphism in the MDR1 and MRP1 gene
(MDR1, MRP1 ja MRP2 ABC transporterid: geneetilise polümorfismi tähtsus MDR1 ja MRP1 geenides), Tartu
Ülikool, Arstiteaduskond.
Teadustöö põhisuunad
ETIS KLASSIFIKAATOR: 3. Terviseuuringud; 3.7. Kliiniline meditsiin; TÄPSUSTUS: Kliiniline
farmakoloogia, farmakokineetika, farmakogeneetika
ETIS KLASSIFIKAATOR: 3. Terviseuuringud; 3.7. Kliiniline meditsiin; CERCS KLASSIFIKAATOR: B200
Tsütoloogia, onkoloogia, kantseroloogia; TÄPSUSTUS: Infektsioonide nõrgestatud organisms,
farmaokineetilised ja farmakogeneetilised uuringud onkoloogiliste ravimitega
ETIS KLASSIFIKAATOR: 3. Terviseuuringud; 3.7. Kliiniline meditsiin; CERCS KLASSIFIKAATOR: B726
Kliiniline bioloogia ; TÄPSUSTUS: onkoloogia, kartsinogenees
Lisainfo
meditsiinidoktor
Tartu Ülikool, 2003
Jooksvad projektid
IUT34-24
"Infektsioonid langenud immuunsusega isikutel – eksperimendist kliinilisse praktikasse
(1.01.2015−31.12.2020)", Irja Lutsar, Tartu Ülikool, Meditsiiniteaduste valdkond, bio- ja siirdemeditsiini
instituut.
Lõppenud projektid
SARAI120119T
"Antibiootikumide doseerimine raskete infektsioonide korral (1.01.2012−31.08.2015)", Joel Starkopf, Tartu
Ülikool, Tartu Ülikool, Arstiteaduskond.
SF0180004s12
"Infektsioon immuunsüsteemi häirega isikutel - haiguse mehhanimidest kliinilise praktikani
(1.01.2012−31.12.2014)", Irja Lutsar, Tartu Ülikool, Arstiteaduskond.
ETF8799
"Meropeneemi farmakokineetika enneaegsetel vastsündinutel (1.01.2011−31.12.2012)", Irja Lutsar, Tartu
Ülikool, Arstiteaduskond.
SF0180059s07
"Uued ravistrateegiad neurodegeneratsiooni ja psüühiliste häirete ravis (1.01.2007−31.12.2012)", Aleksandr
Žarkovski, Tartu Ülikool, Arstiteaduskond.
SF0182726s06
"HIV infektsioon Eestis: viiruse ja peremeesorganismi interaktsioonid molekulaarsel ja kliinilisel tasandil
(1.01.2006−31.12.2011)", Irja Lutsar, Tartu Ülikool, Arstiteaduskond.
ETF6691
"Tiopuriinravimite farmakokineetikat ja -dünaamikat mõjutavad geneetilised ja mitte-geneetilised faktorid.
(1.01.2006−31.12.2007)", Kersti Oselin, Tartu Ülikool, Arstiteaduskond.
SF0182587s03
"Müokardiinfarkti-järgne südamepuudulikkus : raskusastme determinandid, ravi ja prognoos
(1.01.2003−31.12.2006)", Rein Teesalu, Tartu Ülikool, Arstiteaduskond.
SF0182135As02
"Afektiivsete häirete ja neurodegeneratiivsete haiguste farmakoteraapia alused (1.01.2002−31.12.2006)",
Aleksandr Žarkovski, Tartu Ülikool, Arstiteaduskond.
Juhendatud väitekirjad
Katrina Talpsepp, magistrikraad, 2008, (juh) Annika Vaarmann; Kersti Oselin, Glükokortikosteroidravi
mõju inimese tiopuriini metüültransferaasi ekspressioonile ja aktiivsusele, Tartu Ülikool, Arstiteaduskond.
Karin Kipper, magistrikraad, 2008, (juh) Kersti Oselin; Ivo Leito; Annika Vaarmann, HPLC-UV
meetod kesknärvisüsteemi ravimite määramiseks inimese vereplasmas, Tartu Ülikool, Füüsika-
keemiateaduskond.
Riin Tamm, magistrikraad (teaduskraad), 2007, (juh) Kersti Oselin; Andres Metspalu, Inimese
tiopuriinmetüültransferaasi farmakogeneetika: genotüübi-fenotüübi võrdlus ja haplotüübianalüüs eestlaste
populatsioonis, Tartu Ülikool, Bioloogia-geograafiateaduskond.
Kaili Anier, magistrikraad (teaduskraad), 2006, (juh) Uno Mäeorg; Kersti Oselin, HPLC põhise meetodi
väljatöötamine tiopuriini metüültransferaasi aktiivsuse määramiseks Eesti populatsioonis ja
raviminteraktsioonide ennustamine in vitro eksperimentide põhjal, Tartu Ülikool, Füüsika-keemiateaduskond,
Orgaanilise ja bioorgaanilise keemia instituut.
Publikatsioonid
Klass
Aasta
Publikatsioon
1.1.
2019
Oselin, Kersti; Girard, Nicolas; Lepik, Karlin; Adamson-Raieste, Aidi; Vanakesa, Tõnu; Almre, Ingemar;
Leismann, Tiina; Chalabreysse, Lara (2019). Pathological discrepancies in the diagnosis of thymic epithelial
tumors: the Tallinn-Lyon experience. Journal of Thoracic Disease, 11 (2), 456−464.10.21037/jtd.2018.12.123.
1.1.
2018
Padari, Helgi; Metsvaht, Tuuli; Germovsek, Eva; Barker, Charlotte; Kipper, Karin; Herodes, Koit; Standing,
Joseph; Oselin, Kersti; Tasa, Tõnis; Soeorg, Hiie; Lutsar, Irja (2018). Pharmacokinetics of penicillin G in
preterm and term neonates. Antimicrobial Agents and Chemotherapy.10.1128/AAC.02238-17.
5.2.
2017
Tamm, Madli; Oselin, Kersti; Kivistik, Paula Ann; Kals, Mart; Lokk, Kaie; Keerma, Katrin; Saare, Margot;
Roosipuu, Retlav; Leismann, Tiina; Roomere, Hanno; Metspalu, Andres; Tõnisson, Neeme (2017). Monitoring
cancer related mutations in cell-free DNA of lung cancer patients. European Journal of Human Genetics:
European Human Genetics Conference, Copenhagen, Denmark, May 27–30, 2017. Nature Publishing Group,.
1.1.
2016
Tamme, K.; Oselin, K.; Kipper, K.; Tasa, T.; Metsvaht, T.; Karjagin, J; Herodes, K.; Kern, H.; Starkopf J.
(2016). Pharmacokinetics and pharmacodynamics of piperacillin/tazobactam during high volume
haemodiafiltration in patients with septic shock. Acta Anaesthesiologica Scandinavica, 60 (2),
230−240.10.1111/aas.12629.
1.1.
2016
Padari, Helgi; Oselin, Kersti; Tasa, Tõnis; Metsvaht, Tuuli; Lõivukene, Krista; Lutsar, Irja (2016). Coagulase
negative staphylococcal sepsis in neonates: do we need to adapt vancomycin dose or target? BMC Pediatrics, 16
(1), 206−206.10.1186/s12887-016-0753-0.
5.2.
2016
Tamm, Madli; Oselin, Kersti; Kivistik, Paula Ann; Keerma, Katrin; Roosipuu, Retlav; Saare, Margot; Roomere,
Hanno; Metspalu, Andres; Tõnisson, Neeme (2016). Detecting EGFR and related mutations in the cfDNA of
lung cancer patients. European Journal of Human Genetics, 24: European Human Genetics Conference,
Barcelona, Spain May 21-24, 2016. Nature Publishing Group, 313−313. (Supplement 1).
1.1.
2012
Padari, H.; Metsvaht, T.; Kõrgvee, LT.; Germovsek, E.; Ilmoja, ML.; Kipper, K.; Herodes, K.; Standing, JF.;
Oselin, K.; Lutsar, I. (2012). Short versus Long Infusion of Meropenem in Very-Low-Birth-Weight Neonates.
Antimicrobial Agents and Chemotherapy, 56 (9), 4760−4764.10.1128/AAC.00655-12.
1.1.
2011
Heidmets, LT.; Metsvaht, T.; Ilmoja, ML.; Pisarev, H.; Oselin, K.; Lutsar, I. (2011). Blood Loss Related to
Participation in Pharmacokinetic Study in Preterm Neonates. Neonatology, 100 (2), 111−115.
1.1.
2008
Tamm, R.; Oselin, K.; Kallassalu, K.; Magi, R.; Anier, K.; Remm, M.; Metspalu, A. (2008). Thiopurine S-
methyltransferase (TPMT) pharmacogenetics: three new mutations and haplotype analysis in the Estonian
population. Clinical Chemistry and Laboratory Medicine, 46 (7), 974−979.
1.1.
2008
Karjagin, J.; Lefeuvre, S.; Oselin, K.; Kipper, K.; Marchand, S.; Tikkerberi, A.; Starkopf, J.; Couet, W.;
Sawchuk, R.J. (2008). Pharmacokinetics of Meropenem Determined by Microdialysis in the Peritoneal Fluid of
Patients With Severe Peritonitis Associated With Septic Shock. Clinical Pharmacology & Therapeutics, 83 (3),
452−459.10.1038/sj.clpt.6100312.
1.1.
2007
Metsvaht, T.; Oselin, K.; Ilmoja, M.; Anier, K.; Lutsar, I. (2007). Pharmacokinetics of penicillin G in very-low-
birth-weight neonates. Antimicrobial Agents and Chemotherapy, 51 (6), 1995−2000.
1.1.
2007
Oselin, K.; Anier, K. (2007). Inhibition of human thiopurine S-methyltransferase by various nonsteroidal anti-
inflammatory drugs in vitro: a mechanism for possible drug interactions. Drug Metabolism and Disposition, 35
(9), 1452−1454.
3.3.
2007
Brilene, T.; Hedman, A.; Kirss, A.; Kullamaa, A.; Kõrv, J.; Oselin, K.; Otter, K.; Ristimäe, T.; Visnapuu, P.;
Peet, K. (2007). Rasedate farmakoteraapia. Tallinn: Medicina.
1.1.
2006
Oselin, K.; Anier, K.; Tamm, R.; Kallassalu, K.; Mäeorg, U. (2006). Determination of thiopurine S-
methyltransferase (TPMT) activity by comparing various normalization factors: Reference values for Estonian
population using HPLC-UV assay. Journal of Chromatography B-Analytical Technologies in the Biomedical and
Life Sciences, 77−83.10.1016/j.jchromb.2006.02.031.
5.1.
2006
Metsvaht, T.; Ilmoja, ML.; Oselin, K.; Anier, K.; Lutsar, I. (2006). Pharmacokinetics of penicillin G(Pen)
'steady-state' in very low birth weight premature newborns. BIOLOGY OF THE NEONATE, 90. 281−281.
5.2.
2006
Karjagin, J.; Oselin, K.; Lefeuvre, S.; Tikkerberi, A.; Saar, M.; Paju, T.; Marchand, S.; Couet, W.; Starkopf, J.
(2006). Intraperitoneal concentration of meropenem reaches sufficient level in patients with peritonitis. Intensive
Care Medicine, 1. 132.
5.2.
2006
Karjagin, J.; Oselin, K.; Lefeuvre, S.; Tikkerberi, A.; Saar, M.; Paju, T.; Marchand, S.; Couet, W.; Starkopf, J.
(2006). Intraperitoneal concentration of meropenem reaches sufficient level in patients with
peritonitis. Proceedings of 2nd International Baltic Congress of Anaesthesiology and Intensive Care: 2nd
International Baltic Congress of Anaesthesiology and Intensive Care; Tallinn, Estonia; 26-28 October
2006. Tallinn, 127.
1.1.
2003
Oselin, K.; Nowakowski-Gashaw, I.; Mrozikiewicz, PM.; Wolbergs, D.; Pahkla, R.; Roots, I. (2003).
Quantitative determination of MDR1 mRNA expression in peripheral blood lymphocytes: a possible role of
genetic polymorphisms in the MDR1 gene. European Journal of Clinical Investigation, 33 (3), 261−267.
1.1.
2003
Oselin, K.; Mrozikiewicz, PM.; Pahkla, R.; Roots, I. (2003). Quantitative determination of the human MRP1 and
MRP2 mRNA expression in FACS-sorted peripheral blood CD4(+), CD8(+), CD19(+), and CD56(+) cells.
European Journal of Haematology, 71 (2), 119−123.
1.1.
2003
Oselin, K.; Mrozikiewicz, PM.; Gaikovitch, E.; Pahkla, R.; Roots, I. (2003). Frequency of MRP1 genetic
polymorphisms and their functional significance in Caucasians: detection of a novel mutation G816A in the
human MRP1 gene. European Journal of Clinical Pharmacology, 59 (4), 347−350.
1.1.
2003
Oselin, K.; Gerloff, T.; Mrozikiewicz, PM.; Pahkla, R.; Roots, I. (2003). MDR1 polymorphisms G2677T in exon
21 and C3435T in exon 26 fail to affect rhodamine 123 efflux in peripheral blood lymphocytes. Fundamental &
Clinical Pharmacology, 17 (4), 463−469.
1.1.
2003
Kalev, I.; Osolin, K.; Pärlist, P.; Zilmer, M.; Rajasalu, T.; Podar, T.; Mikelsaar, AV. (2003). CC-chemokine
receptor CCR5-del32 mutation as a modifying pathogenetic factor in type I diabetes. Journal of Diabetes and its
Complications, 17 (6), 387−391.
6.6.
2003
Oselin, K. (2003). Iivelduse ja oksendamise farmakoloogiline ravi. Lege Artis, 2(16), 49−52.
1.1.
2002
Gerloff, T.; Schaefer, M.; Johne, A.; Oselin, K.; Meisel, C.; Cascorbi, I.; Roots, I. (2002). MDR1 genotypes do
not influence the absorption of a single oral dose of 1 mg digoxin in healthy white males. British Journal of
Clinical Pharmacology, 54 (6), 610−616.
1.3.
2002
Kalev, I.; Podar, T.; Oselin, K.; Pärlist, P.; Tasa, G.; Mikelsaar, A. (2002). Kemokiiniretseptori CCR5 geeni
polümorfism eestlastel ja mutatsiooni ccr5-delta-32 seos diabeediga. Eesti Arst, 2, 62−69.
1.2.
2001
Kalev, I.; Oselin, K.; Pärlist, P.; Podar, T.; Mikelsaar, A. (2001). CC-chemokine receptor CCR5 gene
polymorphism analysis in diabetes Type I and Type II patients in Estonia. European Journal of Human Genetics,
9 (269), 269.
1.1.
1999
Pahkla, R.; Irs, A.; Oselin, K.; Rootslane, L. (1999). Digoxin: use pattern in Estonia and bioavailability of the
local market leader. Journal of Clinical Pharmacy and Therapeutics, 24 (5), 375−380.
Volker M. Lauschke, 17. September 1984
[email protected]
Karolinska Institutet, Stockholm, Sweden Last updated 03.11.19
Volker M. Lauschke, Curriculum vitae
Address Storängsgatan 1, 115 44 Stockholm, Sweden
E-mail
[email protected]
Phone (+46) 76 0829199
Date of birth September 17th 1984
Nationality German
Marital status Married, three children
ORCID ID 0000-0002-1140-6204
Professional Experience
Since 2018 Associate Professor and Group Leader in Personalized Medicine and Drug Development,
Karolinska Institutet, Stockholm, Sweden
My research group uses 3D cell culture systems of primary human cells, microfluidics and integrative
bioinformatics approaches to identify novel therapeutic strategies for complex metabolic diseases,
such as non-alcoholic fatty liver disease and type 2 diabetes. In addition, we develop machine
learning tools to improve personalized pharmacological therapy and establish novel methods for the
prediction of drug toxicity. Since 2018 I am the Director of the Micro- and Nanofabrication core
facility. Venia legendi in Pharmacology since 2018.
2017 – 2018 Assistant Professor and Group Leader. Same as above
Since 2016 Co-founder and CEO of HepaPredict AB,
HepaPredict AB (www.hepapredict.com) is a contract research organization (CRO) that is part of
the Karolinska Innovations life science incubator program. We offer in-house evaluations of drug
metabolism, pharmacokinetic properties and safety as well as drug target validations based on our
novel long-term stable microphysiological 3D spheroid culture platform and our data has been used
for regulatory purposes within EFSA. I am one of two founders and during my time as CEO, we have
expanded from a start-up to an established profitable service provider in the area of drug discovery
and development with yearly revenue >3M SEK and customers in Europe, UK, US and Japan.
2014 - 2016 Postdoctoral Research Associate and MarieCurie Fellow
Karolinska Institutet, Stockholm, Sweden, Supervisor: Prof. Magnus Ingelman-Sundberg
In my postdoctoral research I contributed to the development of the hepatic spheroid model that
constitutes an integral part of my group’s experimental tool kit. Furthermore, I obtained extensive
experience in the integration of multiple omics data sets, which provides an important basis for our
computational approaches towards understanding inter-individual differences in drug response.
2013 – 2014 Bridging Postdoctoral Research Associate
European Molecular Biology Laboratory (EMBL). Same as below.
2009 – 2013 Dr. rer. nat. (PhD)
Grade 1.0; Graduation Summa cum Laude (best possible grade)
European Molecular Biology Laboratory (EMBL) and the joint faculty of Science and Mathematics
of the Ruperto-Carola University, Heidelberg, Supervisor: Dr. Alexander Aulehla
Thesis title: Scaling of embryonic patterning based on phase-gradient encoding
In my PhD studies, I analyzed how the proportionality of tissues and organs is maintained in the
developing embryo. To address this question, I developed an ex vivo primary cell culture assay in
which tissue self-organization can be observed. Importantly, we found that positional information can
be encoded through integrating information of oscillation phases from multiple oscillator systems,
revealing a novel way of dynamic information encoding in biological systems. The work resulted in
publications in Nature and Cell.
2007 – 2009 Scientific Assistant
Ruperto-Carola University, Heidelberg, Germany; PI: Prof. Gabriele Petersen
In parallel to my second cycle university education I obtained practical experiences in biochemistry,
molecular biology and epigenetics.
1
Volker M. Lauschke, 17. September 1984
[email protected]
Karolinska Institutet, Stockholm, Sweden Last updated 03.11.19
University Studies
2007 – 2009 Master of Science (M.Sc.) in Molecular Biosciences
Grade: 1.0 (best possible grade), Ruperto-Carola University, Heidelberg, Germany
2004 – 2007 Bachelor of Science (B.Sc.) in Molecular and Cellular Biology
Grade: 1.6, Ruperto-Carola University, Heidelberg, Germany and University of Bergen, Norway
Additional Academic Qualifications
2015 – present Bachelor of Laws (LL.B.)
2016 – 2018 Master of Science (M.Sc.) in Business Administration and Economics
2012 – 2016 Bachelor of Science (B.Sc.) in Business Administration and Economics
Current Funding
Swedish Research Foundation (VR) 3R Grant (2,205,000 SEK; PI Lauschke)
ERC Synergy grant SPHERES (10,000,000 SEK; PI Langin)
IMI2 EUbOPEN (1,400,000 SEK; PI Sundström)
Rolf Luft Grant for Diabetes Research (1,050,000 SEK; PI Lauschke)
Swedish Research Foundation (VR) Starting Grant (6,000,000 SEK; PI Lauschke)
Swedish Research Foundation (VR) 3R Grant (2,265,000 SEK; PI Lauschke)
Fellowships, Prizes and Awards
2017 Lennart Philipson Prize
2014 Marie Curie Fellowship
2009 EMBL International PhD Program Graduate Fellowship
Top Master of Science (M.Sc.) Award
2006 Erasmus Fellowship (Ecotoxicology at the University of Bergen, Norway, Supervisor: Prof. A.
Goksøyr)
2002 Fördern, Fordern, Forschen Award (Awarded by the University of Bonn, Germany for university
studies in Astronomy in parallel to high-school education)
Supervision of Graduate Students
Current supervision: Five PhD students (Yitian Zhou, Nuria Oliva-Vilarnau, Joanne Shen, Lena Preiss and Qingyang
Xiao) as main supervisor. One MD/PhD student (Mikael Kozyra) and one PhD student (Leyre Pernaute Lau) as co-
supervisor.
Teaching Portfolio
Teaching activities include seminars and practical courses in local anaesthetics, cardiovascular pharmacology,
pharmacokinetics and receptor pharmacology for biomedical, medical and dentistry students.
Editorial Activities
Editorial Board Member: Frontiers in Pharmacology (IF 3.8; Since 2017), Human Genomics (IF 2.5; Since 2017),
Frontiers in Medicine (IF 3.1; Since 2018), Drug Metabolism Reviews (IF 4.7; Since 2019)
Senior Editor: Annals of Human Genetics (IF 1.3; Since 2019)
Associate Editorial Board Member: Current Drug Metabolism (IF 2.3; Since 2019)
Guest Editor: Special Issue in Journal of Clinical Medicine (IF 5.7; “Importance of Genetic Variants for the Hepatic
Metabolism of Xenobiotics”; June 2020)
2
Volker M. Lauschke, 17. September 1984
[email protected]
Karolinska Institutet, Stockholm, Sweden Last updated 03.11.19
Commissions of Trust and Memberships in Scientific Societies
Since 2019 Member of the Management Committee of the COST Action “Prospective European Drug-Induced
Liver Injury (DILI) Network”
Since 2019 Board member of the Swedish Society of Medicine (Section of Pharmacology)
Since 2019 Swedish delegate to the Federation of European Pharmacological Societies (EPHAR)
Since 2018 Docent with venia legendi in Pharmacology
Since 2018 Member of the IUPHAR (International Union of Basic & Clinical Pharmacology) Young Investigator
Committee
Since 2018 Director of Micro- and Nanofabrication Facility at Karolinska Institutet
Since 2018 Member of the Swedish Strategic Research Program in Diabetes
Since 2018 Oversea Fellow of the Royal Society of Medicine
Since 2018 Member of the Pharmacogene Variation Consortium (PharmVar)
Since 2018 Member of the American Society for Biochemistry and Molecular Biology (ASBMB)
Since 2017 Full member of the International Society for the Study of Xenobiotics (ISSX) and Member of the
ISSX Young Investigator Workgroup
2017 Member of expert panel for the discussion of scientific and regulatory opportunities and challenges of
medicinal product development using genome editing technologies at EMA, London
Since 2016 Member of the Ubiquitous Pharmacogenomics Consortium (UPgx)
Since 2014 Full member of the Society of Bioinformatics in Northern Europe
Bibliography
Total publications (incl. in press): 55 publications
* First and co-first authorships: 17 publications
#
Last and co-last authorships: 21 publications
†
Corresponding author: 29 publications
Additional manuscripts in review/revision: 10 manuscripts
Sum of ISI impact factors: 324.3
Bibliometrics Google Scholar Web of Science
Citations: 1544 1034
H-index: 20 18
3
Tähis VKL-241
Viide PKL-127
Versioon 02
Teatis Eetikakomiteele
Tartu Ülikooli Kliinikumi nõusolek uuringu läbiviimiseks
UURINGU ANDMED
Uuringu täielik nimetus: Study of the effects of previously uncharacterized rare variants in the
genes of CyP450 enzymes
Sponsori protokolli number, versioon ja kuupäev:
Vastutav uurija: Alar Irs
UURINGUKESKUSE ANDMED
Uuringu läbiviimise koht: Südamekliinik
KINNITUS
Olen teadlik ülaltoodud kliinilisest uuringust.
Kliiniliste uuringute koordinaator Katrin Kaarna juhatuse 08.08.2017 nr otsuse nr 1.3-1/296
volituse alusel
Katrin Kaarna
/allkirjastatud digitaalselt/
Eesti bioeetika ja inimuuringute nõukogule
Suur-Ameerika 1
10122 Tallinn
28.02.2020
KAASKIRI
Käesolevalt esitame avalduse Eesti bioeetika ja inimuuringute nõukogule
kliinilise uuringu läbiviimise kooskõlastuse saamiseks.
Plaanitava uuringu nimi: Varasemalt kirjeldamata geenivariatsioonide mõju
ravimite metabolismile (Study of the effects of previously uncharacterized rare
variants in the genes encoding CYP450 enzymes)
Uuringuprotokolli number: Protocol 01-2020, Version 2
E-kirjaga lisatud:
- Kaaskiri
- Taotlus kooskõlastuse saamiseks Eesti bioeetika ja inimuuringute nõukogult
- Uuringuprotokoll
- Kindkustuspakkumine
- Uuritava informeerimise ja teadliku nõusoleku lehed (venekeelse
informeerimise ja nõusoleku lehe plaanime tõlkida siis, kui eestikeelne on
heaks kiidetud)
- Kiri geenidoonorite uuringusse kutsumiseks (esimene pöördumine, venekeelse
informeerimise ja nõusoleku lehe plaanime tõlkida siis, kui eestikeelne on
heaks kiidetud)
Lugupidamisega,
Jana Lass
SA Tartu Ülikooli Kliinikum, apteek
Puusepa 8, 51014 Tartu, Eesti
Tel: +372 7318333
E-post:
[email protected]
Vastus Eesti bioeetika ja inimuuringute nõukogule
1. Selleks, et uuringut läbi viia, on vajalik geenidoonori isiku tuvastamine.
Nõukogule ei ole esitatud vastavalt IGUS §24 lõige 4 geenidoonorite depsudonüünimiseks
vajalikku taotlust.
Vastus: Esitasime Nõukogule taotluse geenidoonorite depseudonüümimiseks. Taotlusesse
on lisatud uus peatükk nr 8. “Request for depseudonymisation”.
2. Tegemist on kõrge riskiga sekkuva uuringuga ja antud taotlusega tutvudes on nõukogu
seisukohal, et uuringust tulenevad riskid on suuremad, kui uuringust saadav kasu.
Vastus: Täname Nõukogu tähelepanu juhtimast, kuid jääme seisukohale, et kuigi
uuringust saadava kasu ulatust ei ole enne uuringutulemuste saamist võimalik täpselt teada,
on uuringuga kaasnevad riskid põhjalikult läbi kaalutud. Uuringu tulemusel on võimalik
kirjeldada seni teadmata geenivariantide mõju ravimite metaboliseerumise määrale.
Uuringus kasutatakse kliinilises praktikas sageli kasutatavaid ravimeid, mille kasutamisega
seotud riskid ja vastunäidustused on hästi teada ning ravimite annused on võimalikult
väiksed. Ravimeid manustatakse haiglas ning kogu uuringu jooksul jälgivad osalejaid
uuringuarstid. Kõiki uuringuprotseduure teevad kogenud õed.
Kõik uuringusse valitud indiviidid kannavad CYP2C19 ja/või CYP2D6 geenides vähemalt
ühte potentsiaalselt funktsioonikaoga mutatsiooni ja/või deletsiooni, mille mõju mitmete
ravimite lagundamise kiirusele pole varem uuritud. Sellepärast võib neil inimestel olla
tavapäraste raviannuste kasutamisel suurem risk ravimite kõrvaltoimete tekkeks. Tavaliselt
otsitakse selliseid mutatsioone peale ravimi tõsiste kõrvaltoimete avaldumist või
ebatavalise ravimi plasmakontsentratsiooni leidmist. Näiteks leiti neerusiirdamise järgselt
patsiendil erakordselt kõrged immuunosuppressant takroliimuse plasmakontsentratsioonid,
mille tõttu uuriti tema eksoomi ja leiti üliaeglase metabolismi põhjusena funktsioonikaoga
mutatsioon CYP3A4 geenis1. Sarnaseid leide on ka ensüümide CYP2C19 ja CYP2D6
puhul, mis metaboliseerivad vastavalt 15% ja 25% ravimitest2.
Lisasime täiendava lõigu taotluses punkti 10.2:
The probe drug experiment has a potential value for the participants in the study group and
the Estonian population in general, as it would clarify the effect of the mutations detected
in their genes encoding CYP enzyme, and thereby help to adjust future treatment with
medicines which are metabolised via the respective CYP enzymes and further estimate the
participants’ personal metabolic activity for the studied drug metabolizing enzymes while
taking into account the patient’s lifestyle and environmental influences in addition to their
personal genetic background.
By the request the participants (please see consent form) results of the pharmacokinetic
analysis will be given in the form of a personal drug metabolism profile and genetic report.
1
Werk et al 2013: https://doi.org/10.1038/clpt.2013.210
2
Guengerich et al 2006: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2751428/
1
This feedback will be prepared and delivered separately as “Feedback to the gene donors”
(“Tagasiside geenidoonoritele”), Approval of the Research Ethics Committee of the
University of Tartu 271/T-2, 19.06.2017).
The results are expected to benefit all participants of the EstBB, other Estonian residents
and other populations as well.
Nõukogu esitas taotlusele järgmised kommentaarid ja küsimused:
3. Tegemist on tervete vabatahtlike uuringuga. Kas on plaanis ka nende vabatahtlike osalemist
kompenseerida? Kui jah, siis kuidas ja missuguses ulatuses. Kas kompenseerimine toimub
või ei toimu, peaks kajastuma informeeritud nõusolekul. Nõukogu on seisukohal, et 50
eurot ei ole piisav kompensatsioon. Palume uuringu meeskonnal tutvuda Euroopa
Ravimiameti poolt uuritavatele kompensatsiooni tasumise nõuetega.
Vastus: Vastavalt EU kliiniliste uuringute regulatsioonile „Clinical trials regulation (eu)
no 536/2014“ https://ec.europa.eu/health/sites/health/files/files/eudralex/vol-
10/regulation5362014_qa_en.pdf ei tohiks uuringus osalemise kompensatsioon ületada
otseseid töötasu vähenemisega ja otseselt uuringus osalemisega seotud kulusid.
Vastav lõik regulatsioonist: „compensation should not cover more than expenses and loss
of earning, directly related to the participation in the clinical trials. Examples of expenses
directly related to the participation in the clinical trials are travel costs for the participating
subject and the legally designated representative (if applicable) or (if applicable) the person
accompanying the subject, costs for accommodation, or additional costs due to
participation in the clinical trial collected by the subjects’ health insurance (compulsory
patient contributions/own risk).
Uuringuravimi manustamine on plaanitud nädalavahetuse päeval ning osalejale sobival
ajal. Uuringu ajal on plaanis katta kuludokumentide alusel osaleja transpordikulud. Kuna
uuringukeskused on nii Tallinnas kui Tartus, ei ületa transpordikulud Eestis tõenäoliselt
väga palju 50.-. Kui osalejal ei ole võimalik uuringukeskusesse tulla uuringuravimi
manustamise päeva hommikul või lahkuda uuringupäeva järgsel õhtul, siis tasustatakse ka
ööbimiskulud.
Vastav lõik on lisatud taotlusesse: The study drug administration is scheduled for the
weekend. During the study, it is planned to cover the participant's transportation costs on
the basis of expense receipt(s). As the research centers are located in both Tallinn and Tartu,
transport costs in Estonia are unlikely to exceed 50€/visit. As the participant has to come
to the study center twice during the study, altogether the travel compensation is up to 100€.
If the subject is unable to come to the study center in the morning on the day when the drug
will be administered or travel home in the evening after the day of the study,
accommodation costs will also be reimbursed. As participants are healthy subjects we do
not foresee necessity for involving an accompanying person.
Lisatud ka järgnevad lõigud informeeritud nõusoleku lehele:
2
Uuringus osalejatel on vaja käia kahel uuringuvisiidil, mis toimuvad haiglas (Tartu Ülikooli
Kliinikum või Põhja Eesti Regionaalhaigla). Haiglasse sõitmise kulud kompenseeritakse
Teile sõidudokumentide alusel, maksimaalselt kuni 50 € ulatuses visiidi kohta.
Uuringuravimi manustamine on plaanitud nädalavahetuse päeval ning Teile sobival ajal.
Uuringu ajal on plaanis katta kuludokumentide alusel Teie transpordikulud. Kui Teil ei ole
võimalik uuringukeskusesse tulla uuringuravimi manustamise päeva hommikul või
lahkuda uuringupäeva järgsel õhtul, siis tasutakse ka Teie ööbimiskulud.
4. Tegemist on väga suure farmakokineetilise uuringuga tervetel vabatahtlikel, kus
plaanitakse hõlmata 200+/-50 isikut (informeeritud nõusoleku vormis 250) erinevate
CYP450 (ilmselt CYP2D6 ja CYP2C19) geenivariantidega. Samas ei ole kirjeldatud, miks
nii suurt valimit on tarvis, kas on mingid piirarvud teatud geeni variantidele jne. Uurijad
peaksid põhjendama valimi suuruse kujunemist ja analüüsima, missuguseid meetodeid
kasutatakse tagamaks, et oleks piisav arv uuritavaid erinevate geenivariantidega. Kas
sarnase uuringu saaks läbi viia ka oluliselt väiksema isikute hulgaga? Uuringusse
kutsutakse osalema 200+/-50 isikut, aga neist kõik ei pruugi sobida või nõustuda. Pole aga
selge, kui palju uuritavaid on vajalik hõlmata uuringu farmakokineetilisse perioodi, et
tõestada/ümber lükata püstitatud hüpoteese.
Vastus: Uuringusse on plaanis kutsuda geenidoonorid, kellel esineb potentsiaalselt
funktsioonikaoga mutatsioon või deletsioon (geneetika leid) ravimeid metaboliseerivates
ensüümides. Sellliste isikute arv geenivaramu andmebaasis on 984 ja kõiki neid kutsutakse
uuringus osalema. Seega on plaanis kirjeldada üksikjuhtude (erinevate mutatsioonidega
isikute) põhjal statistilisi PK parameetreid ning vajalikku uuritavate arvu (sample size)
hinnangut ei ole asjakohane teha. Lisasime allpool oleva küsimuse nr 7 juurde tabeli
erinevate genotüüpidega isikute arvu kohta, keda on plaanis uuringusse kutsuda.
Lisasime taotlusele punkti nr 7 lause: It is planned to describe the statistical PK
parameters on a case-by-case basis (individuals with different mutations) and the sample
size estimate is therefore not applicable.
5. Ravimitele on palju vastunäidustusi. Kas need tehakse kindlaks patsiendi sõnade põhjal või
vaadatakse ka haiguslugusid?
Vastus: Vastavalt uuringuprotokollile tuvastatakse patsiendi sobivus uuringus osalemiseks
esimesel uuringu visiidil (pre-dosing visit) haiglas, sealjuures ka võimalikud
vastunäidustused ravimitele. Selleks võetakse patsiendilt suuline meditsiiniline anamnees
ning vajadusel vaadatakse ka osaleja eelmisi haiguslugusid. Uurijad vaatavad varasemaid
haiguslugusid vaid osaleja nõusolekul ning vaadatakse vaid neid haiguslugusid, mis on
antud uuringu kontekstis olulised – sellised, kust saab vajadusel kinnitust osaleja sobivuse
kohta uuringus osalema (nt ravimite vastunäidustused). Varasematest haiguslugudest võib
olla vaja vaadata infot varasemate diagnooside, kasutatavate ravimite ja allergiate kohta.
3
6. Taotluses on vaja palju selgemat lahti kirjutamist uuringusse kaasamise protsess – kes
helistab ja kust telefoninumbrid saadakse, kas kõik, kellele helistatakse kutsutakse ka
esimesele visiidile või jäävad mõned isikud juba pärast telefoni kontakti välja? Kui palju
isikuid ja milliseid haaratakse farmakokineetilisse faasi? Vt ka eelmist kommentaari.
Vastus: Kirjeldame täpsemalt uuritavate kaasamise protsessi punktis 9 „Description of the
study-related procedures”. Taotlusele on lisatud ka uuringusse kutsumise kiri, mis esmalt
geenidoonoritele saadetakse.
7. Kas uuring sellise formaadiga omab piisavat teaduslikku kvaliteeti? Miks ei ole rakendatud
lisaks ka populatsiooni kineetika uuringut lisaks parameetrilisele farmakokineetilisele
analüüsile.
Vastus: Kuna uuringusse kaasatakse varem kirjeldamata geneetilise mutatsiooniga
inimesed, ei ole teada, kas mutatsioon üldse mõjutab ravimite farmakokineetikat. Uuringu
eeldus on, et uuringusse kaasatud isikute metabolismivõime on väga erinev ning erineva
genotüübiga indiviide, keda uuringusse soovime kaasata, on vähe. Lisatud on tabel
erinevate genotüüpidega osalejate numbritega. Leiame, et antud uuringus ei anna
populatsiooni farmakokineetika lisaväärtust.
Allele 1 Allele 2 N Nmax Coordinate
CYP2C19_del+CYP2D6_del CYP2C19_Normal+CYP2D6_LoF 3 3
CYP2C19_del+CYP2D6_del CYP2C19_Normal+CYP2D6_Normal 3 3
CYP2C19_del+CYP2D6_del CYP2C19_Increased+CYP2D6_LoF 2 2
CYP2C19_del+CYP2D6_del CYP2C19_LoF+CYP2D6_Normal 2 2
CYP2C19_del+CYP2D6_del CYP2C19_Increased+CYP2D6_Normal 1 1
CYP2C19_del+CYP2D6_del CYP2C19_LoF+CYP2D6_LoF 1 1
CYP2C19_del CYP2C19_del 1 1
CYP2C19_del CYP2C19_Increased 162 10
CYP2C19_del CYP2C19_LoF 54 10
CYP2C19_del CYP2C19_Normal 324 10
CYP2C19_Novel_missense 1 1 chr10:96535248
CYP2C19_Novel_missense 1 1 chr10:96580257
CYP2C19_Novel_missense 4 4 chr10:96540331
CYP2C19_Novel_missense 1 1 chr10:96541688
CYP2C19_Novel_missense 1 1 chr10:96580323
CYP2C19_Novel_missense 1 1 chr10:96602648
CYP2C19_Novel_missense 1 1 chr10:96535156
CYP2C19_Novel_missense 1 1 chr10:96602634
CYP2D6_Novel_LoF CYP2D6_normal 14 10 chr22:42524820
CYP2D6_Novel_LoF CYP2D6_LoF 12 10 chr22:42524820
CYP2D6_Novel_LoF 6 10 22:42522982
CYP2D6_Novel_LoF CYP2D6_LoF 1 1 chr22:42523847
CYP2D6_Novel_LoF 1 1 chr22:42522916
CYP2D6_Novel_missense 1 1 chr22:42523889
CYP2D6_Novel_missense 1 1 chr22:42523916
4
CYP2D6_Novel_missense 2 2 chr22:42523928
CYP2D6_missense? * 109 10 chr22:42522613
CYP2D6_missense? * 86 10 chr22:42523943
CYP2D6_missense? * 45 10 chr22:42526694
CYP2D6_missense? * 33 10 chr22:42524814
CYP2D6_missense? * 30 10 chr22:42526763
CYP2D6_missense? * 23 10 chr22:42525811
CYP2D6_missense? * 23 10 chr22:42525821
CYP2D6_missense? 10 10 chr22:42524947
CYP2D6_missense? 6 10 chr22:42523558
CYP2D6_missense? 4 4 chr22:42523613
CYP2D6_missense? 3 3 chr22:42523567
CYP2D6_missense? 3 3 chr22:42524310
CYP2D6_missense? 2 2 chr22:42523897
CYP2D6_missense? 2 2 chr22:42525115
CYP2D6_missense? 1 1 chr22:42522601
CYP2D6_missense? 1 1 chr22:42523844
CYP2D6_missense? 1 1 chr22:42526712
Total 984 197
*) depending on the function of the 2nd allele (normal, LoF, increased) we will invite 10 individuals from
each group to participate, i.e. Possibly multiply nr of individuals to recruit with 3.
Abbreviations: N = number of carriers, Nmax = number that will be recruited, del = deletion, LoF = Loss of
Function, Increased = Increased function, Normal = Normal function (wild type), missense = amino acid
change, missense? = amino acid change with unknown function
8. Kas uuringus on ülemine vanusepiir? Kui on, siis tuleks see taotluses märkida.
Vastus: ülemist vanusepiiri ei ole, lisame selle info taotlusele punktis 7.
Inclusion criteria: Biobank participants (> 18 years, no upper limit of age)
9. Milliseid haiguslugusid vaadatakse (Access to medical records is only allowed to people
mandated by the sponsor....)?
Vastus: Uurijad vaatavad vaid uuringu jaoks asjakohaseid haiguslugusid, mis on
potentsiaalselt seotud ravimite vastunäidustuste kindlaks tegemisega.
Lisasime taotlusesse:
Punkti nr 9: At the pre-dosing visit patient's eligibility for the study will be ascertained,
including possible contraindications to the probe drugs. Relevant medical history will be
documented in the electronic medical record. If necessary, the participant's previous medical
history is reviewed. Only the past electronic medical records will be examined that are relevant
5
in the context of the study (information on diagnoses, medications used and allergies) and with
the consent of the participant.
Punkti nr 10:
All collected data will remain confidential and anonymous. Investigators who are mandated to
access the participants’ past electronic medical records are documented in the study delegation
log, are also employees of the study centres (NEMC or TUH) and have access to electronic
health systems of the hospitals.
10. Ei ole selge, kui kaua uuring kestab ja kui kaua sellest uuritav haiglas veedab. Kas uuringu
kestvus uuritava jaoks on 72 tundi või 10 tundi?
Vastus: uuring kestab kuni viimase kontakteerumiseni telefoni teel. Esimese uuringuvisiidi
pikkus on umbes 1 tund ja teise uuringuvisiidi kestus on 10 tundi. Lisasime vastava info
taotluses punkti nr 9.1.
Informeeritud nõusoleku lehel on juba kirjas lause: Teine visiit kestab kuni 10 tundi ja seetõttu
toimub see nädalavahetusel. Lisasime informeeritud nõusoleku lehele: Uuringu esimesel
visiidil kulub haiglas aega umbes 1 tund.
11. Nõukogu on seisukohal, et 10 tunnise haiglas viibimise kohta ainult hommikusöök on
ebapiisav. Uuringus osalejale tuleb tagada toitlustamine.
Vastus: Uuritavatele tagatakse toitlustamine terve päeva jooksul, mil uuring toimub. Tegime
vastava muudatuse taotluses ja patsiendi infolehel.
Lisatud lause taotlusele: After probe drug administration and the first PK analyses a breakfast
will be served at the study centres. The participants will be served a hot lunch. If requested, the
subjects will receive one additional light meal.
Lisatud lõik informeeritud nõusoleku lehele: Pärast uuringuravimite manustamist pakutakse
Teile uuringukeskuses hommikusööki ning toitlustus tagatakse terve uuringupäeva jooksul.
12. Taotluse järgi on uuringu meeskonnas meditsiiniõed. Taotluses peavad olema vastavad
isikud märgitud ja nendelt allkirjad võetud.
Vastus: Saadame uuringuõdede nimed Nõukogule täiendusega siis, kui uuringu alguse aeg on
selgunud. Uuringuõdedeks on mõlemas uuringukeskuses plaanitud õed, kelle igapäevatöö on
uuringuprotseduuridele analoogsete meditsiiniliste tegevuste läbiviimine.
Lisasime taotlusele lõigu: COMMENT: an additional application will be submitted to the
Estonian Committee on Bioethics and Human Research for adding medical personnel from
study centers (nurses) to the list of investigators.
6
13. Taotluses on ebaselge kui palju vereanalüüse võetakse peale ravimikokteili manustamist.
Taotluse punktis 8.1 on lisaks 10 analüüsile (viimane 8 tundi pärast ravimi manustamist)
ka märgitud analüüsid 12, 24, 48 ja 72 tundi pärast ravimi manustamist. Mujal taotluses ja
protokollis aga mainitakse 10 analüüsi võtmist, sealjuures viimane analüüs võetakse 8 tundi
pärast ravimi manustamist. Kuna metoprololi poolväärtusaeg SPC andmetel on 3.5 tundi,
siis viimase analüüsi võtmine 8 tundi pärast ravimi manustamist võib osutuda ebapiisavaks
ja seda eriti pidades silmas, et uuringusse kontsentreeruvad aeglased metaboliseerijad.
Uurijad peaksid seda selgitama ja olema veendunud, et nimetatud uuringust saadud
tulemused annavad vastuse neid huvitavale küsimusele.
Vastus: Lähtume uuringus farmakokineetiliste analüüside võtmisel varem
fenotüpiseerimiskokteiliga tehtud uuringu (Donzelli et al) tulemustest, milles oli kaasatud ka
aeglased metaboliseerijad ning kus selgus, et lühem vereproovide võtmise periood on olnud
piisav uuritavate ravimite farmakokineetilise profiili kirjeldamiseks. Lühema uuringuperioodi
rakendamine on lisaks ka uuritavate huvides, kes ei pea veetma haiglas ööd.
Lisasime taotlusesse lõigu: The sampling schedule is based on the results of a previous
phenotyping cocktail study (Donzelli et al, 2014) that included slow metabolizers and showed
that a shorter blood sampling period was sufficient to describe the pharmacokinetic profile of
the studied drugs. In addition, the use of a shorter study period is also in the interest of subjects
who do not have to spend the night at the hospital.
14. „Side effects will be documented and reported to the State Agency of Medicines“. Selgitada
oleks tarvis, kas kõik kõrvalnähud või ainult tõsised kõrvalnähud (serious adverse events)
dokumenteeritakse Ravimiametis ja kas neid muudes dokumentides (haige kaart) et
raporteerita.
Vastus: Uuringu ajal raporteerime Ravimiametile vaid tõsistest kõrvalnähtudest.
Tegime vastavad muudatused eetikakomitee taotluses.
Muudatus taotluses: According to the protocol, all participating doctors and nurses will be
obliged to report any study related serious adverse effects to the State Agency of Medicines
and Ethics Committee.
Uuringuprotokollis on punktis 11 lause:
11. Safety reporting
All participating doctors, nurses and pharmacists are obliged to report to PI and PI is obliged
to report to State Agency of Medicines and Ethical Committee about any suspected unexpected
serious adverse adverse reactions (SUSAR).
15. Taotluses on märgitud, et haigele helistatakse 1 nädal pärast uuringukokteili võtmist. Miks
selline ajamääratlus? Kas on kaalutud, et võib esineda ravimite manustamisest probleeme
ka esimestel päevadel .
7
Vastus: Uuritavatele helistatakse nädal pärast uuringuravimite manustamist, kuna
uuringuravimite põhjustatud kõrvalnähud tõenäoliselt hiljem enam ei avaldu. Uuritaval on
võimalus uurijatega telefoni teel ühendust võtta kogu uuringu ajal ja teavitada uurijat
võimalikust ravimi kõrvaltoimest.
Lisasime taotlusesse punkti nr 9 lõigu: Follow-up phone call 1 week after the phenotyping
probe drugs administration to document possible ADRs. The call will be made a week after the
study medication is given as side effects are unlikely to occur later. The subject has the
opportunity to contact investigators by telephone throughout the study and to inform the
investigator of any adverse drug reaction.
Lisasime infolehele järgmise lause: Teil on võimalus uurijatega telefoni teel ühendust võtta
kogu uuringu ajal ja teavitada uurijat võimalikust ravimi kõrvaltoimest.
16. Kuna tegemist on ravimuuringuga siis on vajalik uuritavatele rakendada eraldi
kindlustuskaitse.
Vastus: Uuringu ajaks küsitakse uuritavatele kindlustuspoliis. Lisas kindlustuspakkumine.
17. Taotluses 9.2 isiku autonoomia respekteerimise lõik peaks puudutama ka prospektiivset
uuringut.
Vastus: Täiendasime vastavat peatükki:
Participation in this study is voluntary. The gene donor shall be provided with sufficient
information on the nature of the trial to assist him or her in making an informed decision. The
subject may at any time opt-out or discontinue the trial without justification.
The study data of the subject who discontinued the study shall be kept for 5 years, separately
from the data of the other subjects and shall not be included in the analysis. If a participant asks
the PI to delete their data, we will give them 2 options, a) delete data + destroy sample, or b)
delete the code key. The requested data will be deleted and this action will be documented.
16. Kas geenivaramust võetakse mingid koeproovid, kuna punktis 10.1 kirjutatakse: „The
tissue samples, ... are issued from the Gene Bank only in pseudonymised form“
Vastus: Parandasime vea punktis 10.1. Uuringu käigus ei võeta geenivaramust koeproove.
Lause uus sõnastus: Descriptions of DNA are issued from the Gene Bank only in
pseudonymised form, as a set of data and on the condition that samples or data concerning at
least five gene donors are issued at a time (HGRA § 22, section (4)).
8
18. Ei taotlusest ega informeeritud nõusolekust ei selgu, kuidas uuritavaid ravimeid
manustatakse. Kas ravimvorm lahustatakse 50 ml kraanivees? Või uuringuks spetsiaalselt
valmistatud tablettide või kapslitena. See vajab selgitust nii taotluses kui ka informeeritud
nõusoleku lehel.
Vastus: Kirjutasime vastava punkti täpsemalt lahti taotluses, protokollis punktis 9.2
(description of dosing):
Muudetud lõik taotluses:
Modified version of Basel cocktail will be used. Single oral dose of phenotyping probe drugs
will be administered with 50 mL of tap water:
20 mg omeprazole (full 20mg capsule)
12,5 mg metoprolol (12,5 mg of metoprolol as an active substance which dose is
measured and packed according to the standard procedures (SOP) of the hospital
pharmacy of Tartu University Hospital). The reason to use extemporaneous product
is caused by the fact that no marketed product of metoprolol is available at such a
low dose.
Täiendus patsiendi infolehel:
Omeprasool on kapslis valmispreparaat ja metoprolool antakse Teile puhta toimeaine pulbrina,
mille uuringuõde lisab 50ml-le kraaniveele ja annab Teile sisse võtmiseks. Ka omeprasooli
võtmiseks antakse teile kraanivett.
18. Informeeritud nõusolekust johtub, et haigele antakse kaasa soovitus ravimikokteili
võtmiseks. Samas on aga isik samaaegselt haiglas. Niisuguses uuringus on ilmselt ohutum kui
uuringuravimi valmistab ja manustab uuringuga seotud meditsiinitöötaja.
Vastus: Muutsime sõnastuse täpsemaks. Informeeritud nõusoleku lehel on kirjas, et esimesel
uuringuvisiidil antakse koju kaasa info selle kohta, kas uuringus osaleja võib uuringupäeva
hommikul võtta oma isiklikud ravimid, mida ta regulaarselt tarvitab.
Kuna uuringus osalevad terved vabatahtlikud ja täiskasvanud inimesed, siis annavad
uuringuõed suu kaudu manustatava ravimi patsiendi kätte, kes selle uuringuõe järelvalve all
endale ise manustab.
Täiendasime vastavat lõiku informeeritud nõusoleku lehel: Kui tarvitate regulaarselt ravimeid,
lepitakse Teiega esimesel visiidil kokku, kas võite uuringupäeva hommikul oma isiklikke
ravimeid võtta. Selle kohta antakse Teile kaasa täpne soovitus.
19. Isikute ohutuse tagamiseks palume lisada informeeritud nõusolekule telefoninumber, kuhu
ja kellele uuritav probleemide korral võib ööpäevaringselt helistada.
9
Vastus: Lisame informeeritud nõusoleku lehele telefoninumbrid mõlemast uuringukeskusest
(uurijate isiklikele telefonidele suunatud kabineti telefoni numbrid), kuhu uuritavad saavad
uuringu ajal ööpäevaringselt helistada. Numbrid täpsustuvad uuringu eelseks hetkeks.
20. Kui kaua ja kus säilitatakse prospektiivse uuringu andmeid ning koodi võtit?
Vastus: Uuringu andmeid säilitatakse peale uuringu lõppu geenivaramus tähtajatult ning
samuti säilitatakse geenivaramus ka koodi võtit.
21. Mis juhtub andmetega, kui osalemine katkestada?
Vastus: Uuringu katkestanud isiku uuringuandmeid säilitatakse 5 aastat, teiste uuritavate
andmetest eraldi Geenivaramus ja neid andmeid analüüsi ei kaasata. Kui osaleja palub oma
andmed kustutada, anname talle 2 võimalust, andmed kustutada+ proov hävitada või koodivõti
kustutada, siis andmed kustutatakse ning see tegevus dokumenteeritakse.
Lisasime taotlusele punkti 10.2: The study data of the subject who discontinued the study shall
be kept for 5 years, separately from the data of the other subjects and shall not be included in
the analysis. If a participant asks the PI to delete their data, we will give them 2 options, a)
delete data + destroy sample, or b) delete the code key. The requested data will be deleted and
this action will be documented.
22. Infolehes peab olema isikuandmete kaitse osa selgitatud vastavalt IKS –le.
Vastus: Lisasime infolehes isikuandmete kaitse kohta täienduse: Kõik uuringu raames kogutud
andmed on konfidentsiaalsed ja uuritavate isikuandmed on kaitstud vastavalt rahvusvaheliste
ja Eestis kehtestatud reeglitele (kooskõlas Isikuandmete Kaitse seadusega).
23. Mida tähendab „Info dokumenteeritakse elektroonilises haigusloos.“ Kas haigla
programmis (n ESTER)?
Vastus: Jah, uuringuvisiidil dokumenteeritakse info vastavalt uuringukeskusele vastava haigla
elektroonilises haigusloos (Ester Põhja-Eesti Regionaalhaiglas või eHL Tartu Ülikooli
Kliinikumis).
Täiendasime informeeritud nõusoleku vormi: Info dokumenteeritakse elektroonilises
haigusloos vastava haigla IT süsteemis sarnaselt sellele, kuidas andmeid dokumenteeritakse
tavalise arstivisiidi käigus.
24. Nõusoleku vormi lause: Ma annan uuringuga seotud isikutele loa juurdepääsuks oma
10
meditsiinilistele dokumentidele – on liiga laialt formuleeritud. Kas siin on silmas peetud kõiki
andmeid TISis?
Vastus: Uurijad vaatavaid vaid uuringu jaoks asjakohaseid haiguslugusid, mis on
potentsiaalselt seotud ravimite vastunäidustuste kindlaks tegemisega.
Lisasime informeeritud nõusoleku vormile lõigud: Uurijad võivad vaadata ka Teie varasemaid
haiguslugusid, mis on potentsiaalselt seotud ravimite vastunäidustuste kindlaks tegemisega.
Selleks küsitakse Teilt eraldi nõusolek.
Täiendasime informeeritud nõusoleku vormi lauset: 3. Ma annan uuringuga seotud isikutele
loa juurdepääsuks oma meditsiinilistele dokumentidele (uuringu jaoks vajaliku ravimitega
seotud info jaoks varasematest elektroonilistest haiguslugudest haigla infosüsteemis)
25. Uuritavale tuleb esitada kogu info, mis puudutab andmete kasutamist, muuhulgas ka lisada,
et prospektiivse uuringu andmed edastatakse ka Biopanka.
Vastus: Lisame infolehele lause, et et prospektiivse uuringu andmed edastatakse ka Biopanka,
kus toimub andmete kodeerimine ja pseudonümiseeritud kujul analüüs.
26. Kuna on kaks visiiti ja üks telefonikõne kõige lõpus, ei saa uuring olla päris anonüümne,
vahepeal on vaja andmeid isiku lõikes kokku viia (All information collected will remain strictly
confidential and anonymous ja All generated individual level data will be submitted to the
Estonian Biobank for incorporation into the biobank database at the end of the study) Infolehel
on kirjas: „Visiidi käigus dokumenteeritakse Teie isikuandmed“.
Vastus: Uuritavate ohutuse tagamiseks on patsiendiga otseselt kokkupuutuvatele uurijatele
uuringu ajal uuritava isik teada, et oleks võimalik tutvuda uuritava asjakohaste haiguslugudega.
Uuringuandmeid analüüsitakse ja avaldatakse teaduskirjanduses anonüümselt.
Lisasime taotlusesse täpsustava lõigu:
11.3 Storage of data collected during study
The EstBB senior data encoder will depseudonymise the personal data of participants that is
necessary for contacting the study subjects. The initial contact and invitation to participate in
the study will only be done by the EstBB staff authorized to handle personal data. Once the
individuals have agreed to participate in the study, their first visit will be scheduled by the
EstBB staff. At this point, the personal data of the participants will be visible for the
investigators at the study centre. During the first visit at the study centres (hospital) participants
personal information (name, id code) will be used for documenting the study visit to the
electronic medical systems and for ordering study related medical analyses (blood tests) from
11
the local laboratories. For the study participants unique study codes will be designated and
these codes will be used for the further study related procedures. Same codes will be
documented on the consent form, used in the screening logs, and on each blood sample taken
for PK analysis. Plasma samples for the PK analyses will be sent to the laboratory at Karolinska
Institute marked with the same unique codes and no personal information (ID codes, names)
will be sent out from the study centres (TUC, NEMC). The samples will be analysed and the
results will be sent to the EstBB using the same codes. All study records, measurements, sample
results will be submitted to the EstBB and entered into the biobank database. The final results
will then be coded for research use and made accessible through the EstBB database for the
researchers of the study.
27. Ravimikontsentratsioonide määramine tehakse Rootsis, Karolinska Instituudis. See oluline
informatsioon tuleb lisada ka informeeritud nõusolekule.
Vastus: Lisasime vastava info informeeritud nõusolekule: Ravimikontsentratsioonid
määratakse Rootsis, Karolinska Instituudis.
28. Infolehel on lause: Selles uuringus osalemisest ei pruugi Teile olla otsest kasu. Sellest
uuringut uuritavale otsest kasu ei ole ja nii tuleks seda ka öelda.
Vastus: Uuringust ei pruugi olla uuritavale otsest kasu, kuid juhul kui farmakokineetiline
uuring näitab, et uuritav ei ole võimeline uuringuravimeid metaboliseerima, võib sellest
teadmisest olla uuritavale tulevikus kasu ka teiste CYP2D6 või CYP2C19 ensüümi poolt
metaboliseeritud ravimite korral. Lisaks vaatab uuritava läbi uuringuarst ning uuringu ajal
tehakse osalejale laboratoorsed analüüsid, mille interpreteerimine uurijate poolt võib samuti
uuritavale kasu tuua.
Lisasime taotlusele lõigu: The probe drug experiment has a potential value for the participants
in study group as it could help to adjust future treatment with medicines which are metabolised
via the studied CYP enzymes and further estimate the participants’ personal metabolic activity
for the respective drug metabolizing enzymes while taking into account the patient’s lifestyle
and environmental influences in addition to their personal genetic background.
By the request the participants (please see consent form) results of the pharmacokinetic
analysis will be given in the form of a personal drug metabolism profile and genetic report.
This feedback will be prepared and delivered separately as “Feedback to the gene donors”
(“Tagasiside geenidoonoritele”), Approval of the Research Ethics Committee of the University
of Tartu 271/T-2, 19.06.2017).
Lisasime informeeritud nõusoleku vormile täiendavalt:
12
Teil on võimalus saada teada, kas olete uuringus kasutatud ravimite kiire või aeglane
metaboliseerija ning saada personaalse farmakogeneetika raporti, mis on koostatud Teie kohta
Geenivaramus hoitavate geeniandmete põhjal. Farmakogeneetika raport kajastab inimese
geneetiliste eripärade mõju ravimite omastamisele, sobivusele või kõrvaltoimete tekkimisele.
Raportis on andmed 28 erineva toimeaine kohta. Uuringu tulemused ja raport saadetakse Teile
soovi korral e-mailile või tavapostiga.
Palun tehke valik ja märkige sobivasse kasti ees- ja perekonnanime esitähed
Soovin teada uuringu tulemusi Soovin saada raportit
Ei soovi teada uuringu tulemusi Ei soovi saada raportit
Kirjutage trükitähtedega e-maili või postiaadress, kuhu saadetakse tulemused ja/või raport.
Neid andmeid ei kasutata mingil muul otstarbel ja ei kanta mingisse andmebaasi, kuid nad
jäävad tähtajatult hoiule Geenivaramusse.
………………………………………………………………………………………….
29. Uuritavatele esitatud tekst peab olema tavainimese jaoks arusaadav.
Vastus: Hindasime uuesti üle uuritavale esitatava teksti arusaadavuse ja tegime vastavad
parandused.
13
Sweden, Stockholm, Karolinska University Hospital
-------------------------------------------
Date: 2020-02-25
Dr. Anton Pohanka
--------------------------------------------
Date:
Dr. Volker M Lauschke
--------------------------------------------
Date:
Prof. Erik Eliasson, MD
Protocol 27.02.2020
CLINICAL STUDY PROTOCOL
Protocol 1-2020, Version 2
Study of the effects of previously uncharacterized rare variants in the genes
encoding CYP450 enzymes
1
Protocol 27.02.2020
Table of Contents
Protocol Signature Sheet and Acknowledgement 3
1. Protocol Synopsis 4
2. Protocol team 7
3. Participating institutions and units 9
4. Background and rationale 9
5. Study objective 13
6. Study design 13
7. Study population 14
8. Study procedures 15
8.3 Pharmacokinetic sampling and sample handling 18
9. Study medications 18
9.2 Description of dosing 19
Single doses of the following probe drug combinations will be administered Error!
Bookmark not defined.
with 50 mL of tap water: Error! Bookmark not defined.
omeprazole 20 mg for CYP2C19 Error! Bookmark not defined.
metoprolol 12.5 mg for CYP2D6 Error! Bookmark not defined.
9.3 Concomitant medication 20
10. Analytical procedures 20
11. Safety reporting 20
12. Study management and monitoring 22
13. Statistical considerations 22
13.1 Pharmacokinetic analysis 22
14. Ethical considerations and confidentiality 22
14.1 Informed consent 22
15. Administrative aspects 23
15.1 Handling and storage of data and documents 23
15.2 Annual progress report 23
15.3 End of study report 24
16. Scientific communication 24
2
Protocol 27.02.2020
Protocol Signature Sheet and Acknowledgement
I have read this Protocol and agree that it contains all necessary details for carrying out the
study described. I understand that it must be reviewed by the Independent Ethics Committee
and approved or given favourable opinion before implementation.
The signature of the Principal Investigator and Sponsor or it’s representative below constitute
their approval of this protocol and proved the necessary assurances that this study will be
conducted according to the Declaration of Helsinki, ICH GCP guidelines and applicable
regulatory requirements.
_________________________________________ _________________
Sponsor’s printed name and signature Date
__________________________________________ _________________
Principal investigator’s printed name and signature Date
3
Protocol 27.02.2020
1. Protocol Synopsis
Sponsor InstituEstonian Genome Center Science Center, University of
Tartu
Principal Investigator of the Alar Irs, Tartu University Hospital, Heart Clinic
clinical trial
Coordinating Investigator Jana Lass, University of Tartu, Institute of Genomics,
Research Fellow of Clinical pharmacology
Monitoring Riina Janno, National Centre of Translational and
Clinical Research
Title of Study Study of the effects of previously uncharacterized rare
variants in the genes encoding CYP450 enzymes
Protocol Number Protocol 1-2020, Version 2
Study Centres and units 1. Institute of Genomics, University of Tartu
2. Tartu University Hospital
Haematology and Oncology Clinic
3. North Estonia Medical Centre Foundation
Oncology and Haematology Clinic
4. Karolinska University Hospital
Department of Clinical Pharmacology
Study medicines Single oral dose of:
20 mg omeprazole
12.5 mg metoprolol
Study population Adult (>18 years) volunteers from the Estonian biobank
population not using interfering concomitant medicines
Methodology Prospective, multicentre, single dose phenotyping study.
For all of the genotyped participants full
pharmacokinetic profiles of the probe drugs and their
main metabolites will be determined in plasma.
Study timetable Study start date: 03.2020
Study completion date: 02.2025
Objectives To asses if the newly described mutations in cytochrome
2D6 and 2C19 change the metabolizing activity of these
enzymes.
Study design Prospective trial
Inclusion criteria 1. All biobank participants (> 18 years, no upper limit
of age) who have (according to performed
genotyping analysis) previously not
described/studied mutations or deletions in the
metabolizing enzymes (CYP2D6 and CYP2C19)
4
Protocol 27.02.2020
2. Able to understand the nature of the study and
content and meaning of consent.
Exclusion criteria 1. Clinically relevant abnormality of renal or liver
function or anemia identified at the laboratory
screening
2. Pregnancy or lactation
3. History or clinical evidence of alcoholism or drug
abuse within the last year period prior to screening
4. Excessive alcohol consumption within 2 days
before the first drug administration
5. Previous treatment with any medicines interfering
with the measurement of phenotyping probe drugs
6. Any of the probe drugs contraindicated or had a
history of allergy to any study medication
7. Patient's weight 50% more or less than their ideal
body weight (for assessment the on-line calculator
will be used e.g.https://www.calculator.net/ideal-
weight-calculator.html)
Study flow - Biopank participant screening
- E-mail contact
- Phone contact
- Pre-dose visit
- Drug administration and sample collection visit
- Phone follow up on Day 7 after drug administration
visit
Duration of subject Subjects will be on study for up to 1 week after
participation administration of study medicines.
Pharmacokinetics
PK sampling A total of 10 blood samples will be collected:
1st – before the start of drug cocktail dosing
(baseline)
2nd – 15 min after the administration of study dose
3rd – 30 min after the administration of study dose
4th – 45 min after the administration of study dose
5th – 1 h after the administration of study dose
6th – 2 h after the administration of study dose
7th – 3 h after the administration of study dose
8th – 4 h after the administration of study dose
9th – 6 h after the administration of study dose
10th – 8 h after the administration of study dose
Statistical methods Descriptive statistics:
PK parameters (AUC, T1/2, VD, CLt, CLr, Cmax)
5
Protocol 27.02.2020
Outcome Pharmacokinetic endpoints, area under the
concentration–time curve (AUC) ratios (AUC0–24h
parent / AUC0–24h metabolite)
6
Protocol 27.02.2020
2. Protocol team
Principal investigator
Dr. Alar Irs
Tartu University Hospital
Heart Clinic
511 8592
[email protected]
/signed electronically/
Sub-investigators
Dr. Lili Milani
Estonian Genome Centre
Institute of Genomics
University of Tartu
Riia 23b, 51010 Tartu
737 4039
[email protected]
/signed electronically/
Dr. Alar Irs
Tartu University Hospital
Heart Clinic
511 8592
[email protected]
/signed electronically/
Dr. Kersti Oselin
North Estonia Regional Hospital
Oncology and Haematology Clinic
617 1792
[email protected]
/signed electronically/
Dr. Jana Lass
Tartu University Hospital
Estonian Genome Centre
Institute of Genomics
University of Tartu
Riia 23b, 51010 Tartu731 8333
[email protected]
/signed electronically/
Kristi Krebs, MSc
Estonian Genome Centre
Institute of Genomics
University of Tartu
7
Protocol 27.02.2020
Riia 23b, 51010 Tartu737 4039
[email protected]
/signed electronically/
Tuuli Jürgenson, BSc (statistics)
Estonian Genome Centre
Institute of Genomics
University of Tartu
Riia 23b, 51010 Tartu
[email protected]
/signed electronically/
Dr. Anton Pohanka
Karolinska University Hospital
Department of Clinical Pharmacology
[email protected]
/signature in Annex/
Dr. Volker M Lauschke
Dept of Physiology and Pharmacology
Karolinska Institutet
[email protected]
/signature in Annex/
Prof. Erik Eliasson, MD
Department of Laboratory Medicine
Clinical Pharmacology
Karolinska Institutet
[email protected]
/signature in Annex/
Director of the institution or head of the structural unit of the principal investigator
Katrin Kaarna
Head of the Clinical Research Centre, University of Tartu
Ravila 19, 50411 Tartu
[email protected]
737 4119
/signed electronically/
Consent from director or authorised person of the institution(s)/partner organisation(s)
Institute of Genomics
University of Tartu
Riia 23b, 51010 Tartu
Mait Metspalu
Director
737 5052
8
Protocol 27.02.2020
[email protected]
/signed electronically/
3. Participating institutions and units
1. Estonian Genome Center Science Center, University of Tartu
2. Tartu University Hospital
Haematology and Oncology Clinic
3. Oncology and Haematology Clinic, North Estonia Medical Centre Foundation
5. Pharmacological laboratory, Karolinska Institute, Sweden
4. Background and rationale
Cytochrome P450 (CYP) enzymes play an important role in drug metabolism by being
responsible for oxidative metabolism of approximately 50 % of drugs and xenobiotics.
Variation in the CYP genes can produce enzyme products with abolished, reduced, altered or
increased enzyme activity. In addition to metabolizing enzymes of which the CYP genes are
the by far most well studied, drug transporter proteins are important sources of pharmacokinetic
variability in drug response (Kozyra et al, 2016).
Considerable inter- and intra-individual variability in the expression and function of CYP
enzymes exists, which is determined by multiple factors. A large degree of variability exists
within any particular genotype group, which confirms that in addition to known genetic
variants, novel rare genetic factors as well as non-genetic host factors (age, gender, disease
states), and environmental influences (such as smoking, diet, concomitant drugs) are also
important (Wilkinson et al, 2005). Consequently, each individual has its own CYP450
metabolic profile and the phenotype (i.e. the real activity) of an individual enzyme is important
for predicting possible therapeutic failures or toxic reactions to medicines.
Several common genetic variants have been described which lead to altered enzyme activity
and thus variation in treatment outcome (Reisberg et al, 2019). However, the effect of some
novel rare genetic variants is not known on drug metabolism. The aim of our study is to examine
in a clinical trial the effect of novel predicted loss-of-function (LoF), missense genetic variants
and large deletions that were detected in the Estonian population by analysing the whole
genome sequence data of 2500 participants of the Estonian Biobank (Tasa and Krebs et al,
2018). The effect of the variants was first assessed with bioinformatic tools, incl. Variant Effect
Predictor (VEP, https://www.ensembl.org/info/docs/tools/vep/index.html) and filtered for loss-
of-function and missense variants. For this study, we have also included missense variants that
were selected using a recently published framework for pharmacogenetic variants (Zhou et al,
2018).
In order to determine the effect of the previously uncharacterized genetic variants, we will use
in vivo phenotyping by using previously tested and validated phenotyping probe drugs. This
will allow us to determine the enzyme activities and describe the net effect of all influencing
9
Protocol 27.02.2020
factors on CYP activity. It has been shown that using phenotyping probe drugs is an accurate
and minimally invasive method for the in vivo assessment of CYP enzyme activities in a single
experiment. Probe drugs can be used in various combinations (Donzelli et al, 2014; Christensen
et al, 2003; Keller et al. 2017), allowing for the in vivo assessment of multiple pathways of drug
metabolism in a single experiment, taking into account genetic, non-genetic and environmental
influencing factors. Probe drugs should predominantly be metabolized by an individual CYP
enzyme, can be safely administered to humans and have no other significant cause of variability,
in addition to the one for which they will be used as a probe.
There are several phenotyping cocktails used in clinical studies, each of these having their
benefits and flaws. The basel phenotyping cocktail (containing caffeine, efavirenz, losartan,
omeprazole, metoprolol, and midazolam as probe drugs for CYP1A2, CYP2B6, CYP2C9,
CYP2C19, CYP2D6 and CYP3A4, respectively) has been well tolerated and has had good
correlations of metabolic ratios with AUC (Area Under The Curve - one of the most important
evaluation metrics for checking any classification model’s performance) ratios of the
corresponding probe drugs and their metabolites (Derungs et al. 2016).
References
1. Kozyra et al. “Rare genetic variants in cellular transporters, metabolic enzymes, and
nuclear receptors can be important determinants of interindividual differences in drug
response”. Genet. Med. (2016)
2. Wilkinson. “Drug metabolism and variability among patients in drug response”. N
Engl J Med. 2005;352(21):2211–21
3. Reisberg et al. "Translating genotype data of 44,000 biobank participants into clinical
pharmacogenetic recommendations: challenges and solutions." Gen Medicine 21.6
(2019): 1345.
4. Tasa et al. "Genetic variation in the Estonian population: pharmacogenomics study of
adverse drug effects using electronic health records." Eur J Human Genetics 27.3
(2019): 442.
5. Donzelli et al. The basel cocktail for simultaneous phenotyping of human cytochrome
P450 isoforms in plasma, saliva and dried blood spots. Clin Pharmacokin 2014, 53(3),
271-282.
6. Christensen et al. "The Karolinska cocktail for phenotyping of five human cytochrome
P450 enzymes." Clin Pharmacol Therapeutics 73.6 (2003): 517-528.
7. Keller et al. "In vivo phenotyping methods: cytochrome P450 probes with emphasis
on the cocktail approach." Curr pharm design 23.14 (2017): 2035-2049.
8. Derungs et al. "Effects of cytochrome P450 inhibition and induction on the
phenotyping metrics of the basel cocktail: a randomized crossover study." Clin
Pharmacokin 55.1 (2016)
9. Zhou et al. “Computational Methods for the Pharmacogenetic Interpretation of Next
Generation Sequencing Data.” Front Pharmacol 4;9:1437. (2018)
4.1 Genotyping probe drugs
It has been shown that the method of using phenotyping probe drugs is accurate and
minimally invasive methods for in-vivo assessment of CYP enzyme activities in a single
experiment. Probe drugs can be used in various combinations allowing for the in vivo
assessment of multiple pathways of drug metabolism in a single experiment, taking into
account genetic, non-genetic and environmental influencing factors
10
Protocol 27.02.2020
Probe drugs should meet certain criteria - they should predominately be metabolized by an
individual CYP enzyme, can be safely administered to humans and have no other significant
cause of variability, in addition to the one for which they will be used as a probe.
The phenotyping procedure involves following steps:
1. administration of a small dose of the probe drug(s)
2. measurement of the drug and metabolites concentration in plasma/urine
3. calculation of a specific metabolic index
4. correlation of the resulting index value with a known activity of the evaluated enzyme.
There are several phenotyping cocktails used in clinical studies, each of these having their
benefits and flaws.
The Basel phenotyping cocktail has been well tolerated and has had good correlations of
metabolic ratios with AUC ratios of the corresponding probe drugs and their metabolites
(Derungs et al. 2016).
The composition of the Basel cocktail is following:
100 mg caffeine,
50 mg efavirenz,
12.5 mg losartan,
10 mg omeprazole,
12.5 mg metoprolol
2 mg midazolam.
Practical considerations in the selection of CYP substrates
Cytochrome Probe drug
CYP1A2 Caffeine Complex metabolism involving many enzymes (CYP1A1,
1A2, 2A6, 2E1, 3A, NAT-2 and XO).
Metabolism rate variable and 2 to 12 h half-life in humans.
Urine collection period, renal clearance, smoking and
dietary/ influence PK.
Disagreement about the dose, time of evaluation, sample
matrix (blood /urine), and the best metabolic quotient.
CYP2B6 Efavirenz Upon repeated dosing, it is a moderate inducer of CYP3A4.
In vitro CYP inhibition of CYP1A2, 2C9, 2C19, 2D6 and
3A4 isoforms (no in vivo data available).
Because of CYP liability, very low dose required and
necessities sensitive assay.
Long half-life (52-76 h) and slow plasma clearance resulting
in longer sampling intervals and washout periods
CYP2C9 Losartan Metabolism not specific to CYP2C9 and mediated by
CYP3A4 also through metabolism rate is 4-times greater for
CYP2C9 than for CYP3A4
11
Protocol 27.02.2020
CYP2C19 Omeprazole Half-life is very short (0.5-1 h), and sampling within a few
hours after dosing.
Omeprazole is a competitive inhibitor of p-glycoprotein.
adverse effects such as headache, dizziness, cough, upset
stomach etc.
CYP2D6 Metoprolol Weak correlation of activity ss. urinary MR (M/HM) or
urinary S/R-metoprolol ratio.
Significant first-pass metabolism.
Adverse reactions (hypotension, orthostatic symptoms etc.).
CYP3A4/5 Midazolam Multiple- blood samples needed for AUC measurement.
Metabolism is related to two different organ enzymes
(hepatic and intestinal CYP3A).
Oral and intravenous dosing necessary to characterize the
hepatic and intestinal contributions.
At increased CYP3A4/5 activity, midazolam clearance may
exhibit hepatic blood flow dependence. This may
present issues with the interpretation of the results.
First-pass metabolism may be saturated.
Side effects (i.e., dizziness and sedation).
Based on the genetic profiles of the biobank patients, the composition of the cocktail was
reduced to 2 components (omeprazole and metoprolol) to cover the most important and
common drug metabolizing CYP enzymes (2D6 and 2C19).
References
● Derungs et al. "Effects of cytochrome P450 inhibition and induction on the
phenotyping metrics of the basel cocktail: a randomized crossover study." Clinical
pharmacokinetics 55.1 (2016)
● Donzelli, et al. The basel cocktail for simultaneous phenotyping of human cytochrome
P450 isoforms in plasma, saliva and dried blood spots. Clin. Pharmacokinet., 2014,
53(3), 271-282.
4.2 Sample collection for pharmacokinetic analysis
A total of 10 blood samples will be collected from antecubital veins (inserted catheters):
1st – before the start of drug cocktail dosing (baseline)
2nd – 15 min after the administration of study dose
3rd – 30 min after the administration of study dose
4th – 45 min after the administration of study dose
5th – 1 h after the administration of study dose
6th – 2 h after the administration of study dose
7th – 3 h after the administration of study dose
8th – 4 h after the administration of study dose
9th – 6 h after the administration of study dose
10th – 8 h after the administration of study dose
12
Protocol 27.02.2020
5. Study objective
The aim of the study is to assess if the newly described mutations in cytochrome 2D6 and 2C19
change the metabolizing activity of these enzymes.
6. Study design
A prospective study will be performed at Tartu University Clinic’s Hematology and Oncology
Clinic and North Estonia Medical Centre Foundation’s Oncology and Haematology Clinic.
The subjects will be selected and re-contacted based on the availability of whole genome
sequencing data, the health status of the subjects and their suitability for such a study, according
to standard ethical procedures regarding clinical studies involving drugs.
Based on initial review of the existing whole genome sequencing data of 2500 the Estonian
Biobank (EstBB) participants, we have detected the following number of individuals with
previously uncharacterized genetic variants in the CYP450 genes:
Table 1. Number of individuals with rare genetic variants in the CYP450 genes
Allele 1 Allele 2 N Nmax Coordinate
CYP2C19_del+CYP2D6_del CYP2C19_Normal+CYP2D6_LoF 3 3
CYP2C19_del+CYP2D6_del CYP2C19_Normal+CYP2D6_Normal 3 3
CYP2C19_del+CYP2D6_del CYP2C19_Increased+CYP2D6_LoF 2 2
CYP2C19_del+CYP2D6_del CYP2C19_LoF+CYP2D6_Normal 2 2
CYP2C19_del+CYP2D6_del CYP2C19_Increased+CYP2D6_Normal 1 1
CYP2C19_del+CYP2D6_del CYP2C19_LoF+CYP2D6_LoF 1 1
CYP2C19_del CYP2C19_del 1 1
CYP2C19_del CYP2C19_Increased 162 10
CYP2C19_del CYP2C19_LoF 54 10
CYP2C19_del CYP2C19_Normal 324 10
CYP2C19_Novel_missense 1 1 chr10:96535248
CYP2C19_Novel_missense 1 1 chr10:96580257
CYP2C19_Novel_missense 4 4 chr10:96540331
CYP2C19_Novel_missense 1 1 chr10:96541688
CYP2C19_Novel_missense 1 1 chr10:96580323
CYP2C19_Novel_missense 1 1 chr10:96602648
CYP2C19_Novel_missense 1 1 chr10:96535156
CYP2C19_Novel_missense 1 1 chr10:96602634
CYP2D6_Novel_LoF CYP2D6_normal 14 10 chr22:42524820
CYP2D6_Novel_LoF CYP2D6_LoF 12 10 chr22:42524820
CYP2D6_Novel_LoF 6 10 22:42522982
CYP2D6_Novel_LoF CYP2D6_LoF 1 1 chr22:42523847
CYP2D6_Novel_LoF 1 1 chr22:42522916
CYP2D6_Novel_missense 1 1 chr22:42523889
13
Protocol 27.02.2020
CYP2D6_Novel_missense 1 1 chr22:42523916
CYP2D6_Novel_missense 2 2 chr22:42523928
CYP2D6_missense? * 109 10 chr22:42522613
CYP2D6_missense? * 86 10 chr22:42523943
CYP2D6_missense? * 45 10 chr22:42526694
CYP2D6_missense? * 33 10 chr22:42524814
CYP2D6_missense? * 30 10 chr22:42526763
CYP2D6_missense? * 23 10 chr22:42525811
CYP2D6_missense? * 23 10 chr22:42525821
CYP2D6_missense? 10 10 chr22:42524947
CYP2D6_missense? 6 10 chr22:42523558
CYP2D6_missense? 4 4 chr22:42523613
CYP2D6_missense? 3 3 chr22:42523567
CYP2D6_missense? 3 3 chr22:42524310
CYP2D6_missense? 2 2 chr22:42523897
CYP2D6_missense? 2 2 chr22:42525115
CYP2D6_missense? 1 1 chr22:42522601
CYP2D6_missense? 1 1 chr22:42523844
CYP2D6_missense? 1 1 chr22:42526712
Total 984 197
*) depending on the function of the 2nd allele (normal, LoF, increased) we will invite 10 individuals from
each group to participate, i.e. Possibly multiply nr of individuals to recruit with 3.
Abbreviations: N = number of carriers, Nmax = number that will be recruited, del = deletion, LoF = Loss of
Function, Increased = Increased function, Normal = Normal function (wild type), missense = amino acid
change, missense? = amino acid change with unknown function
Coordinate = chromosome and position according to human genome build hg37. The deletion of CYP2C19
spans exons 1-5 and the deletion of CYP2D6 the entire gene.
7. Study population
7.1 Inclusion criteria
1. All biobank participants (> 18 years, no upper limit of age) who have (according to
performed genotyping analysis) previously not described/studied mutations or
deletions in the metabolizing enzymes (CYP2D6 and CYP2C19)
2. Able to understand the nature of the study and content and meaning of consent.
7.2. Exclusion criteria
1. Clinically relevant abnormality of renal or liver function or anemia identified at the
laboratory screening
2. Pregnancy or lactation
14
Protocol 27.02.2020
3. History or clinical evidence of alcoholism or drug abuse within the last year period
prior to screening
4. Excessive alcohol consumption within 2 days before the first drug administration
5. Previous treatment with any medicines interfering with the measurement of
phenotyping probe drugs
6. Any of the probe drugs contraindicated or had a history of allergy to any study
medication
7. Patient's weight 50% more or less than their ideal body weight (for assessment the on-
line calculator will be used e.g.https://www.calculator.net/ideal-weight-
calculator.html)
Informed consent will be taken from the study participants before the study-related procedures.
Informed consent form allows to:
- Take blood samples for the PK analysis
- Administer probe drugs
- Assess relevant electronic medical records
The study procedures will be described thoroughly during the first contact by the phone.
The informed consent will be sought by the responsible study team member who is
documented at the delegation log.
There will be 2 copies of informed consent sheet:
- For the study participant
- For the study record
7.3. Removal of subjects from the study
Subjects could withdraw consent at any time without prejudice. The investigator could
withdraw a subject from the study if, in his or her clinical judgment, it was in the best interest
of the subject or if the subject could not comply with elements of the protocol or necessary for
the scientific integrity of the study. If the investigator withdrew a subject from the study, the
investigators explained the reason for withdrawing the participant
8. Study procedures
8.1 Study visits and patients monitoring
1. Contacting participants (please see Table 2)
Selected biobank subjects (up to 984 people) will be contacted and invited to participate in the
study first by e-mail or regular post if email address is not available (please see Invitation letter
Appendix 2). In case of nonresponse one reminder will be sent after 1 week, and a phone call
will be made 1 week after the reminder. The initial contact will only be made by personnel at
the EstBB who are specifically authorized by the director of the Institute of Genomics to handle
personal data.
15
Protocol 27.02.2020
2. All participants, who give positive response to the first invitation are scheduled for a phone
call with the authorized personnel at the EstBB in the course of which
introduction of the study and
pre-screening interview takes place
Pre-screening interview includes mapping of
o inclusion criteria
Suitable subjects are offered to participate at the study and invited to the study centre (Tartu
University Hospital or North Estonia Medical Centre) for a pre-scheduled pre-dosing visit.
3. Pre-dosing visit at the hospitals:
Duration of the visit is approximately 1 hour (time spent at the hospital).
verify the inclusion criteria
sign informed consent
collect medical history (previous and current medical conditions, surgical
history, prior and concomitant medications, allergies) and baseline characteristics
perform local laboratory tests
o haematological parameters: WBC, haemoglobin, haematocrit, platelets
o renal function measurements: urea, creatinine
o other tests: Na, K, Ca, glucose, transaminases
perform clinical examination (weight, height, blood pressure, heart rate)
At the pre-dosing visit patient's eligibility for the study will be ascertained, including possible
contraindications to the probe drugs. Relevant medical history will be documented to the
electronic medical record. If necessary, the participant's previous medical history is reviewed.
Only the past electronic medical records will be examined that are relevant in the context of the
study (information on diagnoses, medications used and allergies) and with the consent of the
participant.
Eligible study subjects will be invited to receive a dose of the probe drugs at a separate visit
(Dosing and PK sampling visit) at the study centre (Tartu University Hospital (TUH) or North
Estonia Medical Centre (NEMC)).
4. Probe drugs administration and PK sampling visit
Duration of the visit is up to 10 hours (time spent in hospital)
● Recheck eligibility according to the study inclusion and exclusion criteria
● Verify the inclusion criteria
● Perform clinical examination (evaluation of core body temperature, weight, height,
blood pressure, heart rate)
● Pregnancy test from urine (for female participants until menopause)
o Single dose administration of probe drugs:
o 20 mg omeprazole (full 20mg capsule)
o 12,5 mg metoprolol (12,5 mg of metoprolol as an active substance which
dose is measured and packed according to the standard procedures (SOP)
of the hospital pharmacy of Tartu University Hospital). The reason to
use extemporaneous product is caused by the fact that no marketed
product of metoprolol is available at such a low dose.
16
Protocol 27.02.2020
● Proceed to PK procedures
o 5 ml blood, 10 timepoints (altogether 50ml) will be taken from the inserted
venous cannula
● Observation and monitoring of the patient during PK sampling period (8 hours)
● Recording of the vital parameters (blood pressure, heart rate) and adverse events (ADR)
● Recording the concomitant medications (all OTC and prescription medications taken 24
hour before study dose)
Participants will be asked not to eat in the morning before the study visit when probe drugs are
administered in order to assess the PK profile at fasting state.
After probe drug administration and first PK analyses, a breakfast will be served at the study
centres. The participants will be served a hot lunch. If requested, the subjects will receive one
additional light meal.
Administration of participant’s regular medicines in the morning before administration of probe
drugs will be discussed and agreed during the pre-dose visit at the study centres. Specific
instructions will be given to every participant.
5. Follow-up phone call 1 week after the phenotyping probe drugs administration to document
possible ADRs. The call will be made a week after the study medication is given as side effects
are unlikely to occur later. The subject has the opportunity to contact investigators by telephone
throughout the study and to inform the investigator of any adverse drug reaction.
Record all Adverse Events (ADR) that have occurred since Day1
8.2 Schedule of study assessments
Contacting Phone contact, Pre-dose Dosing and PK Follow-up
pre-screening visit sampling visit phone call
interview
Invitation letter, e-mail
x
(phone call)
Inclusion criteria x x x
Medical history and x x
patient characteristics
Informed consent x
Recheck eligibility x
Clinical examination x
x Immediately
before the Study
Dose
Haematological x
parameters
Na, K, Ca, glucose, x
transaminases
Renal function
x
(urea, creatinine)
17
Protocol 27.02.2020
Urine pregnancy test for
x
female participants
Study medicines
x
administration
PK Sampling x
Concomitant
medications x
documentation
Adverse event reporting x x
8.3 Pharmacokinetic sampling and sample handling
Blood samples for pharmacokinetic analysis of probe drugs and metabolites will be collected
before dosing and 0.25, 0.50, 0.75, 1, 2, 3, 4, 6 and 8 h after drug administration from an
antecubital vein into ethylenediaminetetraacetic acid tubes. A cannula is used for blood
sampling. The tubes will be centrifuged (1500g for 10 min at 4 °C) and plasma will be stored
at −80 °C until analysis.
Sampling schedule is based on the results of a previous phenotyping cocktail study (Donzelli
et al, 2014) that included slow metabolizers and showed that a shorter (8h) blood sampling
period was sufficient to describe the pharmacokinetic profile of the studied drugs. In addition,
the use of a shorter study period is also in the interest of subjects who do not have to spend
the night in the hospital.
For the plasma concentration measurements of probe drugs and metabolites (omeprazole,
metoprolol, hydroxymetoprolol, metoprolol, metoprolol-d7, omeprazole, 5-
hydroxyomeprazole, omeprazole-d3) high performance liquid chromatography (HPLC) will be
used at the Karolinska institute. The frozen plasma samples of all study participants will be
shipped on dry ice to the Pharmacological laboratory, at the Department of Clinical
Pharmacology, Karolinska University Hospital, Sweden (Collaborators listed in Section 2.2).
For issuing of blood samples to Sweden a new application will be submitted to the Estonian
Committee on Bioethics and Human Research and thereafter to the Senate of the University of
Tartu.
Pharmacokinetic endpoints: A noncompartmental model of disposition of probe drugs and its
main metabolites (CL, Vd, AUC, Cmax, Tmax).
9. Study medications
Modified version of Basel cocktail will be used. Single oral dose of phenotyping probe drugs
will be administered:
Single dose administration of probe drugs:
o 20 mg omeprazole (full 20mg capsule)
o 12,5 mg metoprolol (12,5 mg of metoprolol as an active substance which dose
is measured and packed according to the standard procedures (SOP) of the
hospital pharmacy of Tartu University Hospital). The reason to use
18
Protocol 27.02.2020
extemporaneous product is caused by the fact that no marketed product of
metoprolol is available at such a low dose.
9.1 Contraindications
The following contraindications exist for using phenotyping probe drugs and
participants with these conditions shall be excluded:
o Known hypersensitivity for the study medicines
o Severe hepatic impairment (ChildPugh Class C)
o Uncontrolled heart failure (metoprolol)
o Bradycardia (metoprolol)
o Sick-sinus syndrome (metoprolol)
o Prinzmetal's angina (metoprolol)
o Untreated phaeochromocytoma (metoprolol)
o Metabolic acidosis (metoprolol)
o Severe peripheral arterial disease (metoprolol)
o History of bronchospasm and asthma (metoprolol)
o Hypotension (metoprolol)
o Diabetes if associated with frequent episodes of hypoglycaemia (metoprolol)
o Chronic obstructive pulmonary disease (metoprolol)
o Renal or hepatic failure (metoprolol)
o Therapy resistant hypokalaemia and hyponatraemia, hypercalcaemia,
symptomatic hyperuricaemia, anuria (metoprolol)
9.2 Description of dosing
Modified version of Basel cocktail will be used. Single oral dose of phenotyping probe drugs
will be administered with 50 mL of tap water:
20 mg omeprazole (full 20mg capsule)
12,5 mg metoprolol (12,5 mg of metoprolol as an active substance which dose is
measured and packed according to the standard procedures (SOP) of the hospital
pharmacy of Tartu University Hospital). The reason to use extemporaneous
product is caused by the fact that no marketed product of metoprolol is available at
such a low dose.
19
Protocol 27.02.2020
9.3 Concomitant medication
All concomitant medications used will be registered into the CRF stating from recruitment until
study dose.
10. Analytical procedures
For the plasma concentration measurements of probe drugs and metabolites (omeprazole,
metoprolol, hydroxymetoprolol, metoprolol, metoprolol-d7, omeprazole, 5-
hydroxyomeprazole, omeprazole-d3) high performance liquid chromatography (HPLC) will be
used at the Karolinska institute. The frozen plasma samples of all study participants will be
shipped on dry ice to the Pharmacological laboratory, at the Department of Clinical
Pharmacology, Karolinska University Hospital, Sweden (Collaborators listed in Section 2.2).
For issuing of blood samples to Sweden a new application will be submitted to the Estonian
Committee on Bioethics and Human Research and thereafter to the Senate of the University of
Tartu.
11. Safety reporting
All participating doctors, nurses and pharmacists are obliged to report to PI and PI is obliged to
report to State Agency of Medicines and Ethical Committee about any suspected unexpected
serious adverse adverse reactions (SUSAR).
11.1 Serious Adverse event evaluating and reporting
An adverse event is any untoward medical occurrence in a clinical study subject administered
a medicinal (investigational or non-investigational) product. An AE does not necessarily have
a causal relationship with the treatment. An AE can therefore be any unfavourable and
unintended sign (including an abnormal finding), symptom, or disease temporally associated
with the use of a medicinal (investigational or non-investigational) product, whether or not
related to that medicinal (investigational or non-investigational) product. This includes any
occurrence that is new in onset or aggravated in severity or frequency from the baseline
condition, or abnormal results of diagnostic procedures, including laboratory test abnormalities.
Pre- or post-treatment complications that occur as a result of protocol mandated procedures
(e.g., blood draw) during or after screening will be considered an AE. Clinically significant
changes in physical examination findings and abnormal objective test findings (e.g., clinical
laboratory, vital signs) should also be recorded as AEs.
In the differentiation between medical history and AEs, the following points will be considered:
- Conditions that started before signing of the informed consent, and for which no
symptoms or treatment are present until signing of either informed consent, are recorded
as medical history.
- Conditions that started before signing of the informed consent, and for which symptoms
or treatment are present after signing of either informed consent, at unchanged intensity,
are recorded as medical history.
20
Protocol 27.02.2020
- Conditions that started or deteriorated after signing of the informed consent will be
documented as AEs.
All AEs will be reported from the time a signed and dated ICF is obtained, until completion of
the last study-related procedure. The investigator is responsible for collecting all AEs (both
serious and non-serious). All AEs occurring during the clinical investigation will be
documented in the source documents and the eCRF. AEs will be discussed in the Clinical study
report (CSR).
11.1.1 Serious adverse event
Serious adverse event (SAE) is defined as any adverse experience that meets any of the
following criteria:
- Results in death. Death is not an adverse event but an outcome. It is the cause of death
that should be regarded as the adverse event. The only exception to this rule is “sudden
death” where no cause has been established; in this latter instance, “sudden death”
should be regarded as the adverse event and “fatal” as its reason for being serious.
- Is life-threatening. The term “life-threatening” refers to an event in which the participant
was at risk of death at the time of the event; it does not refer to an event which
hypothetically might have caused death if it were more severe.
- Requires prolongation of existing hospitalization.
- Results in persistent or significant disability/incapacity. Disability means a substantial
disruption of a person’s ability to conduct normal life’s functions.
- Is another medically important serious event as judges by the Investigator, and is defined
as requiring intervention to prevent one of the outcomes listed in the definition above.
11.1.2 Suspected unexpected serious adverse reactions
Unexpected adverse reactions are adverse reactions, of which the nature, or severity, is not
consistent with the applicable product information (as described in the SmPC, provided in the
Investigator’s Brochure).
11.1.3 Follow-up of adverse events
All participants will have before the probe drugs administration taken medical history and the
following analysis (from clinical charts): Na, K, Ca, glucose, creatinine, transaminases and
haematological parameters.
AEs will be handled according to common clinical practice. If necessary, in order to obtain
additional information to ensure the safety of the subject, additional blood and urine samples
may be taken at the Investigator’s discretion. Information relative to other means of
investigational diagnostics used in relation to the AE will also be communicated.
All AEs occurring at any time during the study (including the follow-up period) will be
followed until satisfactory resolution or stabilization or until final database lock. In the case of
ongoing AEs at the moment of database closure, the data obtained at the moment of database
closure will be used in the statistical analysis. The follow-up of the AE will be documented in
the source documents and will be described in the final CSR, only if considered relevant by the
Investigator.
All participating doctors, nurses and pharmacists are obliged to report to PI and PI is obliged to
report to the State Agency of Medicines and Ethical Committee about any study related adverse
effects.
21
Protocol 27.02.2020
12. Study management and monitoring
At all stages the study will be performed in accordance with standard operating procedures
(SOPs), available for monitoring.
The study will be monitored by the representative of Estonian National Centre of Translational
and Clinical Research.
Data will be collected at the investigational site on source documents, which will be transcribed
at the site into eCRFs (provided by Redcap). The eCRFs are to be completed on an ongoing
basis during the study. The medical chart and the source documents are the source of
verification of data. The PI is responsible for maintaining accurate, complete, and current
records for each subject. The PI is also responsible for maintaining any source documentation
related to the study, including clinical laboratory data, and electronic records.
13. Statistical considerations
13.1 Pharmacokinetic analysis
PK variables for each of the drugs and metabolites were calculated by noncompartmental
methods using WinNonlin Version 5.2.1 (Pharsight Corp, Mountain View, California). PK
variables evaluated included Cmax, time to reach Cmax (tmax), apparent oral clearance (CL/F),
terminal elimination rate (λz), and the AUC from time 0 to the 24‐hour blood draw (AUC0‐24 h)
calculated by the linear trapezoidal rule. Concentrations below the LLOQ were removed.
Area under the curve was extrapolated to 24 hours when the 24‐hour time point was below the
LLOQ by extrapolating concentration at 24 hours (last concentration above
LLOQ·exp(−λz·Δt)) and applying the linear trapezoidal rule.
PK variables are reported as geometric mean ± standard deviation. Demographic variables are
reported as arithmetic mean ± standard deviation.
14. Ethical considerations and confidentiality
14.1 Informed consent
The informed consent forms (ICF) are approved by the EC. See representative ICFs for the
study attached as Appendix No. 1.
Informed consent will be obtained from patient. This will allow the research team to commence:
● Detailed monitoring of the patient
● Collection of samples at specific times
● Access to the patient’s medical notes or clinical data
● The information sheet and researcher will explain the risks of the study (Drug cocktail
administration and blood sampling)
22
Protocol 27.02.2020
The information sheet/informed consent will be provided and used to structure a discussion.
Patients will be allowed ample time to make their decision. They will be asked how long they
would like to consider the information and what time is convenient for them when the
researcher may return to answer any questions they may have.
At the second discussion they will then be asked if they need more time to make a decision or
if they feel that they are sufficiently informed to make the decision.
The informed consent process will be delivered by the team member and listed on the delegation
log.
The study team will adopt a process of “ongoing consent” during which the progress of
participants and the study will be discussed, parents/patients will be given repeated
opportunities to ask questions, clarify any issues about the study and confirm or withdraw their
agreement to participating in the study. The aim of this process is to optimize the comfort of
patients with the study when the time comes for blood sampling, OR, to give the opportunity
to withdraw consent if they feel that that is appropriate.
If a patient withdraws consent, data up until the point of withdrawal will be included in the
study unless the patient or parents object.
Two copies of the signed consent form (attached to the information sheet) for 1) patient, 2)
study chart.
14.2 Ethical considerations
The study will be conducted in accordance with the International Conference on Harmonization
(ICH) Guideline for Good Clinical Practice (GCP) all applicable subject privacy requirements
and the guiding principles of the Declaration of Helsinki.
The study has been designed and will be conducted in accordance with the ICH Harmonised
Tripartite Guideline for clinical investigation of medicinal products (ICH E11) and all other
applicable ethical guidelines.
14.3 Confidentiality
All information collected will remain strictly confidential and anonymous. Access to medical
records is only allowed to people mandated by the sponsor and involved in the progress of the
project, as well as a representative of regulatory authorities in order to check collected data
accuracy.
Regulatory authorities may conduct a regulatory inspection of this study. Such inspections can
occur at any time during or after completion of the study. If an audit or inspection occurs, the
investigator and institution agree to allow the inspector direct access to all relevant documents
and to allocate his/her time and the time of his/her staff to the inspector to discuss findings and
any relevant issues.
15. Administrative aspects
15.1 Handling and storage of data and documents
The consent forms will be stored at the North Estonia Medical Centre in the investigators room
in a locked drawer. At Tartu University Hospital the consent forms will be stored in the special
locked clinical research room, which is located on the premises of the hospital pharmacy. After
completion of the study the consent forms will be transferred to the biobank and stored in
23
Protocol 27.02.2020
similar conditions and during the same time period as it is stated by the law for the consents of
the gene donors (HGRA, §12, section (6)).
15.2 Annual progress report
Annual progress reports will be presented to the Tartu University Hospital and Ethics
Committee.
15.3 End of study report
End of study report will be presented to the Tartu University Hospital.
16. Scientific communication
The scientific results of the study will be published at the international peer-reviewed journals
and presentations will be made at the international conferences.
24
Varasemalt kirjeldamata geenivariantide mõju ravimite metabolismile
Hea geenidoonor! Lisa 1.1
Geenivaramu on alustanud teadusuuringut, kuhu kaasatakse geenidoonoreid. Teie olete üks
nendest, kes on valitud sellesse uuringusse. Uurimistöö pealkiri on „Varasemalt kirjeldamata
geenivariantide mõju ravimite metabolismile“ ja selle viivad läbi Tartu Ülikooli Eesti
Geenivaramu, Tartu Ülikooli Kliinikum, Põhja-Eesti Regionaalhaigla ja Rootsi Karolinska
Instituudi teadlased ja arstid.
Uuringu eesmärk on hinnata, kuidas teatud geenivariandid mõjutavad ravimite lagundamise
kiirust inimese organismis. Uuringu tulemused aitavad kaasa sellele, et tulevikus saaks
geeniinfot teades annustada inimestele ravimeid täpsemalt ja vältida teatud kõrvaltoimeid.
Teie vereproovi alusel Geenivaramus tehtud geenianalüüs viitab sellele, et mõnede ravimite
lagundamise kiirus võib Teie organismis olla tavapärasest erinev. Käesoleva uuringu eesmärk
on täpsustada, kas leitud geenivariatsioon ka tegelikkuses sellist toimet avaldab. Sarnaseid
uuringuid on tehtud ka varasemalt.
Vastuvõttude sujuvaks korraldamiseks oleme tänulikud, kui võtate meiega ühendust kahe
nädala jooksul. Kui me selleks ajaks ei ole Teilt vastust saanud, saadame Teile uue kirja. Kui
me ka korduvale kirjale Teilt vastust ei saa, siis võtame Teiega ühendust telefoni teel, sest
eeldame, et Teie kontaktaadress on muutunud. Teie kontaktandmed oleme saanud Teilt
geenivaramuga liitumise ajal või andmete täiendamisel rahvastikuregistrist.
Oma huvist uuringus osaleda või loobumisest palume teada anda:
Geenivaramu telefonil 520 6959 (tööpäevadel kell 9-16),
SMS-i teel või meiliaadressil
[email protected]
Samadelt kontaktidelt on võimalik saada lisainformatsiooni uuringu kohta.
Kui olete nõus uuringus osalema, reserveeritakse Teile telefoni teel vastuvõtuaeg esimeseks
visiidiks. Kokku toimub kaks visiiti ja Te saate valida, kas soovite tulla Tartu Ülikooli Kliinikumi
või Põhja-Eesti Regionaalhaiglasse (Tallinnas).
Esimesel visiidil selgitatakse Teile põhjalikult uuringu olemust, toimub arstlik läbivaatus ning
võetakse vereproov, et hinnata Teie sobivust uuringusse. Te saate esitada küsimusi, et
lõplikult otsustada, kas Te soovite uuringus osaleda. Juhul kui sobite uuringus osalema ja
allkirjastate nõusolekuvormi, lepitakse Teiega kokku teise uuringuvisiidi aeg.
Teisel visiidil antakse Teile ühekordne annus kahte sageli kasutatavat ravimit, mille abil
hinnatakse ravimit lagundavate ensüümide aktiivsust (omeprasooli ja metoprolooli) ning
võetakse vereproovid (kuni 50 ml veeniverd). Teisel visiidil tuleb uuringukeskuses (haiglas)
viibida kuni 10 tundi ning visiit toimub nädalavahetusel. Visiitidele sõiduga seotud
transpordikulud hüvitatakse Teile esitatud sõidudokumentide alusel. Uuringu jooksul on
tagatud toitlustamine.
Soovi korral on kõigil uuringus osalejatel võimalus saada ravimitega seotud geeniandmete
kohta personaalset tagasisidet.
Soovin Teile kõike head ja tänan koostöö eest Tartu Ülikooli Eesti Geenivaramuga!
1
Varasemalt kirjeldamata geenivariantide mõju ravimite metabolismile
Dr. Lili Milani
Tartu Ülikooli Eesti Geenivaramu teaduskeskuse juht
2
Varasemalt kirjeldamata geenivariantide mõju ravimite metabolismile
Hea geenidoonor! Lisa 1.2
See on korduv kutse uuringus osalemiseks.
Geenivaramu on alustanud teadusuuringut, kuhu kaasatakse geenidoonoreid. Teie olete üks
nendest, kes on valitud sellesse uuringusse. Uurimistöö pealkiri on „Varasemalt kirjeldamata
geenivariantide mõju ravimite metabolismile“ ja selle viivad läbi Tartu Ülikooli Eesti
Geenivaramu, Tartu Ülikooli Kliinikum, Põhja-Eesti Regionaalhaigla ja Rootsi Karolinska
Instituudi teadlased ja arstid.
Uuringu eesmärk on hinnata, kuidas teatud geenivariandid mõjutavad ravimite lagundamise
kiirust inimese organismis. Uuringu tulemused aitavad kaasa sellele, et tulevikus saaks
geeniinfot teades annustada inimestele ravimeid täpsemalt ja vältida teatud kõrvaltoimeid.
Teie vereproovi alusel Geenivaramus tehtud geenianalüüs viitab sellele, et mõnede ravimite
lagundamise kiirus võib Teie organismis olla tavapärasest erinev. Käesoleva uuringu eesmärk
on täpsustada, kas leitud geenivariatsioon ka tegelikkuses sellist toimet avaldab. Sarnaseid
uuringuid on tehtud ka varasemalt.
Vastuvõttude sujuvaks korraldamiseks oleme tänulikud, kui võtate meiega ühendust kahe
nädala jooksul. Kui me selleks ajaks ei ole Teilt vastust saanud, saadame Teile uue kirja. Kui
me ka korduvale kirjale Teilt vastust ei saa, siis võtame Teiega ühendust telefoni teel, sest
eeldame, et Teie kontaktaadress on muutunud. Teie kontaktandmed oleme saanud Teilt
geenivaramuga liitumise ajal või andmete täiendamisel rahvastikuregistrist.
Oma huvist uuringus osaleda või loobumisest palume teada anda:
Geenivaramu telefonil 520 6959 (tööpäevadel kell 9-16),
SMS-i teel või meiliaadressil
[email protected]
Samadelt kontaktidelt on võimalik saada lisainformatsiooni uuringu kohta.
Kui olete nõus uuringus osalema, reserveeritakse Teile telefoni teel vastuvõtuaeg esimeseks
visiidiks. Kokku toimub kaks visiiti ja Te saate valida, kas soovite tulla Tartu Ülikooli Kliinikumi
või Põhja-Eesti Regionaalhaiglasse (Tallinnas).
Esimesel visiidil selgitatakse Teile põhjalikult uuringu olemust, toimub arstlik läbivaatus ning
võetakse vereproov, et hinnata Teie sobivust uuringusse. Te saate esitada küsimusi, et
lõplikult otsustada, kas Te soovite uuringus osaleda. Juhul kui sobite uuringus osalema ja
allkirjastate nõusolekuvormi, lepitakse Teiega kokku teise uuringuvisiidi aeg.
Teisel visiidil antakse Teile ühekordne annus kahte sageli kasutatavat ravimit, mille abil
hinnatakse ravimit lagundavate ensüümide aktiivsust (omeprasooli ja metoprolooli) ning
võetakse vereproovid (kuni 50 ml veeniverd). Teisel visiidil tuleb uuringukeskuses (haiglas)
viibida kuni 10 tundi ning visiit toimub nädalavahetusel. Visiitidele sõiduga seotud
transpordikulud hüvitatakse Teile esitatud sõidudokumentide alusel. Uuringu jooksul on
tagatud toitlustamine.
Soovi korral on kõigil uuringus osalejatel võimalus saada ravimitega seotud geeniandmete
kohta personaalset tagasisidet.
3
Varasemalt kirjeldamata geenivariantide mõju ravimite metabolismile
Soovin Teile kõike head ja tänan koostöö eest Tartu Ülikooli Eesti Geenivaramuga!
Dr. Lili Milani
Tartu Ülikooli Eesti Geenivaramu teaduskeskuse juht
4
Life Science Liability Policy
LS 1:6 2017
Introduction This is a Chubb commercial liability insurance policy. This Policy contains four
sections:
Section 1: Public Liability
Section 2: 2A Product and Service Liability; and
2B Clinical Trials
Section 3: Product and Service Errors and Omissions Liability
Please read the entire policy carefully.
Insuring Agreement Chubb European Group Limited (the ‘Company’) agrees to provide the
insurance described in each applicable Section of this insurance policy (the
‘Policy’) subject to the following conditions:
• the Insured must have paid or agreed to pay the premium set out in the
Schedule.
• the information provided by the Insured together with any additional
information supplied to the Company on behalf of the Insured form the
basis of and are part of this Policy.
Please Note The term “Schedule” in this wording is equivalent to the Swedish term
“Försäkringsbrev”.
All parts of this Policy, including the Schedule and any endorsements, shall be
read together and considered as one contract.
The operative Sections of this Policy are indicated in the Schedule. Unless a
particular Section is identified in the Schedule as operative, it is of no effect
and no cover is granted under it.
Words that appear in bold print are defined in the Definitions.
Section 1
Public Liability
Bodily Injury, Under this Section of Part 2, the Company will indemnify the Insured for
Property Damage damages and related claimants’ costs that the Insured becomes legally liable to
pay in respect of:
• bodily injury; or
• property damage
caused by an occurrence in connection with the Insured’s business.
This Section will apply only if such bodily injury, property damage
happens:
• during the Period of Insurance; and
• within the Territorial Limits.
This Section does not apply to any damages, loss, cost or expense arising out of
the Insured’s product or the Insured’s service or any clinical trial.
Section 2
Product and Service Liability and Clinical Trials
Cover under this Section is divided into two sub-sections: Section 2A (Product Liability) and Section 2B
(Clinical Trials). Both Sections 2A and 2B are subject to the overall Limit of Indemnity for Section 2 shown
in the Schedule.
Section 2A
Product and Service Liability
Bodily Injury and Under this Section 2A, the Company will indemnify the Insured for damages
Property Damage and related claimants’ costs that the Insured becomes legally liable to pay in
respect of:
• bodily injury; or
• property damage;
caused by an occurrence in connection with the Insured’s business and
resulting from the Insured’s product or the Insured’s service.
This Section 2A will apply only if:
1. such bodily injury or property damage happens after the
Retroactive Date shown in the Schedule and before the end of the Period
of Insurance;
2. such bodily injury or property damage happens within the
Territorial Limits;
3. a claim by a person or organisation for damages for such bodily injury
or property damage is first made against the Insured:
• during the Period of Insurance or within 30 (thirty) days of its
termination;
• and the claim is reported by the Insured to the Company within
12 (twelve) months from when the Insured first became aware of
such claim ; or
• in accordance with the condition entitled “Insured’s Duty to
Report Circumstances”; and
4. such claim is made within the Territorial Limits.
This Section 2A does not apply to any damages, loss, cost or expense arising
out of any injury or damage sustained by any research subject in connection
with any activities relating to any clinical trial conducted by or on behalf of
the Insured.
Section 2B
Clinical Trials
Bodily Injury and Under this Section 2B, the Company will indemnify the Insured for:
Property Damage
Agreed Compensation Cover
• compensation agreed under the applicable Clinical Trial
Compensation Guidelines; or
Legal Liability Cover
• damages and related claimants’ costs that the Insured becomes legally
liable to pay, if and to the extent that settlement is not concluded under
the Agreed Compensation Cover (above);
in respect of bodily injury or property damage:
• sustained by a research subject;
• caused by an occurrence in connection with the Insured’s business;
and
• resulting from a clinical trial conducted by or on behalf of the Insured.
This Section 2B will apply only if:
1. such bodily injury or property damage happens after the
Retroactive Date stated in the Schedule and before the end of the Period
of Insurance;
2. such bodily injury or property damage happens within the
Territorial Limits;
3. a claim by a person or organisation for such compensation or damages
(as applicable) for such bodily injury or property damage is first
made against the insured
• during the Period of Insurance or within 30 (thirty) days of its
termination;
• and the claim is reported by the Insured to the Company within
12 (twelwe) months from when the Insured first became aware or
should have become aware of such claim; or
• in accordance with the condition entitled “Insured’s Duty to
Report Circumstances”; and
4. such claim is made within the Territorial Limits.
Furthermore, notwithstanding anything to the contrary above, this Section 2B
applies only to clinical trials if:
• the product being investigated is a life science product;
• exposure to such product upon or within research subjects during
such trial first happened after the Retroactive Date stated in the
Schedule and before the end of the Period of Insurance; and
• the Insured has acted in compliance with the Clinical Trials Special
Conditions set out in this Policy.
Section 3
Product and Service Errors and Omissions Liability
Financial Injury Under this Section, the Company will indemnify the Insured for damages and
related claimants’ costs that the Insured becomes legally liable to pay in
respect of financial injury caused by an act in connection with the Insured’s
business and resulting from:
1. a defect, deficiency or inadequacy in:
• the Insured’s product; or
• the Insured’s service; or
2. the failure:
• of the Insured’s product to perform; or
• to perform the Insured’s service;
in accordance with the terms of a contract or agreement.
This Section will only apply if:
1. such act happens after the Retroactive Date shown in the Schedule and
before the end of the Period of Insurance;
2. such act happens within the Territorial Limits;
3. a claim by a person or organisation for damages for such financial
injury is first made against the Insured:
• during the Period of Insurance or within 30 (thirty) days of its
termination;
• and the claim is reported by the Insured to the Company within
12 (twelwe) months from when the Insured first became aware or
should have become aware of such claim; or
• in accordance with the condition entitled “Insured’s Duty to
Report Circumstances”; and
4. such claim is made within the Territorial Limits.
Notwithstanding anything to the contrary above, where cover under this
Section applies in respect of injury or damage resulting from a clinical trial,
cover will only apply if the Insured has acted in compliance with the Clinical
Trials Special Conditions set out in this Policy.
Limits of Indemnity
Limits of Indemnity If more than one Section of this Policy would otherwise apply to the same
occurrence, act or claim or series of occurrences, acts or claims
consequent on or attributable to the same or substantially the same source or
original cause, then the aggregate maximum Limit of Indemnity under all
Sections shall not exceed the highest applicable Limit of Indemnity under any
one Section of Part 2.
The Limits of Indemnity apply separately to each consecutive annual period
and to any remaining period of less than 12 months, starting with the
beginning of the Period of Insurance shown in the Schedule, unless the Period
of Insurance is extended after issuance for an additional period. In that case,
the additional period will be deemed to form part of the last preceding period
for purposes of determining the Limits of Indemnity.
The Company’s obligations end when the applicable Limit of Indemnity has
been exhausted.
Part 2, Section 1 Irrespective of the number of claims, the liability of the Company under
Section 1 for:
(Public Liability)
• damages and related claimants’ costs;
• other amounts described as reducing the Limits of Indemnity (see
below);
shall not exceed the applicable aggregate Limit of Indemnity stated in the
Schedule. Any such sums the Company pays will reduce the amount of such
aggregate limit available for any other payment. The remaining amount of the
aggregate limit is the most that will be available for any other payment.
Part 2, Section 2 Irrespective of the number of claims or occurrences, the liability of the
Company under Section 2 for:
(Product and Service
Liability and Clinical • compensation or damages (as applicable) and related claimants’ costs;
Trials) and
• other amounts described as reducing the Limits of Indemnity (see
below);
shall not exceed the applicable aggregate Limit of Indemnity stated in the
Schedule. Any such sums the Company pays will reduce the amount of such
aggregate limit available for any other payment. The remaining amount of the
aggregate limit is the most that will be available for any other payment.
Part 2, Section 3 Irrespective of the number of claims or acts, the liability of the Company
under Section 3 for:
(Errors and Omissions
Liability) • damages and related claimants’ costs; and
• other amounts described as reducing the Limits of Indemnity (see
below);
shall not exceed the applicable aggregate Limit of Indemnity stated in the
Schedule. Any such sums the Company pays will reduce the amount of such
aggregate limit available for any other payment. The remaining amount of the
aggregate limit is the most that will be available for any other payment.
Pollution and Subject to all other Limits of Indemnity, irrespective of the number of
occurrences or claims, the liability of the Company in connection with
Contamination pollution or contamination under all Sections (save for Section 3 – Employers’
Liability) for:
• damages and related claimants’ costs; and
• other amounts described as reducing the Limits of Indemnity (see
below);
shall not exceed the applicable aggregate Limit of Indemnity stated in the
Schedule. Any such sums the Company pays will reduce the amount of such
aggregate limit available for any other payment. The remaining amount of the
aggregate limit is the most that will be available for any other payment.
Payments that Reduce Payments made:
the Limits of
Indemnity • for any compensation or damages (as applicable) and related claimants’
costs;
• under the Extension entitled ‘Defence Costs’ and
• for any amounts under any other Extension;
will reduce the applicable Limits of Indemnity.
Extensions
Extensions are subject to the terms and conditions (including Exclusions and, save where provided to the
contrary, Limits of Indemnity) applicable to the Section(s) under which the Extension is provided.
The Company’s obligations under any Extension end when the applicable Limit of Indemnity has been
exhausted.
Compensation for Under Sections 1, 2, and 3 , the Company shall pay the following sums to the
Court Attendance Insured in the event that a partner, director, officer or employee of the
Insured, at the request of the Company:
• attends a court or arbitration hearing as a witness - up to EUR 300 for
each day on which that person attends as a witness.
• is interviewed by the lawyers conducting the defence against a claim for
the purpose of composing a witness statement - up to EUR 60 per hour
in respect of the time certified by the lawyers as time being interviewed.
• attends a court or arbitration hearing as an observer - up to EUR 60 for
each day on which that person attends as an observer, provided that the
Company shall only be liable to compensate for the occupation of one
observer per day.
Personal Data Under Section 1, the Company will indemnify the Insured for damages
incurred by a third party natural person relating to that person’s Personal
data that the insured in his capacity as Controller may be liable to pay
according to Privacy Regulations within the territorial limits stated in the
policy schedule.
The Company’s obligation to indemnify the Insured under this extension is
limited to:
• EUR 100,000 each occurrence and in the aggregate for the period of
insurance; or
• The limit of indemnity (or sublimit) stated in the policy schedule and
referring to “Personal data”
Whichever is the greater.
This extension shall not apply:
• in respect of costs and expenses for rectifying or erasing Personal data;
• in respect of costs and expenses for notifying third parties;
• in respect of administrative fines;
• for loss arising out of unauthorised access to Computer Systems where the
Personal data is stored;
• for loss arising from Insured’s fraud or dishonesty; or
• if the Insured has undertaken to store, process or supply Personal data
for a fee or by mutual arrangement.
DEFINTIONS
Controller under this extension means a legal person which alone or jointly
with other, determines the purposes and means of the processing of Personal
data.
Privacy Regulations under this extension means laws and regulations
associated with the care, custody, control or use of Personal Data.
Personal Data under this extension means
• an individual's name, national identity number or national insurance
number, medical or healthcare data, other protected health information,
driver's licence number, state identification number, credit card number,
address, telephone number, email address, account number, or password;
and
• any other non-public personal information as defined in the Privacy
Regulations
in any format if such information creates the potential for an individual to be
uniquely identified or contacted.
Defence Costs Under Sections 1, 2 and 3 the Company will indemnify the Insured for legal
defence costs provided they are incurred with the Company's prior written
consent.
Under Sections 1 and 2 the Company will indemnify the Insured for the
following, provided they are incurred with the Company's prior written
consent:
• legal fees for defence of the Insured against proceedings for
manslaughter (including appeal against conviction) resulting from an
occurrence which may be the subject of indemnity under this Part of
this Policy.
Extended Reporting Under Sections 2 and 3, if for a reason other than for non-payment of
Period premium, the Company cancels or refuses to renew this Policy, then the
Insured may:
• by giving written notice to the Company no later than 30 days after the
effective date of cancellation or non-renewal; and
• upon payment of a non-refundable additional premium (not to exceed
200% of the Policy premium for those Sections to which it applies), paid
to the Company within 30 days of the cancellation or non-renewal;
secure an Extended Reporting Period (not to exceed 5 years) following the
effective date of such cancellation or non-renewal to report claims made
against the Insured, notice of which has been received and recorded by the
Insured during that period. Provided that the injury or damage or act (as
applicable) giving rise to the claim happened prior to the effective date of
cancellation or non-renewal, such claims shall be deemed to have been made
and reported during the Period of Insurance.
An Extended Reporting Period:
• does not extend the Period of Insurance or change the scope of cover
provided.
• does not reinstate or increase any Limit of Indemnity.
• may not be cancelled once in effect.
Fees and Expenses - Under Section 3, to mitigate potential claims against the Insured by a
Mitigation of Potential customer, the Company may at its discretion make payment to the Insured in
Claims Against the respect of fees and expenses invoiced to such customer but not collected by the
Insured continued Insured provided that:
• such fees and expenses are in respect of the Insured’s product having
been supplied to, or the Insured’s service having been rendered to, the
customer;
• during the Period of Insurance, the customer has refused to pay such
fees and expenses; and
• the basis of the customer’s refusal to pay is expressed by the customer to
be a direct consequence of financial injury.
This Extension will only apply if:
1. a request for payment under this Extension is first made by the Insured
and notified to the Company during the Period of Insurance.
2. the Insured can show to the Company’s satisfaction that:
• it has taken reasonable steps to collect such fees and expenses;
• taking further steps to collect such fees and expenses would be
likely to provoke a claim against the Insured; and the likelihood
of a claim being brought is reduced by desisting in efforts to
collect such fees and expenses.
3. such claim would be covered under Section 3 of this Policy.
4. the Insured takes all necessary steps to prevent loss and follows all
instructions issued by the Company and provides the Company with all
relevant documents including contracts, correspondence, records,
invoices and any other information.
5. the Insured consents to the interviewing of relevant employees by the
Company.
Conditions Relating to this Extension
1. If a payment is made by the Company under this Extension and a claim
relating to substantially the same supply of the Insured’s product or
rendering of the Insured’s service is subsequently made against the
Insured, then any amounts paid under this Extension will be deemed to
have been paid on account of such claim.
2. Following any payment by the Company under this Extension, the
Insured shall take no further steps to collect any sums in respect of
substantially the same supply of the Insured’s product or rendering of
the Insured’s service. If the Insured, in breach of this condition, takes
any such further steps and a claim is brought against the Insured, then
there shall be no cover under any part of this Policy in respect of any
such claim.
3. The Company shall not be liable to make payment in respect of any
element of profit included in fees and expenses invoiced or any Value
Added Tax.
4. Payment by the Company under this Extension, in itself, does not
constitute an admission or assumption of liability or a conclusion that
the Insured’s product or the Insured’s service failed or is defective,
deficient or inadequate.
Limit and Deductible
This Extension is subject to the Limit of Indemnity applicable to
Section 3. Any sums paid under this Extension will:
• reduce the amount of that limit available for any other payment; and
• be deemed to be damages
The amount of the Deductible shall in no case be less than:
• the amount of the Deductible applicable under Section 3 of this Policy;
or
• 10% of the fees and expenses invoiced;
whichever is the greater.
Indemnity to Others
Contract Research Under Section 2 only, at the request of the Insured, the Company will
Organisations or Life indemnify against liability:
Science Product Sales
Contractors or Life • contract research organisations;
Science Service • life science product sales contractors; or
Contractors
• life science product service contractors;
with respect to their liability for damages for bodily injury or property
damage incurred in the regular course of their business, but only:
• if and to the minimum extent that the Insured is obliged (pursuant to a
written contract or agreement between the Insured and such person or
organisation ) to provide them with cover under this Policy; and
• with respect to activities happening after the execution of such contract
or agreement.
In respect of contract research organisations, this Extension will apply
only if such injury or damage results from activities in connection with a
clinical trial to which this Policy applies.
In respect of life science product sales contractors, this Extension will
apply only if such injury or damage results from the distribution or sale of the
Insured’s life science product to which this Policy applies.
In respect of life science product service contractors, this Extension will
apply only if such injury or damage results from activities within the scope of
the Insured’s life science product service to which this Policy applies.
However, this Extension does not apply to any:
• assumption of liability or obligations by any such contract research
organisation, life science product sales contractor or life
science product service contractor in a contract or agreement.
• This limitation does not apply to the liability for damages for bodily
injury or property damage, to which this Policy applies, that such
person or organisation would have in the absence of such contract or
agreement.
• representation or warranty unauthorized by the Insured.
• chemical or physical change in the Insured’s product made
intentionally by such person or organisation.
• of the Insured’s products which, after distribution or sale by the
Insured, have been labeled or relabeled or used as a container,
ingredient or part of any other thing or substance by or for such person
or organisation.
This limitation does not apply to:
• the relabeling of the Insured’s product in the regular course of
dispensing or furnishing the required amount or dosage of such
product.
• contract research organisation s.
• life science product service contractors.
Partners, Directors, 1. Under Sections 1, 2 and 3, at the request of the Insured, the Company
Officers, Employees, will indemnify against liability the Insured’s partners, directors, officers
Principals Or Various or employees (whilst acting within the scope of their duties as such).
Others
2. Under Sections 1, 2 and 3, at the request of the Insured, the Company
will indemnify against liability:
a. officers or members of the Insured’s social, canteen, welfare or
first aid organisations or fire or ambulance services in their
respective capacities as such.
b. employees in respect of private work undertaken by an
employee with the prior consent of the Insured.
c. principals for whom the Insured is or has been carrying out work,
in respect of an occurrence for which the Insured is responsible,
but only:
• if and to the minimum extent that the Insured is obliged
(pursuant to a written contract or agreement between the
Insured and such person or organisation ) to provide them
with cover under this Policy; and
• with respect to activities happening after the execution of
such contract or agreement.
Vendors Under Section 2 only, at the request of the Insured, the Company will
indemnify against liability vendors of the Insured’s product with respect to
their liability for damages for bodily injury or property damage resulting
from the distribution or sale of the Insured’s product in the regular course of
their business, but only:
• if and to the minimum extent that the Insured is obliged (pursuant to a
written contract or agreement between the Insured and such vendor) to
provide them with cover under this Policy;
• with respect to activities happening after the execution of such contract
or agreement; and
• if and to the extent that this Policy applies to such products.
However, this Extension does not apply to any:
• assumption of liability by any such vendor in a contract or agreement.
This limitation does not apply to the liability for damages for bodily
injury or property damage, to which this Policy applies, that such
vendor would have in the absence of such contract or agreement.
• representation or warranty unauthorized by the Insured.
• chemical or physical change in the Insured’s product made
intentionally by such vendor.
• of the Insured’s products which, after distribution or sale by the
Insured, have been labelled or relabelled or used as a container,
ingredient or part of any other thing or substance by or for such vendor.
• repackaging, unless unpacked solely for the purpose of inspection,
demonstration or testing, or the substitution of parts under instruction
from the manufacturer and then repacked in the original container.
• failure to make such inspections, adjustments, tests or servicing as such
vendor has agreed to make or normally undertakes to make in the
regular course of their business in connection with the distribution or
sale of the Insured’s product.
• demonstration, installation, servicing or repair operations, except such
operations performed at such vendor’s premises in connection with the
distribution or sale of the Insured’s product.
Limitations on The provisions of this ‘Indemnity to Others’ Extension apply provided that:
Indemnity to Others
• the injury or damage results from activities in connection with the
Insured’s business;
• such person or organisation shall observe, fulfil and be subject to the
terms and conditions of this Policy;
• such person or organisation is not entitled to indemnity under any other
insurance;
• such person or organisation has no conflict of interest with the Insured;
and
• the Company shall be entitled (but not obliged) to take over and conduct
the investigation, defence and settlement of any claim at its discretion.
However, this Extension does not apply to any rendering of or failure to render
any healthcare service whether or not such service is ordinary to the
Insured’s profession.
This limitation does not apply to contract research organisations.
Further, no indemnity will be provided to any person or organisation from
whom the Insured has acquired its product, or any container, ingredient or
part entering into, accompanying or containing such product.
Indemnity to Ethics Under Section 2B (Clinical Trials) only, at the request of the Insured, the
Committees Company will indemnify an ethics committee and its individual members
(whilst acting within the scope of their duties as members of such ethics
committee):
• against liability; and
• for legal fees for their defence against proceedings for manslaughter
(including appeal against conviction) incurred with the Company’s prior
written consent;
resulting from an occurrence in connection with a clinical trial which may
be the subject of indemnity under this Policy, but only:
• if and to the minimum extent that the Insured is obliged (pursuant to a
written contract or agreement between the Insured and such person or
organisation ) to provide them with cover under this Policy; and
• with respect to activities happening after the execution of such contract
or agreement.
provided that:
• the injury or damage results from activities in connection with the
Insured’s business;
• such ethics committee and its individual members shall observe and
fulfil the terms and conditions of this Policy;
• such ethics committee or its individual members is not entitled to
indemnity under any other insurance;
• such ethics committee and its individual members have no conflict of
interest with the Insured; and
• the Company shall be entitled (but not obliged) to take over and conduct
the investigation and defence and settlement of any claim at its
discretion.
This Extension does not apply to any assumption of liability or obligations by
any such person or organisation in a contract or agreement.
This limitation does not apply to the liability for damages for bodily injury or
property damage, to which this Policy applies, that such person or
organisation would have in the absence of such contract or agreement.
Legal Costs - Criminal Under Section 2B (Clinical Trials), the Company will indemnify the Insured
Act 1962:700 and, at the request of the Insured, a partner, director, officer or employee of
the Insured for necessary and reasonable legal fees and expenses (including
prosecution costs awarded) reasonably incurred with the Company’s prior
written consent, in the defence against a prosecution or an appeal against
conviction resulting from an actual or alleged breach of the:
• Criminal Act 1962:700 or
similar legislation in respective country where loss has occurred.
Limitations on Legal The provisions of this Legal Costs Extension apply provided that the
Costs proceedings relate to an occurrence:
• in connection with the Insured's business; and
• which may be the subject of indemnity under this Policy.
In the event of any dispute arising concerning whether any prosecution should
be defended, or an appeal made, such dispute shall be referred to leading
counsel (the identity of whom shall be mutually agreed between the Insured
and the Company, or in default of agreement nominated by the President of
the Law Society) whose decision shall be final and binding on both parties.
New Acquisitions Under Sections 1, 2 and 3 at the request of the Insured, the Company will
indemnify against liability a subsidiary organisation acquired or formed by
the Insured during the Period of Insurance, provided that in respect of any
newly acquired or formed organisation:
• full underwriting information is provided within 30 days of acquisition
or formation, or within such other period as may be agreed by the
Company;
• the business of the subsidiary organisation is similar to the
Insured’s business; and
• the Insured accepts any additional terms and conditions determined by
the Company and pays any additional premium required.
Personal Overseas Under Section 1, at the request of the Insured, the Company will indemnify
Liability the Insured’s partners, directors, officers or employees, or members of their
families, against liability for damages in respect of bodily injury or
property damage incurred in a personal capacity whilst temporarily outside
their normal country of residence in connection with the Insured’s business.
This Extension does not apply to liability for any damages, loss, cost or
expense arising out of any:
• ownership or occupation of any land or building; or
• possession, ownership or use of any motor vehicle for which insurance
or security is required under the provision of any road traffic legislation
Exclusions
The following exclusions apply to all Sections of this Policy.
This Policy does not apply to any:
Assumed Liability In respect of Sections 1 and 2:
damages, loss, cost or expense arising out of any liability or obligation
assumed in a contract or agreement.
This exclusion does not apply to liability for damages for bodily injury or
property damage, to which this Policy applies, that the Insured would have
in the absence of such contract or agreement.
Deliberate Acts damages, loss, cost or expense arising out of any act or omission that:
• is intended by the Insured; or
• would reasonably be expected from, the perspective of a person in the
circumstances of the Insured, to cause injury or damage, even if the
actual injury or damage caused is of a different degree or type than
expected or intended.
This exclusion does not apply to bodily injury or property damage:
• which is intended to result from reasonable use of a medicinal
product or other life science product within or upon research
subjects during a clinical trial;
• which may be expected, from the perspective of a reasonable
professional conducting a clinical trial, to result from reasonable use
of a medicinal product or other life science product within or
upon research subjects during a clinical trial; or
• resulting from the use of reasonable force to protect persons or tangible
property.
Employment Related damages, loss, cost or expense arising out of any injury or damage sustained by
Practices any person, whether or not in the course of employment by the Insured,
arising out of any employment-related act, omission, policy, practice or
representation, including any:
• dismissal, discharge or termination of employment;
• breach of any contract of service or apprenticeship;
• harassment, whether sexual or otherwise;
• discrimination;
• deprivation of career opportunity;
• negligent evaluation or training;
• negligent reference;
• misrepresentation, defamation or disparagement, breach of data
protection laws, invasion of privacy, breach of confidentiality, malicious
falsehood or false imprisonment; or
• retaliation on account of whistleblowing or the exercise by any person of
their legal rights;
or for any award made by an Employment Tribunal (whether or not relating to
one of the above actions).
Fines, Penalties or • liquidated damages or penalties (contractual or otherwise) or any
Restitution criminal or civil fines.
• amount that constitutes unjust enrichment, including any restitution or
return of any fees or expenses or any consideration owed (whether or
not disputed) or paid to the Insured.
• loss, cost or expense to perform any obligation assumed by or on behalf
of the Insured.
• loss, cost or expense incurred, or agreed to, by or on behalf of the
Insured, except in a settlement agreed to by the Company.
Exclusions – Sections 1, 2 and 3
(Public, Product and Service and Errors and Omissions
Liability)
The insurance provided by Sections 1, 2 and 3 does not apply to any:
Abuse or Molestation damages, loss, cost or expense arising out of any:
1. actual or threatened abuse or molestation, by anyone, of any person; or
2. retention, employment, investigation or supervision, or reporting to or
failure to report to the proper authorities, of anyone for whom the
Insured is or ever was legally responsible and whose conduct would be
excluded in subparagraph 1 above.
Adjustment, Recall, In respect of Sections 1 and 2:
Repair or Replacement
damages, loss, cost or expense arising out of any loss of use of or adjustment,
disposal, inspection, recall, removal, repair, replacement or withdrawal of:
• the Insured’s product; or
• any property containing or incorporating the Insured’s product;
if such product or property is recalled or withdrawn from the market or from
use by any person or organisation because of a known or suspected defect,
deficiency, inadequacy or dangerous condition in it.
In respect of Section 3:
damages, loss, cost or expense arising out of any adjustment, disposal,
inspection, recall, removal, repair, replacement or withdrawal of:
• the Insured’s product or the Insured’s service;
• any property containing or incorporating the Insured’s product or the
Insured’s service;
• any property on which the Insured’s service is or was performed;
or
• any content, information or material.
Aircraft, Spacecraft, damages, loss, cost or expense arising out of any aircraft, spacecraft, aerial or
Aerial or Aerospatial aerospatial device or missile, or any related product, including any:
Device or Missile
Products • article, equipment, material, part or spare part installed or otherwise
incorporated in, on or under any aircraft, spacecraft, aerial or
aerospatial device or missile, or furnished or used in connection
therewith;
• air or space communication, guidance or navigation system;
• ground control, handling or support equipment or tools furnished or
used in connection therewith;
• equipment or tools furnished or used in connection with manufacturing,
repairing or servicing any of the foregoing;
• blueprints, designs, drawings, information, instructions, manuals,
maps, opinions, reports, representations, software, specifications,
surveys, training aids, warnings or warranties or engineering or other
data furnished or used in connection with any of the foregoing; or
• engineering or other advice, instruction, labour or service relating to any
of the foregoing.
Anti-trust or Anti- damages, loss, cost or expense arising out of any actual or alleged breach of
Competitive Practices any law or regulation designed to prevent any anti-trust or
anti-competitive practice, abuse of dominant position, cartel or price-fixing
activity or to otherwise protect competition.
Asbestos damages, loss, cost or expense arising out of or in any way related to any:
• actual, alleged or threatened contaminative, pathogenic, toxic or other
hazardous properties of asbestos;
• request, demand, order or regulatory or statutory requirement that the
Insured or others test for, monitor, clean up, remove, contain, treat,
detoxify or neutralize, or in any way respond to, or assess the effects of
asbestos; or
• claim or proceedings by or on behalf of a government authority or
others for any damages, loss, cost or expense arising out of any testing
for, monitoring, cleaning up, containing, treating, detoxifying or
neutralizing, or in any way responding to, or assessing the effects of
asbestos.
Benefit Programmes damages, loss, cost or expense arising out of any:
• actual or alleged breach of any law; or
• duty or obligation (whether contractual or otherwise) of any Insured;
in connection with any benefit programme, including any administration,
design, disclosure, enrolment, establishment, funding, maintenance,
management, marketing or similar activity relating to any such programme.
This exclusion applies regardless of whether any Insured is acting:
• as a fiduciary or in any other capacity; or
• on behalf of any employee or any other person or organisation.
Cross Liabilities damages, loss, cost or expense arising out of any injury or damage sustained
by:
1. the Insured.
2. any person or organisation that either directly or indirectly controls the
Insured through:
• controlling or holding a majority of its voting rights; or
• the right to appoint or remove a majority of its board of directors.
3. any subsidiary organisation.
4. any manager, member or partner of any limited liability company,
partnership or joint venture in which the Insured has an interest.
5. any partner, director, officer or employee of any person or
organisation described above.
6. any agent, heir, representative or successor of any person or
organisation described above.
Damage to the damages, loss, cost or expense for any property damage to the Insured’s
Insured’s Product product if arising out of it or any part of it.
Damage to Property in damages, loss, cost or expense arising out of any property damage to:
the Insured’s Care,
1. any property owned, held in trust or occupied by, leased or rented to or
Custody or Control
in the care, custody or control of the Insured.
(except leased or
rented premises or 2. that particular part of any property upon which the Insured or any
personal effects) employee of the Insured is or has been carrying out work, if arising out
of such work.
In respect only of Section 1 (Public Liability), subparagraph 1. of this exclusion
does not apply to property damage to:
• personal property of partners, directors, officers or employees of the
Insured or of visitors to the Insured’s premises.
• premises or the fittings or fixtures thereof while leased or rented to the
Insured.
• premises or the fittings or fixtures thereof, not owned by or leased or
rented to the Insured, while temporarily occupied by the Insured for the
purpose of carrying out work in or on such premises.
Employees damages, loss, cost or expense arising out of any injury or damage sustained
by any employee arising out of or in the course of employment by the
Insured.
Healthcare or Other damages, loss, cost or expense arising out of the rendering of, or failure to
Professional Services render any:
In respect of Sections 1 and 2:
• healthcare service; or
• professional service or advice other than a life science product
service;
In respect of Section 3:
• healthcare service; or
• accounting, actuarial, architectural, surveying or legal service or advice;
whether or not such service or advice is ordinary to the Insured’s profession
and regardless of whether or not a claim or proceedings are brought by any
client or any other person or organisation .
In respect of Sections 1 and 2 only, this exclusion does not apply to bodily
injury or property damage to which this Policy applies:
• caused by cardiopulmonary resuscitation or other first aid services
(other than in connection with a clinical trial); or
• resulting from the service provided within the scope of and in
accordance with the applicable written protocol of a clinical trial.
Information damages, loss, cost or expense arising out of any actual or alleged breach of
Distribution Laws any law or regulation relating to any unsolicited communication, distribution,
publication, sending or transmitting of content, information or material.
Intellectual Property damages, loss, cost or expense arising out of, giving rise to or in any way
Laws or Rights related to any actual, alleged or threatened assertion, infringement or
violation by any person or organisation of any intellectual property law or
right.
Nuclear damages, loss, cost or expense arising out of or in any way related to any:
• ionising radiation or contamination by radioactivity from any nuclear
fuel or from any nuclear waste from the combustion of nuclear fuel; or
• radioactive, toxic, explosive or other hazardous properties of any
nuclear assembly or nuclear component thereof.
With respect to Sections 1 and 2 only, this exclusion does not apply to bodily
injury or property damage caused by radioactive isotopes used as a
component of or in connection with a medical device or used in medical
research.
Pollution or damages, loss, cost or expense arising out of or in any way related to any:
Contamination
1. actual, alleged or threatened discharge, dispersal, seepage, migration,
release or escape of smoke, vapours, soot, fumes, acids, alkalis,
chemicals, waste materials or other solid, liquid, gaseous or thermal
irritants, contaminants or pollutants;
2. request , demand, order or regulatory or statutory requirement that the
Insured or others test for, monitor, clean up, remove, contain, treat,
detoxify or neutralize, or in any way respond to, or assess the effects of
any irritants, contaminants or pollutants; or
3. claim or proceedings by or on behalf of a government authority or
others for any damages, loss, cost or expense arising out of any testing
for, monitoring, cleaning up, containing, treating, detoxifying or
neutralizing, or in any way responding to, or assessing the effects of any
irritants, contaminants or pollutants.
In respect of Sections 1 and 2 of this Part 2, subparagraph 1. of this exclusion
does not apply to liability for damages for bodily injury or property
damage to which this Policy applies, caused by a sudden, identifiable,
unintended and unexpected event happening anywhere in the world, other
than in the United States of America or its possessions or territories.
Prior Claims or Known (with respect to coverage for an individual person or organisation against
Circumstances liability to which this Policy applies) damages, loss, cost or expense arising out
of any:
• injury, damage, claim or other circumstance known or that should have
been known by such person or organisation, before the beginning of the
Period of Insurance, which could reasonably be expected to result in any
payment under this Policy; or
• injury or damage known or that should have been known by such person
or organisation, before the beginning of the Period of Insurance, to have
happened or to have begun, including any change, continuation or
resumption thereof at any time.
Furthermore, no person or organisation is entitled to any indemnity under
this Policy in connection with any damages, loss, cost on expense arising out of
any:
1. injury, damage, claim or other circumstance:
• reported, in whole or in part at any time, to the Company or any
other insurer under any insurance that is prior to this insurance;
or
• known or that should have been known by any of the Insured´s
directors, partners or officers, before the beginning of the Period
of Insurance, which could reasonably be expected to result in any
payment under this Policy; or
2. injury or damage known or that should have been known by any of the
Insured´s directors, partners or officers, before the beginning of the
Period of Insurance, to have happened or to have begun, including any
change, continuation or resumption thereof at any time.
For the purposes of this exclusion, such injury, damage, claim or other
circumstance will be considered known by an organisation if such
circumstance was known or should have been known by any of such
organisation´s directors, partners or officers.
Securities Laws damages, loss, cost or expense arising out of any actual or alleged breach of
any securities law.
Specific Diseases damages, loss, cost or expense arising out of any:
1. specific disease, including any similar or other condition, injury,
illness or disease related thereto, by whatever name known;
2. causative agent of any such condition, injury, illness or disease,
regardless of whether such agent gives rise to any such condition, injury,
illness or disease or any other condition, injury, illness or disease, by
whatever name known; or
3. actual or attempted counselling or testing for, or containing,
detoxifying, mitigating, monitoring or neutralizing of, or responding to,
or assessing the effects of any:
• condition, injury, illness or disease; or
• causative agent;
described in subparagraph 1 or 2 above, including any:
• actual or attempted cure, diagnosis, prevention or treatment of any such
condition, injury, illness or disease;
• actual or attempted cleaning-up, disposing, handling or removing of any
such causative agent; or
• failure to perform any of the foregoing
Specific Products or damages, loss, cost or expense arising out of any defect, deficiency, inadequacy
Specific Classes of or dangerous condition in, including the actual, alleged or threatened
Products contaminative, pathogenic, toxic or other hazardous properties of any:
1. specific products in any form, including their presence or use in any
alloy, by-product, compound or other material or waste;
2. goods, products or materials that have the same or substantially the
same chemical formula as any goods, products or materials described in
subparagraph 1 above, by whatever name known; or
3. goods, products or materials that are derivatives of any goods, products
or materials described in subparagraphs 1 or 2 above, by whatever name
known; or
4. specific classes of products, by whatever name known.
Successor Liability damages, loss, cost or expense arising out of any:
• ownership, maintenance or use of any assets, business or organisation
acquired by the Insured; or
• conduct of any person or organisation in connection with any assets,
business or organisation acquired by the Insured;
for any act, occurrence, injury or damage happening, in whole or in part,
before such acquisition is executed.
Unapproved Clinical damages, loss, cost or expense, in connection with any clinical trial, arising
Trials out of any unapproved exposure to material, upon or within research
subjects during such a trial, that happens after:
• a hold has been placed on the trial;
• clinical trial authorization or similar authorization applicable to the
trial has been withdrawn; or
• the trial has been ordered to be discontinued;
by any governmental or regulatory authority having jurisdiction.
Unapproved Goods or damages, loss, cost or expense arising out of the actual, alleged or threatened
Products hazardous properties of goods or products:
1. declared unsafe by any governmental or regulatory authority on the
basis of such hazardous properties, regardless of whether such goods or
products were declared unsafe before or after:
• the goods or products were sold, supplied, leased or licensed to
others, manufactured, repaired, installed, inspected, adjusted,
erected, altered, cleaned or treated; or
• such damages, loss, cost or expense were incurred; or
2. sold, supplied, leased or licensed to others, manufactured, repaired,
installed, inspected, adjusted, erected, altered, cleaned or treated
without approval by the applicable governmental or regulatory
authority.
Subparagraph 1 above does not apply to the Insured’s product, to which this
Policy applies, if such goods or products were sold, supplied, leased or licensed
to others, manufactured, repaired, installed, inspected, adjusted, erected,
altered, cleaned or treated before it was known by the Insured, or would have
been known from the perspective of a person in the circumstances of the
Insured, that the goods or products had been declared unsafe.
Unauthorised Access damages, loss, cost or expense arising out of any actual, alleged or threatened
unauthorised access to or use of:
• the Insured’s product or the Insured’s service;
• any property containing or incorporating the Insured’s product or the
Insured’s service;
• any property on which the Insured’s service is or was performed; or
• any content, information (to include but not being limited to personal
data and corporate data) or material;
by any person or organisation.
Vehicles damages, loss, cost or expense arising out of any ownership, maintenance,
possession or use by or on behalf of the Insured of any:
1. mechanically propelled vehicle or trailer attached thereto
whilst being used in circumstances which require compulsory
insurance or equivalent security to comply with the
requirements of any legislation applicable to the use of such
vehicle, including road traffic legislation.
2. aircraft, spacecraft, aerial or aerospatial device, hovercraft or
waterborne craft.
In respect of Section 1 only, subparagraph 2. of this exclusion does not apply to
bodily injury or property damage caused by the use of a waterborne craft
that is:
• a hand or sail propelled craft of less than 15 metres in length: or
• not owned by the Insured, provided that such craft is rented to the
Insured, with a supplied crew, for business entertainment.
This Exclusion does not apply to cover provided under the Extension entitled
‘Motor Liability - Contingent, Incidental Movement, Loading/Unloading or
Tool of Trade’.
War damages, loss, cost or expense arising out of war.
Exclusions – Section 3
(Product and Service Errors and Omissions Liability)
The insurance provided by Section 3 does not apply to any:
Bodily Injury, damages, loss, cost or expense for any bodily injury, property damage
Property Damage or or nuisance.
Nuisance
Ceasing Support damages, loss, cost or expense arising out of any actual, alleged or
threatened decision by the Insured:
• not to provide or support; or
• to cease to provide or support;
the Insured’s product or service.
Continuing Acts damages, loss, cost or expense arising out of any continuation or resumption
Following Non- of any act, following non-renewal or cancellation of this Policy or
Renewal or subsequent renewal or replacement of this Policy that is issued by the
Cancellation Company and which would otherwise apply to such act.
Crime, Dishonesty Or damages, loss, cost or expense arising out of any criminal, dishonest,
Fraud fraudulent or malicious conduct committed by any party with the consent or
prior knowledge of any officer, director or partner, or spouse of any officer,
director or partner of the Insured.
Disappearance or damages, loss, cost or expense arising out of any burglary, inventory
Theft shortage, inventory shrinkage, mysterious disappearance, robbery or theft.
Delay in Delivery or damages, loss, cost or expense arising out of any actual, alleged or
Performance threatened:
1. a. delay in delivery of; or
b. failure to deliver;
the Insured’s product or any part or phase thereof; or
2. a. delay in performance of; or
b. failure to begin;
the Insured’s service or any part or phase thereof.
Government Claims or damages, loss, cost or expense arising out of any claim made or proceedings
Proceedings brought by or on behalf of any central or local governmental authority.
This exclusion does not apply to financial injury sustained by such
authority resulting from its ownership, maintenance or use of the Insured’s
product or the Insured’s service.
Maintenance of damages, loss, cost or expense arising out of any actual, alleged or
Contracts or Licenses threatened:
• failure to effect, maintain, procure or secure; or
• cancellation, lapse, modification, non-renewal, revocation,
suspension or other impairment of;
in whole or in part at any time, any bond, insurance, lease, licence, order,
permit or other contract or agreement that the Insured is obliged to effect,
maintain, procure or secure.
Reputational Injury damages, loss, cost or expense arising out of any actual, alleged or
threatened reputational injury by any person or organisation.
Conditions
The following Conditions apply to all parts of this Policy
Adjustment If any part of the Premium is calculated on estimates, then the Insured shall
within one month from the expiry of each Period of Insurance furnish such
details as the Company may require, and the Premium for such period shall be
adjusted subject to any Minimum Premium.
Adverse Event Reporting an adverse event to the Company, another insurer or a
Reporting governmental or regulatory authority, in itself does not constitute:
• a conclusion that the Insured’s product or the Insured’s service
caused or contributed to such event;
• an admission or assumption of liability;
• a notice as described under the claims condition entitled ‘Insured’s Duty
to Report Circumstances’;
• knowledge of a circumstance that would be expected to result in
payment under this Policy; or
• that injury or damage was expected or intended.
Apportionment of If any award or settlement in respect of any claim exceeds the applicable Limit
Defence Costs of Indemnity, then the liability of the Company in respect of related legal
defence costs shall be limited to an amount that is in the same proportion as
the Company's contribution to such award or settlement.
Assignment Assignment of interest under this Policy shall not bind the Company without
its prior consent.
Audits or Inspections At any time during the Period of Insurance or thereafter, the Insured shall
make available to the Company (and the Company shall have the right to
audit, inspect and copy) any books, papers and other records of the Insured
(including those of its agents and brokers) in connection with this Policy or the
subject matter hereof.
Cancellation The Company can cancel the insurance with fourteen (14) days written notice
from the day the cancellation was sent by the Company, if
a) the Policyholder or the Insured has significantly neglected the
obligations towards the Company or;
b) a circumstance stated in the insurance that is of significant importance
for the risk has changed in a way that the Company could not have taken
into consideration.
The Company shall cancel the insurance without unreasonable delay after the
Company received knowledge of the circumstances underlying the
cancellation. Should the Company fail to do so, the Company will lose the
right to cancel the insurance on these conditions, provided that the
Policyholder or the Insured has not acted decisively or in contrary to good
faith and honour. The Company may choose to change or amend the terms
and conditions of the insurance instead of cancelling the insurance.
Changes This Policy may be changed only by a written endorsement issued by a duly
authorised representative of the Company.
Choice of Law and This policy shall be governed by and construed in accordance with the the
Forum provisions of the Swedish Insurance Contracts Act of 2005:104 (FAL). Any
dispute or difference arising under or in respect of this Policy shall be subject
to and determined within the exclusive jurisdiction of the courts of Sweden.
Currency All sums are in the currency expressed in the Schedule, and all payments will
be made in that currency. If any calculation or payment is to be made in any
other currency, then the rate of exchange to apply shall be that applicable on
the date of settlement as published on www.oanda.com.
First Named Insured The person or organisation first named as the Insured in the Schedule is
primarily responsible for the payment of all premiums. The first named
Insured will act on behalf of all other persons or organisations indemnified
under this Policy for the giving and receiving of all notices and the receipt of
any return premiums that become payable under this Policy.
Material Change in The Insured shall advise the Company immediately in writing of any material
Risk change, of which it is aware or ought reasonably to be aware, in the risk
insured under this Policy.
Other Insurance If interests covered by this insurance are also covered by another insurance,
and if the latter contains a provision regarding double insurance, the same
provision shall apply to both insurances. However each insurer is liable
towards the insured as if it had been the solely insurer. The insured does not
have the right to a total reimbursement from the insurers that exceeds what
corresponds to the loss. The liability will be distributed between the
insurances in accordance with Chapter 6, Section 4 of the Insurance Contracts
Act (2005:104).
Prohibition This Policy does not apply to the extent that trade or economic sanctions or
other laws or regulations prohibit the Company from providing such
insurance.
Reasonable Care The Insured is obliged, at its own expense, to take all reasonable precautions
to prevent injury, damage or loss which may give rise to liability, to comply
with all statutory or other obligations and to take all reasonable steps to:
• ensure that only competent employees are employed;
• keep all plant, premises, machinery and ways in good repair;
• remedy any defect or danger and to take all necessary precautions as
soon as possible after discovery; and
• ensure that its products are free from defect and fit for their intended
purpose.
Third Party Rights A person or organisation who is not party to this Policy has no rights to
enforce any term or condition of this policy.
Clinical Trials – Special Conditions
Clinical Trials – Any cover under this Part of this Policy in respect of any clinical trial is
Special Conditions conditional upon the following.
The Insured:
• shall conduct all clinical trials strictly in accordance with all
applicable agreements, laws, regulations and procedures;
• shall make all filings that it is required to make under all applicable laws
and regulations;
• is at all material times in receipt of all necessary authorisations in
connection with such clinical trials; and
• has not recklessly or wilfully violated or consented to any violation of
any agreement, contract, law, procedure, protocol or regulation
applicable to the conduct of such clinical trial.
With respect to any clinical trial involving exposure to any product upon or
within research subjects during such clinical trial that first happens after
the beginning of the Period of Insurance, where the Insured is the sponsor of
the trial, in connection with:
• ‘First-in-Man’ clinical trials;
• research subjects who are cognitively impaired;
• research subjects who are pregnant;
• research subjects who are under eighteen years of age;
• planned Emergency Use Research testing; or
• prisoners;
it is a condition precedent to cover under this Policy that the Company has
specifically agreed by endorsement to this Policy to provide cover in respect of
such clinical trial. The Company may impose additional terms and
conditions in respect of such trial and may require additional premium to be
paid.
Claims Conditions
The following Conditions apply to all parts of this Policy.
Company’s Rights: The Company is entitled (but not obliged), at its discretion, to:
Investigation, Defence
and Settlements • take over and conduct (including in the name of the Insured) the
investigation, defence (including appeals) or settlement of any claim;
and
• prosecute for its own benefit any claim for indemnity, damages or
otherwise.
The Company, at its discretion, may at any time pay:
• the applicable Limit of Indemnity (after deduction of any sums already
paid); or
• any amount for which any claim can be settled;
and may then relinquish any conduct or control of, and shall be under no
further liability in respect thereof.
Insured’s Duty to If, during the Period of Insurance, the Insured becomes aware of a
Report Circumstances circumstance which may result in a claim and, as soon as practicable during
the Period of Insurance gives the Company written notice thereof, then
subsequent claims notified in accordance with the ‘Insured’s Duties in the
Event of a Claim’ will be deemed to be claims made during the Period of
Insurance.
Written notice of such circumstance shall contain:
• particulars sufficient to identify the Insured;
• all available information concerning the circumstance, including how,
when and where it happened; and
• all available names and addresses of any party who has suffered injury,
loss or damage and of all available witnesses.
Insured’s Duties in the In the event of any circumstance arising that may result in a claim under this
Event of a Claim Policy, written notice containing:
• particulars sufficient to identify the Insured;
• all available information concerning the circumstance, including how,
when and where it happened; and
• all available names and addresses of any party who has suffered injury,
loss or damage and of all available witnesses;
shall be given to the Company as soon as practicable after the circumstance
becomes known to the Insured.
The Insured shall give written notice to the Company of any claim or
proceedings as soon as practicable after such claim or proceedings come to the
knowledge of the Insured (and in any event within 12 (twelve) months from
the time such proceedings or claim first came to the knowledge of the Insured)
and shall, as soon as practicable, forward to the Company every pre-action
letter, demand, notice, summons, claim form or other process received by the
Insured.
If the Insured wishes to bring legal proceedings against the Company with
regard to a claim, that Insured must commence such proceedings within 10
(ten) years of when the claim was first made. However, if written notice of the
claim is given to the Company within the time required by the paragraph
immediately above, the insured may always commence such proceedings
within 6 (six) months of the time when the Company states that it has made its
final decision regarding the Claim. If the Insured does not commence such
proceedings within the time required by this paragraph, the Insured shall lose
the right to insurance cover in respect of the Claim.
When the Company has given its final decision about an Insured´s claim of
insurance cover under this Policy, the Company may by written notice to the
Insured demand that the Insured commence legal proceedings against that
Company regarding that decision within such time (but not less than 12
(twelve) months of that written notice as the Company shall stipulate. If the
Insured does not commence legal proceedings within that time, the Insured
shall lose the right to do so.
The Insured shall not admit liability for or negotiate the settlement of any
claim without the written consent of the Company.
The Insured shall co-operate with and provide all required assistance to the
Company and, at the Company’s request and in accordance with its
instructions, shall:
• assist in negotiating or concluding settlements;
• co-operate in the conduct of any proceedings enforcing any right of
contribution or indemnity against any person or organisation who may
be liable to the Insured because of injury or damage with respect to
which insurance is afforded; and
• attend hearings and trials and assist in securing and giving evidence and
obtaining the attendance of witnesses.
Subrogation The Company shall be subrogated to all the Insured's rights of recovery against
any person or organisation, before or after any payment under this Policy. The
Insured shall execute and deliver instruments and papers and do whatever else
is necessary to secure such rights. The Insured shall do nothing after loss to
prejudice such rights. For the purposes of this condition, ‘the Insured’ shall
include all persons and organisations indemnified under this Policy.
Definitions
Words with specific meanings appear in bold print and are defined here. All other words used in this Policy
bear their plain English meaning. The following definitions apply to all parts of this Policy.
Act • means an act, error or omission.
• includes all related acts, errors or omissions and all series of continuous,
repeated or related acts, errors or omissions.
Adverse Event means any:
1. outcome of the following types, regardless of whether or not such
outcome is expected or intended:
• congenital anomaly or birth defect;
• death;
• disability or incapacity;
• hospitalization; or
• life threatening injury, illness or disease;
of any person;
2. intervention to prevent any outcome described above;
3. malfunction of the Insured’s product that may give rise to any outcome
described in subparagraphs above; or
4. condition that may give rise to any outcome described above, requiring
notification to a governmental or regulatory authority.
Asbestos means asbestos in any form, including its presence or use in any alloy, by-
product, compound or other material or waste. Waste includes material to be
recycled, reconditioned or reclaimed.
Benefit Programme means any:
• accident, dental, disability, healthcare, homeowners, life, motor vehicle,
unemployment or employee compensation;
• deferred compensation, financial planning, investment subscription,
pension, profit sharing, retirement, severance or share ownership; or
• expense reimbursement, holiday, savings, training or travel;
account, insurance, payment, plan or programme, or any similar benefit.
Bodily Injury means physical:
• injury;
• illness; or
• disease;
sustained by a person, including resulting death, mental anguish, mental
injury or shock at any time. All such resulting loss shall be deemed to happen
at the time of the injury, illness or disease that caused it.
Clinical Trial means:
1. an investigation in research subjects intended to:
• discover or verify the clinical, pharmacological or other
pharmacodynamic effects of one or more investigational
medicinal product;
• identify any adverse reactions to one or more investigational
medicinal product; or
• study absorption, distribution, metabolism or excretion of one or
more investigational medicinal product with the object of
ascertaining its safety or efficacy; or
2. other investigation or testing of a life science product upon or within
research subjects to establish the effectiveness or safety of such
product.
includes:
• the provision of information necessary to obtain the informed
consent of human beings to participate in such investigation or
testing; and
• other activities in connection with such investigation or testing.
Clinical Trial means (as applicable):
Compensation
Guidlines • the Association of British Pharmaceutical Industries (“ABPI”) Clinical
Trial Compensation Guidelines (Issued 1991) or subsequent revisions;
• the ABPI Guidelines for Phase 1 Clinical Trials (2007 Edition) or
subsequent revisions;
• the Association of British Health-Care Industries Medical Devices
Clinical Investigation Compensation Guidelines (1995) or subsequent
revisions;
• guidelines that are imposed on the Insured by a government or
regulatory authority of competent jurisdiction; or
• written guidelines that are voluntarily accepted by the Insured and
specifically agreed to by the Company by endorsement to this Policy;
which prescribe the manner and rules by which to determine whether, and to
what extent, a research subject in a clinical trial should be paid
compensation by the Insured in respect of bodily injury or property
damage sustained by such research subject as a result of his or her
participation in a clinical trial to which this Policy applies.
Cognitively Impaired means suffering from any:
• alcohol or drug dependency;
• degenerative disease affecting the brain;
• dementia or similar disorder;
• disabling physical handicap;
• mental retardation or similar disorder;
• neurosis, psychosis or similar disorder;
• terminal physical illness; or
• other condition, disease, injury or sickness;
that diminishes a human being’s capacity for judgment or reasoning.
Contract Research means an organisation engaged to provide service or advice in connection
Organisation with:
1. a. clinical;
b. laboratory; or
c. research;
testing activities, within the scope of and in accordance with the
applicable written protocol; or
2. the planning, monitoring or review;
of a clinical trial.
Cosmetic means an article that is intended to be applied to the human body for altering
appearance, beautifying, cleansing or promoting attractiveness.
Device Family means a medical device or a group of such devices manufactured by or for
the same organisation and having the same basic design and performance
characteristics and intended function and use.
Dietary Supplement means a good or product, other than conventional food, that is or includes:
• an amino acid, herb or other botanical, mineral, vitamin or similar
substance; or
• a combination, concentrate, constituent, extract or metabolite of the
substances described above;
which is intended to supplement the diet of human beings
Employee means any person employed under a contract of service or apprenticeship with
the Insured, whether such contract is expressed, implied, oral or in writing,
including persons:
• supplied by labour only sub-contractors;
• providing their services on a labour only basis;
• engaged in work experience or similar schemes;
• providing their services on a voluntary basis; or
• on secondment with the Insured.
For the purposes of this Policy, voluntary participation by an employee in a
clinical trial is not an activity arising out of or in the course of that
employee’s employment by the Insured.
Ethics Committee means a board, committee, group or similar organisation designated, directed
or requested by an institution or other person or organisation to review a
clinical trial, including:
• approval; or
• periodic review;
of such clinical trial.
Financial Injury means economic injury, including that resulting from loss of software, data
and other information in electronic form, sustained by a person or
organisation in connection with the Insured’s product or the Insured’s
service, or a part or phase thereof.
Healthcare Service means any:
• cosmetic service, advice, instruction or treatment;
• dental, medical, nursing, physiotherapy, surgical or x-ray service,
advice, instruction or treatment;
• handling or treatment of dead bodies, including autopsies, organ
donations or similar procedures;
• health or therapeutic service, advice, instruction or treatment; or
• related dispensing or furnishing of any beverages or food, or any life
science product or other dental, medical or surgical appliances or
supplies.
Information and means:
Network Technology
1. communication, computer, electronic, information, Internet, network or
Product
website:
• equipment or parts; or
• programs or systems; and
2. software, data or other information that is in electronic form.
Information and means analysis, design, integration, maintenance, management, processing,
Network Technology programming, repair or support services in connection with any information
Service and network technology product.
Intellectual Property means any:
Law or Right
1. right to, or law recognising an interest in, any:
• certification mark;
• copyright or moral right, database right or mask work or
semiconductor topography right;
• design right;
• patent;
• trade dress (including get up);
• trade mark;
• trade secret, know-how or confidential information; or
• other intellectual property;
2. law relating to passing off, piracy, unfair competition or similar
practice; or
3. law or right similar to any of the foregoing, anywhere in the world.
Legal Defence Costs means the costs, fees and expenses incurred for the defence of the Insured in
the investigation, defence and settlement of that part of a specific claim
covered by this Policy.
Life Science Product means a cosmetic, dietary supplement, medicinal product or medical
device.
Life Science Product means a person or organisation engaged to provide service or advice in
Sales Contractor connection with the dispensing, sale or supply of a life science product,
other than in connection with a clinical trial.
Life Science Product means:
Service
• clinical;
• design or development review;
• laboratory; or
• research;
service or advice in connection with a life science product.
Life Science Product means a person or organisation engaged to provide life science product
Service Contractor service, other than in connection with a clinical trial.
Medical Device means an instrument, apparatus, appliance, material or other article, whether
used alone or in combination, (including software necessary for its proper
application) intended by the manufacturer to be used for human beings for the
purpose of:
• diagnosis, prevention, monitoring, treatment or alleviation of disease;
• diagnosis, monitoring, treatment or alleviation of an injury or handicap;
• investigation, replacement or modification of the anatomy or of a
physiological process; or
• control of conception;
and which does not achieve its principal intended action in or on the human
body by pharmacological, immunological or metabolic means, but which may
be assisted in its function by such means.
Medicinal Product means a substance or combination of substances:
• presented as having properties for treating or preventing disease in
human beings; or
• which may be used in or administered to human beings with a view to
restoring, correcting or modifying physiological functions by exerting a
pharmacological, immunological or metabolic action, or to make a
medical diagnosis.
Occurrence means an accidental event, including continuous or repeated exposure to
substantially the same general harmful conditions.
Offshore Activities means any:
• embarkation onto a conveyance (until disembarkation from such
conveyance onto land) for the purpose of travel to or from;
• transit between; or
• activities on or from;
any offshore structure, platform, installation, accommodation vessel or
associated structure.
Prisoner means a human being who is:
1. incarcerated:
• while awaiting arraignment, trial or sentencing; or
• having been sentenced;
pursuant to a civil or criminal statute; or
2. detained for drug detoxification, treatment of alcoholism or other
purposes, pursuant to a civil or criminal statute which allows or
provides for alternatives to incarceration.
Product In respect of Sections 1, 2 and 3:
means:
• goods or products (including life science products) sold, supplied,
leased or licensed to others, manufactured, repaired, installed,
inspected, adjusted, erected, altered, cleaned or treated by or on behalf
of the Insured;
• containers, labels, instructions and packaging relating to such goods
and products.
after such goods or products have ceased to be in the care, custody and control
of the Insured.
Notwithstanding anything to the contrary above, product includes its use at
any time or place whilst loaned or hired to, or located for the use of, another
whether or not such product:
• has been sold; or
• is in the Insured’s possession.
In respect of Section 3:
means:
• goods or products, including life science products, sold supplied,
leased or licensed to others, manufactured, repaired, installed,
inspected, adjusted, erected, altered, cleaned or treated by or on behalf
of the Insured;
• containers, labels, instructions and packaging relating to such goods or
products; and
• the Insured’s service rendered in connection with such goods or
products.
Property Damage means physical damage to tangible property, including resultant loss of use of
such property. Tangible property does not include any software, data or other
information in electronic form.
All such resultant loss shall be regarded as having happened at the time of the
physical damage that caused it.
Reputational Injury means injury caused by an act of:
1. false arrest, false detention or other false imprisonment;
2. malicious prosecution;
3. wrongful entry into, wrongful eviction of a person from or other
violation of a person's right of private occupancy of a dwelling, premises
or room that such person occupies, if committed by or on behalf of its
landlord, lessor or owner;
4. electronic, oral, written or other publication of material including on the
Internet or in other media that:
• libels or slanders a person or organisation (including placing a
person in a false light);
• disparages a person’s or organisation’s products or services; or
• violates a person’s right of privacy; or
5. discrimination, harassment or segregation based on a person’s
protected human characteristics as established by law.
Research Subject means a person participating in a clinical trial or any pre-trial assessment,
including:
• such person’s dependants, heirs, executors, administrators and legal
representatives; and
• children in-utero through the participation of the mother in a clinical
trial.
Securities Law means any law or regulation designed to:
• prevent or prohibit fraudulent, unfair or other similar practices; or
• require full or periodic disclosure of information;
in connection with any:
• offering;
• registration;
• trading; or
• continued listing or registration;
of any instrument or other evidence of creditorship or ownership.
Service means:
• information and network technology services; and
• life science product services;
performed by the Insured or on its behalf (including related consulting,
staffing, training and other support services).
Specific Diseases means:
• Acquired Immune Deficiency Syndrome (AIDS).
• Transmissible Spongiform Encephalopathy (TSE).
• Viral Hepatitis.
Specific Classes of means:
Products
• Anticonvulsant products.
• Aprotinin
• Birth control or fertility products.
• Clopidogrel
• Cox-2 inhibitor products.
• Fibrate products.
• HMG CoA reductase inhibitor products.
• Hormone replacement products.
• Impotence products.
• Isotretinoin
• Metoclopramide
• Orlistat
• Selective Serotonin Reuptake Inhibitor products (SSRI).
• Serotonin Norepinephrine Reuptake Inhibitors (SNRI).
• Thiazolidinediones
• Vaccines.
• Varenicline
Specific Products means:
• Bupropion.
• Botulinum Toxin
• Cisapride.
• Dexfenfluramin.
• Dopamine Agonist
• Di-(2-ethylhexyl) Phthalate (DEHP).
• Diazepines, Oxazepines or Thiazepines.
• Diethylstilbestrol (DES).
• Ephedra or Ephedrine.
• Fenfluramine.
• Hydroquinone.
• Hydroxyquinoline derivative products.
• Infusion Pumps
• Isotretinoin
• L-tryptophan – when used for or as part of any physically ingestible
purpose
• Latex Gloves.
• Mercury.
• Phentermine.
• Phenylpropanolamine (PPA).
• Piper Methysticum (Kava).
• Remoxipride.
• Risperidone.
• Silicone – when used as part of an implantable medical device.
• Thalidomide.
• Thimerosal.
Subsidiary means an organisation that the Insured either directly or indirectly controls
Organisation through:
• holding a majority of the voting rights;
• the right to appoint or remove a majority of its board of directors; or
• controlling alone, pursuant to a written agreement with other
shareholders, a majority of the voting rights therein.
Terrorism means any:
• act including the use of force or violence or the threat thereof, taken by
any person or group of persons, whether acting alone or on behalf of or
in connection with any organisation or government, committed for
political, religious, ideological or similar purposes including the
intention to influence any government or to put the public, or any
section of the public, in fear.
• act or failure to act in controlling, preventing or suppressing
terrorism.
War means any:
1. hostile or warlike action in time of peace or war (including any act or
failure to act in controlling, preventing or suppressing any actual,
impending or expected attack) by any:
• government authority or sovereign power (de jure or de facto) or
by any authority maintaining or using military, naval or air
forces;
• military, naval or air forces; or
• agent of any government power, authority or force;
2. insurrection, rebellion, revolution, civil war, usurped power or any
activity of any organisation the objects of which are or include the
overthrowing or influencing of any government or sovereign power (de
jure or de facto) by any violent means, or any act or failure to act by
government authority or sovereign power (de jure or de facto) in
controlling, preventing or suppressing such activity; or
3. weapon of war employing atomic fission, atomic fusion, radioactive
force or radioactive material, whether in time of peace or war.
Uuritava informeerimise ja teadliku nõusoleku l eht Varasemalt kirjeldamata geenivaria nti de mõju ravimite metabolismile ehk ravimite lagundamise kiirusele inimese organismis Kutse uuringus osalemiseks Kutsume Teid osalema teadusuuringus. Selleks palume tutvuda järgneva teabega . Uuringumeeskonna esindaja on valmis vastama Teie küsimustele. Teil on aega otsustamiseks, kas osaleda uuringus või mitte. Mis on uuringu eesmärk? Geenidoonorite andmeid analüüsides oleme leidnud umbes 9 00 inimest, kellel esineb varasemalt kirjeldamata geenivariante, mis võivad mõjutada teatud ravimite toimet. Uuringu eesmärk on analüüsida nende geenivariantide mõju ravimite lagundamise kiirusele inimese organismis ehk uurida , kuidas organism ravimeid „ töötleb “. Uuringu tulemused aitavad kaasa sellele, et tulevikus saa ks geeniinfot teades ravimeid inimestele täpsemalt annustada . Selleks et ravimid saaksid organismi le süsteemset toimet avaldada, peavad nad liikuma kehas toime avaldumiseks vajalikku kohta (n äiteks jõudma süsteemsesse vereringesse). Mõned ravimid peavad muunduma ( metaboliseeruma ) kehas toimivateks ühenditeks ja osad ravimid peavad metaboliseeruma sellisteks ühenditeks, mida on võimalik kehast eritada. Ravimite ja ka paljude muude kehavõõraste ainete metabolismis on olulisel kohal ensüümide kogum ehk tsütokroom P450 süsteem (CYP450). Selle t sütokroomide süsteemi liikmed osalevad enamike ravimite metabolismis. Tsütokroom P450 ensüümide aktiivsus võib erinevatel inimestel olla väga suurte kõikuvustega ja selle tõttu on erinev ka ravimite metabolis eerimise võime. Sellest tulenevalt võib mõni ravim olla osadel inimestel tugevama või nõrgema toimega, mõnikord võivad osadel inimestel erinevuste tõttu tsütokroomide süsteemis avalduda teatud ravimi kõrvaltoimed . Tsütokroom P450 ensüümide aktiivsust saab organismis hinnata nii, et inimesele antakse teatud kindla ensüümi vahendusel metaboliseeruva ravimi üks annus ning seejärel määratakse kindlatel ajahetkedel võetud vereproovidest manustatud ravimi ja selle laguproduktide (metaboliitide) sisaldust. Miks on Teid välja valitud? Pöördume Teie poole, kuna olete nõustunud geenidoonorina oma geeniinfo uurimisega . Te olete üks umbes 900st geenidoonorist, kellel on leitud tsütokroom P 450 ensüümides variatsioone ehk erinevusi , mis võivad mõjutada ravimite lammutamise kiirust . Plaanime uuringusse kaasata kuni 250 geenidoonorit. Kas ma pean uuringus osalema? Uuringus osalemine on vabatahtlik. Kui otsustate uuringus osaleda, palutakse Teil allkirjastada nõusoleku vorm. Isegi kui annate nõusoleku uuringus osalemiseks, on Teil võimalus igal ajal uuringus osalemi n e katkestada. Selleks palume Teil esitada vabas vormis avaldus kas paberkandjal või e- kirja teel meiliaadressile
[email protected] . Avalduses ei ole vaja välja tuua katkestamise põhjendust . Otsus uuringus mitte osaleda ei mõjuta Teile osutatavat arstiabi. Soovi korral on Teil õigus oma andmetega kohapeal tutvuda ilma et see tooks kaasa mingeid ebameeldivusi. Mida Teiega tehakse, kui otsustate uuringus osaleda? Uuringus osalejatel on vaja käia kahel uuringuvisiidil, mis toimuvad haiglas (Tartu Ülikooli Kliinikum is või Põhja- Eesti Regionaalhaigla s ). Haiglasse sõitmise kulud kompenseeritakse Teile sõidudokumentide alusel, maksimaalselt kuni 50 € ulatuses ühe visiidi kohta . Esimene visiit Sellel visiidil antakse Teile lisaselgitusi ning võetakse Teilt kirjalik nõusolek uuringus osalemise kohta. V isiidi käigus dokumenteeritakse T eie isikuandmed, tehakse mõõt mised (kaal, pikkus), hinnatakse Teie terviseseisundit ja sobivust uuringus osalemiseks ning võetakse vajalikud vereproovid (kokku kuni 10 ml veeniverd). Uurijad võivad vaadata ka Teie varasemaid haiguslugusid, et kindlaks teha, kas Teil on vastunäidustusi mingite ravimite tarvitamisele . Selleks küsitakse Teilt eraldi nõusolek. Info dokumenteeritakse elektroonilises haigusloos haigla info süsteemis sarnaselt sellele, kuidas andmeid dokumenteeritakse tavalise arstivisiidi käigus . Esimese visiidi järgselt selgub, kas Te sobite uuringusse ja soovite selles osaleda ning lepitakse kokku teise visiidi aeg. Kui tarvitate regulaarselt ravimeid, lepitakse Teiega esimesel visiidil kokku, kas võite uuringupäeva hommikul Teile arsti poolt määratud ravimeid võtta. Selle kohta antakse Teile kaasa täpne soovitus. Uuringu esimesel vi siidil kulub haiglas aega umbes 1 tund. Teine visiit Uuringupäeval kontrollitakse veel kord Teie terviseseisundit, küsitletakse Teid ravimite kasutamise kohta ning kinnitatakse sobivus uuringusse . Seejärel antakse Teile suu kaudu korraga kahte sageli kasutatavat ravimit – 20mg omeprasooli ( kõrvetiste ja maohappe tagasivoolusümptomite ravim ) ning 12,5mg metoprolooli ( kõrgvererõhutõve , stenokardia , südame rütmihäirete ja südamepuudulikkuse korral kasutatav ravim ). O meprasool on kapslis valmispreparaat ja metoprolool antakse T eile puhta toimeaine pulbrina, mille uuringuõde lisab 50ml-le kraaniveele ja annab Teile sisse võtmiseks . Ka omeprasooli võtmiseks antakse T eile kraanivett. Ravimite kontsentratsiooni mõõtmiseks veres võetakse Teilt 8 tunni jooksul 10 vereproovi . Ü hekordne võetava vere maht on 5ml. Vereproovi võtmine toimub veenikanüüli kaudu, mis pannakse Teile enne ravimite manustamist. Uuringupäeva hommikul palume Teil mitte süüa, kuna toit võib mõjutada uuringuravimite imendumist. Pärast uuringuravimite manustamist pakutakse Teile uuringukeskuses hommikusööki ning toitlustus tagatakse terve uuringupäeva jooksul. Teine visiit kestab kuni 10 tundi ja seetõttu toimub see nädalavahetusel. Ravimikontsentratsioon id määra takse Teie vereproovist Rootsis, Karolinska Instituudis , kus on selleks olemas kogenud spetsialistid ja vajalik aparatuur. Mida tehakse uuringu tulemustega? Uuringu tulemused avaldatakse teadusajakirjades. Soovi korral saadame Teile uuringu lõppedes kokkuvõtte uuringu tulemustest. Mida ma pean uuringus osalemiseks tegema? Teilt palutakse allkirja nõusoleku lehele, millega kinnitate, et olete nõus uuringus osalemisega. Uuringuravimi manustamine on plaanitud nädalavahetuse päeval ning Teile sobival ajal. Uuringu ajal on plaanis katta kuludokumentide alusel Teie transpordikulud. Kui Teil ei ole võimalik uuringukeskusesse tulla uuringuravimi manustamise päeva hommikul või lahkuda uuringupäeva järgsel õhtul, siis tasutakse ka Teie ööbimiskulud . Mis kasu on uuringus osalemisest ja millised on võimalikud riskid? Selles uuringus osalemisest ei ole Teile otsest kasu, kuid Teil on võimalik soovi korral tutvuda uuringu tulemus tega ning Geenivaramus hoitavate geeniandmete põhjal koostatud farmakogeneetika raportiga. Farmakogeneetika raportis on personaalsed soovitused 2 8 erineva ravimi annustamise kohta. Antud uuring aitab paremini selgitada varem kirjeldamata geeni variatsioonide võimalikku mõju ravimite metaboliseerimise ehk lagundamise võimele. Lisaks omeprasoolile ja metoproloolile lagundavad uuritavad ensüümid ka teisi ravimeid, mille puhul on olemas soovitus ed annuste muutmiseks vastavalt inimese ensüümide aktiivsusele . Näiteks ensüüm CYP2C19 lagundab tsitalopraam i , klopidogreel i , sertraliin i , esomeprasool i , amitriptüliin i ; ensüüm CYP2D6 lagundab kodeiin i , nortriptüliin i , paroksetiin i jt ravimite toimeaineid . Uuringu eesmärgil antakse Teile 2 ravimit – 20mg omeprasooli ning 12,5mg metoprolooli . Nende ravimite annused on küll väikesed ning kõrvaltoimete tekkimine on vähetõenäoline, kuid Teie terviseseisundit jälgitakse ikkagi uuringu jooksul pidevalt . Ühekordse annuse manustamise järgselt võivad Teil nende kahe ravimi kõrvaltoimena tekkida peavalu , pearinglus , südame löögisageduse aeglustumine , iiveldus või suukuivus . Lisaks helistatakse T eile nädal pärast uuringu toimumise päeva ning küsitletakse terviseseisundi kohta. Teil on võimalus uurijatega telefoni teel ühendust võtta kogu uuringu ajal ja teavitada uurijat võimalik e st ravimi te kõrvaltoime te st . Veenikanüüli panek võib olla korraks valulik, aga teeme kõik, et seda ära hoida – vereanalüüsid võtab kogenud õde. Võetava vere maht on teise visiidi jooksul kuni 50 ml ja seda ei peeta tervisele ohtlikuks. Kõik uuritavad on uuringu jooksul eraldi kindlustuskaitsega kaetud. Kas uuringus osaledes on minu isiku andmed kaitstud? Jah. Kõik uuringu raames kogutud isiku andmed (andmed, millega saab Teid otse või kaudselt tuvastada – näiteks nimi, isikukood , terviseandmed ) on konfidentsiaalsed ja kaitstud vastavalt rahvusvaheliste ja Eestis kehtestatud reeglitele (kooskõlas Isikuandmete k aitse seadusega). Uuritavad saavad numbrilise koodi, millega tähistatakse kõik meditsiinilised dokumendid ja vere proovid ning andmeid töödeldakse pseudonüümitud kujul ehk kodeeritult. Uuringu andmed edastatakse ka Geenivaramusse, kus toimub andmete kodeerimine ja analüüsimine. Uuringuga seotud infot hoitakse hästi turvatud Geenivaramu, SA Tartu Ülikooli Kliinikumi ja SA Põhja-Eesti Regionaalhaigla serverites. Haigla serverites hoitakse andmeid samadel alustel nagu Teie teisi terviseandmeid. Geenivaramu serveri tes hoitakse andmeid tähtajatult ja kodeeritud kujul . Kes on hinnanud uuringu sobivust ja ohutust? Uuring on heaks kiidetud Eesti bioeetika ja inimuuringute nõukogu poolt . Uuringut võib igal ajahetkel inspekteerida ka Ravimiamet ja rahvusvahelised organisatsioonid. Kes uuringut organiseerib ja finantseerib? Uuringut korraldab Tartu Ülikooli Eesti Geenivaramu koostöös Tartu Ülikooli Kliinikumi ja Põhja-Eesti Regionaalhaigla arstidega ning seda finantseeritakse SA Eesti Teadusagentuuri teadus grandist. Kontakt lisainformatsiooni saamiseks Vastutav uurija Tartu Ülikooli Kliinikumis: Dr. Alar Irs Tel: ..........
[email protected] Vastutav uurija Põhja Eesti Regionaalhaiglas: Dr. Kersti Oselin Tel: .......
[email protected] Täname Teid, et kaalusite selles uuringus osalemist! Haigla nimetus: _________________________________ INFORMEERITUD NÕUSOLEKU VORM Varasemalt kirjeldamata geenivariantide mõju ravimite metabolismile Nõustumisel p alun märkida kasti ees- ja perekonnanime esimesed tähed 1. Ma olen läbi lugenud nimetatud uuringu infolehe kuupäevaga 02/01/20 (versioon 1) ja sellest aru saanud. Mul on olnud võimalus küsida küsimusi. Kinnitan oma nõusolekut uuringus osalemiseks. 2. Ma mõistan, et osalemine on vabatahtlik ja ma võin uuringus osalemise igal ajal ja põhjust nimetamata katkestada. See ei mõjuta mulle antavat arstiabi. 3. Ma annan uuringuga seotud isikutele loa juurdepääsuks oma meditsiinilistele dokumentidele (uuringu ravimitega seotud info saamiseks varasematest elektroonilistest haiguslugudest haigla infosüsteemis) . 4. Olen nõus, et mulle asetatakse ühekordselt veenikanüül. 5. Olen nõus, et mulle manustatakse ühekordselt 20mg omeprasooli ja 12,5mg metoprolooli . 6. Olen nõus, et kogu uuringu jooksul võetakse analüüsideks kuni 6 0 ml veeniverd. Teil on võimalik soovi korral tutvuda uuringu tulemustega ning Geenivaramus hoitavate geeniandmete põhjal koost atud farmakogeneetika raportiga , mis on koostatud Teie kohta Geenivaramus hoitavate geeniandmete põhjal. Farmakogeneetika raport kajastab inimese geneet iliste eripärade mõju ravimite omastamisele, sobivusele või kõrvaltoimete tekkimisele. Raportis on andmed 2 8 erineva toimeaine kohta. Uuringu tulemused ja raport saadetakse Teile soovi korral e-mailile või tavapostiga. Palun tehke valik ja märkige sobivasse kasti ees- ja perekonnanime esitähed . -993775 22860 0 0 2038350 17780 0 0 Soovin teada uuringu tulemusi Soovin saada raportit -984250 99060 0 0 -3228975 95885 0 0 Ei soovi teada uuringu tulemusi Ei soovi saada raportit Kirjutage trükitähtedega e-maili või postiaadress, kuhu saadetakse tulemused ja/või raport. Neid andmeid ei kasutata mingil muul otstarbel ja ei kanta mingisse andmebaasi ja need hävitatakse 5 aastat pärast uurinu lõppu . …………………………………………………………………………………………. Tean, et uuringu käigus tekkivate küsimuste kohta saan mulle vajalikku täiendavat informatsiooni uurijalt. Kontakt lisainformatsiooni saamiseks Vastutav uurija Tartu Ülikooli Kliinikumis: Dr. Alar Irs Tel: ..........
[email protected] Vastutav uurija Põhja Eesti Regionaalhaiglas: Dr. Kersti Oselin Tel: .......
[email protected] ____________________ Uuritava ees- ja perenimi _______ Kuupäev ________________ Allkiri ___________________ Isikukood ____________________ Nõusoleku võtnud isiku ees- ja perenimi ________ Kuupäev _________________ Allkiri
TÜ Genoomika instituudi vastus Eesti bioeetika ja inimuuringute nõukogu 8-04-2020 esitatud küsimustele ja ettepanekutele seoses uurimistööga „ Varasemalt kirjeldamata geenivariantide mõju ravimite metabolismile “ Genoomika instituut on teinud parandused uuritava informeerimise ja teadliku nõusoleku vormi. Kõikidele EBINi poolt esitatud küsimustele ja ettepanekutele on vastatud, v.a. üks küsimus : Esimene visiit lepitakse kokku telefoni teel. Kuidas annab geenidoonor teada, et ta on nõus ja talle sobivad suhtluskanalid? Põhjendus: uuritava esimese visiidi kokkuleppimine toimus juba eelnevalt ja kogu vajaliku informatsiooni esimese visiidi kokkuleppimise kohta saab uuritav eraldi kirjaga ( Kiri geenidoonorile uuringusse kutsumiseks) , mis saad e takse potentsiaalsetele uuritavatele uuringu alguses . I nformeerimise ja teadliku nõusoleku vormi le selle teabe panek oleks eksitav, ku na inimene on juba esimesel visiidil, mille käigus ta sellele vormile alla kirjutab. Kirja koostaja Helene Alavere
Alar Irs
Sünniaeg 3.07.1973
Telefon 003725118592
ORCID 0000-0002-2244-9699
E-post
[email protected]
Töökohad ja ametid
01.01.2018–... SA Tartu Ülikooli Kliinikum, Tartu Ülikooli Kliinikumi
radioloogiakliinik, arst-õppejõud kardioloogia erialal (0,50)
2017–... SA Tartu Ülikooli Kliinikum, Tartu Ülikooli Kliinikumi
Südamekliinik, arst-õppejõud kardioloogia erialal (0,50)
01.01.2012–... Ravimiamet, meditsiininõunik
01.02.2009– Tartu Ülikool, Kliinilise farmakoloogia lektor (0,25)
31.12.2017
03.08.2004– Newcastle-i Ülikool, Austraalia, kliinilise farmakoloogia
03.11.2004 külalisteadur (1,00)
2004–31.01.2009 Tartu Ülikool, kliinilise farmakoloogia assistent (0,25)
01.01.2003– Ravimiamet, peadirektori asetäitja (1,00)
31.12.2011
01.01.2001– Ravimiamet, registreerimisosakonna juhataja
31.12.2003
01.01.1998– Ravimiamet, kliiniliste ravimiuuringute spetsialist
31.12.2001
01.09.1997– Tartu Ülikool, lepinguline õppetöö kliinilise farmakoloogia alal
31.12.2003 (0,50)
Haridustee
01.09.2012– Kardioloogia residentuur
31.08.2017
1991–1997 MD cum laude, Tartu Ülikooli arstiteaduskond
Teadusorganisatsiooniline ja -administratiivne tegevus
2018−... Eesti Kardioloogide Seltsi juhatuse liige
2017−... Eesti Haigekassa ravimikomisjoni esimees
2017−... Riikliku Siirdemeditsiini ja Kliiniliste Teadusuuringute
Keskuse kliiniliste uuringute keskuse juhtkomitee liige
2012−... Eesti ravijuhendite nõukoja liige
2010−... Euroopa Ravimiameti kardiovaskulaartöörühma liige (2017
asejuhataja)
2009−... Ravimiameti ravimite müügilubade komisjoni ase-esimees
2004−... Euroopa Ravimiameti inimravimite komitee liige
2013−2016 TÜ arstiteaduse programminõukogu liige
2013−2017 Programmi „Tervishoiuteaduste võimekuse edendamine“
(TerVE) tervisetehnoloogiate hindamise (TTH) nõukogu, liige
2011−2016 Ravimiinfo Assotsiatsiooni Euroopa nõukoja liige
2010−2013 Eesti Farmakoloogia Selts, juhatuse liige (president)
2009−2017 Euroopa kliilise farmakoloogia ja teraapia assotsiatsiooni
hariduse alakomitee, liige
2008−2013 Maailma Terviseorganisatsiooni esmavajalike ravimite komitee
liige
2008−2013 Euroopa kliilise farmakoloogia ja teraapia assotsiatsiooni
nõukogu liige
2004−2017 Sotsiaalministeeriumi ravimikomisjoni liige
Teadustöö põhisuunad
ETIS KLASSIFIKAATOR: 3. Terviseuuringud; 3.7. Kliiniline meditsiin; CERCS
KLASSIFIKAATOR: B530 Südame-veresoonkonna haigused ; TÄPSUSTUS:
Aterosklerootilise kardiovaskulaarhaiguse ennetus ja ravi
Lisainfo
Olen kuulanud doktorantuuriprogrammis ettenähtud mahus eetikaloenguid, osalenud
Euroopa Ravimiameti ja ravimijärelevalvevõrgustiku GCP inpektorite
treeningprogrammis, mis hõlmas bioeetikat, ning olles olnud umbes 60 GCP kursuse
koordinaator, olen kuulanud neis peetud eetikaloenguid kõigilt lektoreilt, kes neid on
Eestis pidanud, sh Andres Soosaar ja Aime Keis.
Jooksvad projektid
• (RITA1/01-42-01) "Personaalmeditsiini kliinilised juhtprojektid rinnavähi ja südame-
veresoonkonna haiguste täppisennetuses (1.01.2018−31.12.2020)", Peeter Padrik, SA
Tartu Ülikooli Kliinikum.
Publikatsioonid
2019
Alver, Maris; Palover, Marili; Saar, Aet; Läll, Kristi; Zekavat, Seyedeh Maryam; Tõnisson, Neeme;
Leitsalu, Liis; Reigo, Anu; Nikopensius, Tiit; Ainla, Tiia; Kals, Mart; Mägi, Reedik; Gabriel, Stacey
B; Eha, Jaan; Lander, Eric S; Irs, Alar; Philippakis, Anthony; Marandi, Toomas; Natarajan, Pradeep;
Metspalu, Andres ... Esko, Tõnu (2019). Recall by genotype and cascade screening for familial
hypercholesterolemia in a population-based biobank from Estonia. Genetics in medicine, 21 (5),
1−8.10.1038/s41436-018-0311-2.
Freemantle, Nick; Irs, Alar; De Paulis, Ruggero; Pagano, Domenico; Falk, Volkmar; Beyersdorf,
Friedhelm (2019). Transcatheter versus surgical aortic valve replacement: what does the latest
evidence tell us? European Journal of Cardio-thoracic Surgery, 56 (1), 7−9.10.1093/ejcts/ezz163.
2016
Hatswell AJ, Baio G, Berlin JA, Irs A, Freemantle N. (2016). Regulatory approval of pharmaceuticals
without a randomised controlled study: analysis of EMA and FDA approvals 1999-2014. BMJ Open,
2016 (6, 6), e011666.10.1136/bmjopen-2016-011666.
Bueno H, de Graeff P, Richard-Lordereau I, Emmerich J, Fox KA, Friedman CP, Gaudin C, El-
Gazayerly A, Goldman S, Hemmrich M, Henderson RA, Himmelmann A, Irs A, Jackson N, James
SK, Katus HA, Laslop A, Laws I, Mehran R, Ong S, Prasad K, Roffi M, Rosano GM, Rose M,
Sinnaeve PR, Stough WG, Thygesen K, Van de Werf F, Varin C, Verheugt FW, de Los Angeles
Alonso García M. (2016). Report of the European Society of Cardiology Cardiovascular Round Table
regulatory workshop update of the evaluation of new agents for the treatment of acute coronary
syndrome: Executive summary. European Heart Journal, 2016 (Jun 29, Eur Heart J Acute Cardiovasc
Care), pii: 2048872616649859.10.1177/2048872616649859 [ilmumas].
Sonn, K.; Irs, A.; Laius, O. (2016). Clinical pharmacology and trends in use of sedative-hypnotic and
anxiolytic medications in Estonia. 25. HOBOKEN: Wiley-blackwell, 188−188. (25).
2013
Hoebert, J; Irs, A; Mantel-Teeuwisse, A; Leufkens, H. (2013). Future of the European Union
regulatory network in the context of the uptake of new medicines. British Journal of Clinical
Pharmacology, 76 (1), 1−6.10.1111/j.1365-2125.2012.04476.x.
Lass, J.; Odlind, V.; Irs, A.; Lutsar, I. (2013). Antibiotic prescription preferences in paediatric
outpatient setting in Estonia and Sweden. SpringerPlus, 2, 124−x.10.1186/2193-1801-2-124.
Pintson, Madli; Irs, Alar (2013). Involvement of Residents in the National Guideline Development
Process in Estonia. 10th EACPT Summer School, Edinburgh, UK, 4-6.07.2013.
2012
Kalda, Ruth; Viigimaa, Margus; Irs, Alar; Meren, Mari; Uuetoa, Tiina; Luman, Merike; Muda, Piibe;
Oona, Marje; Jaanson, Eret; Martinson, Katrin; Põldema, Ingrid; Ridaste, Kadri; Palm, Kairit;
Habicht, Triin; Teeäär, Tuuli; Saluse, Janek; Kropotuhhina, Irina; Heidmets, Lenne-Triin; Laidmäe,
Erki; Esnar, Kersti (2012). Täiskasvanute kõrgvererõhktõve käsitlus esmatasandil: Eesti ravijuhend.
Eesti Haigekassa, Tartu Ülikool 2012.
2011
Lass, J.; Irs, A.; Pisarev, H.; Leinemann, T.; Lutsar, I. (2011). Off label use of prescription medicines
in children in outpatient setting in Estonia is common. Pharmacoepidemiology and Drug Safety, 20
(5), 474−481.10.1002/pds.2125.
Raudsepp, D.; Lass, J.; Saar, M.; Kuld, L.; Irs, A. (2011). Ravimite koos- või kõrvaltoimed
erakorralise meditsiini osakonda pöördumise põhjusena - prospektiivne vaatlusuuring. Eesti Arst, 3,
122−128.
2010
Irs, A.; Salupere, R.; Sinisalu, V. (2010). Mittesteroidsete põletikuvastaste ravimite ohutu kasutamine.
Eesti Arst, 89 (6), 417−422.
Kirss, Anne; Maipuu, Lea; Eelmäe, Imbi; Metsvaht, Tuuli; Sirotkina, Meeli; Irs, Alar (2010).
Angiotensiini konverteeriva ensüümi inhibiitori ja angiotensiini II retseptori blokaatori kasutamise
ohud raseduse ajal: haigusjuhu kirjeldus ja kirjanduse ülevaade. Eesti Arst, 89, 502−509.
Lass, J.; Iljuhhina, J.; Laius, O.; Pisarev, H.; Irs, A. (2010). Retseptiravimite raseduseaegne
kasutamine Eestis. Eesti Arst: TÜ Arstiteaduskonna teaduskonverents, 7-8.okt. 2010.
2009
Laius, O.; Irs, A.; Kiivet, R. -A. (2009). FROM USSR TO EU - LONG-TERM TRENDS IN
ESTONIAN DRUG UTILIZATION. 105. MALDEN: Wiley-blackwell Publishing, Inc, 96−96. (105).
Lass, J.; Laius, O.; Leinemann, T.; Pisarev, H.; Irs, A.; Lutsar, I. (2009). Availability of paediatric
information in Summaries of Product Characteristics of drugs prescribed to children in Estonia. 12th
Congress of European Society for Developmental Perinatal & Paediatric Pharmacology, Chamonix,
Prantsusmaa, 17-20.06.2009.
Lass, J.; Laius, O.; Pisarev, H.; Irs, A.; Lutsar, I. (2009). Substantial proportion of ambulatory
prescribing for children is off-label in Estonia. 9th Congress of the European Association for Clinical
Pharmacology and Therapeutics, Edinburgh, Šotimaa, 12-15.07.2009.
2008
Freemantle, N.; Irs, A. (2008). Observational evidence for determining drug safety. British Medical
Journal, 336 (7645), 627−628.10.1136/bmj.39491.493252.80.
Zarkovski, Aleksander; Kalda, Anti; Gavronski, Maia; Hartikainen, Sirpa; Irs, Alar (2008). Kliinik
2008 : ravimitest tulenevad ohud [Videosalvestis]. Kliinik 2008, Tartu Ülikooli Kliinikumi
õenduskonverents; Tartu; 4.-6. veebruar 2008. Tartu: TÜ IT Multimeedia talitus,. (TÜ filmiarhiiv).
2006
Johnson, K.R.; Ringland, C.; Stokes, B.J.; Anthony, D.M.; Freemantle, N.; Irs, A.; Hill, S.R.; Ward,
R.L. (2006). Response rate or time to progression as predictors of survival in trials of metastatic
colorectal cancer or non-small-cell lung cancer: a meta-analysis. The Lancet Oncology, 7 (9),
741−746.
Raal, A.; Fischer, K.; Irs, A. (2006). Determination of drug information needs of health care
professionals in Estonia. Medicina (Kaunas), 42 (12), 1030−1034.
2005
Ristimäe, T.; Irs, A.; Teesalu, R. (2005). Arteriaalne hüpertensioon kui südame-
veresoonkonnahaiguste oluline riskitegur. Eesti Arst, 4, 277−282.
Jesse, M.; Habicht, J.; Aaviksoo, A.; Koppel, A.; Irs, A.; Thomson, S. (2005). Tervisesüsteem
muutustes: Eesti. Tallinn: World Health Organization.
2004
Jesse, M.; Habicht, J.; Aaviksoo, A.; Koppel, A.; Irs, A.; Thomson, S. (2004). Health care systems in
transition: Estonia. Copenhagen: World Health Organization.
2001
Rootslane, L.; Irs, A.; Kiivet, R. (2001). ATC/DDD methodology: a country perspective. WHO Drug
Information, 15 (1), 26−30.
Irs, A.; Rootslane, Ly (2001). The use of antihypertensive drugs in in Estonia compared to the Nordic
countries. Pharmacology & Toxicology, 89, suppl.. 50.
1999
Pahkla, R.; Irs, A.; Oselin, K.; Rootslane, L. (1999). Digoxin: use pattern in Estonia and
bioavailability of the local market leader. Journal of Clinical Pharmacy and Therapeutics, 24 (5),
375−380.
Kask, A.; Pahkla, R.; Irs, A.; Rago, L.; Wikberg, JES.; Schioth, HB. (1999). Long-term administration
of MC4 receptor antagonist HS014 causes hyperphagia and obesity in rats. Neuroreport, 10 (4),
707−711.
Regionaalhaigla
SA Pohja-Eesti Regionaalhaigla koolitustalitus
T't
IUNNISIUS
nr 17lOK-336
Kersti Oselin
isikukood 47307262752
Hbis 04.04.2017 koolituse
Ravimite kliiniliste uuringute, nende ldbiviimise
printsiipide ja heade kliiniliste tavade tdiendkoolitus
Koolituse maht: |0 tundi.
Ir
I11
:fllt^-
ll,,tl
Katrin Kiisk
Ravimiameti peadirektori aset-iitja
Tallinn, 04. aprill 2017